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Abstract
Genetically encoded (GE) contrast agents are proteins that enable visualization of gene expression, cell
proliferation, and metabolite flux. Optical GE contrast agents such as green fluorescent protein (GFP)
have revolutionized the field of biomolecular imaging, but their utility in large opaque organisms is limited
by the strong scattering of light by tissue. There is thus a need for GE contrast agents detectable by
alternative imaging modalities such as magnetic resonance imaging (MRI). MRI is a non-invasive, nonionizing imaging technique that offers excellent spatiotemporal resolution at virtually unlimited
penetration depths. Nuclear hyperpolarization of 129Xe provides a novel strategy to overcome the
sensitivity limitations of conventional 1H MRI. Using hyperpolarized (hp) 129Xe in combination with
chemical exchange saturation transfer, an MR contrast approach known as hyper-CEST, enables
ultrasensitive protein detection for biomolecular imaging applications.
Our group identified TEM-1 β-lactamase (TEM1) as the first monomeric protein capable of serving as a
GE contrast agent for hp 129Xe NMR. TEM1 reports a unique CEST contrast response 60 ppm downfield
of the 129Xe-H2O frequency, allowing nanomolar TEM1 to be detected in mammalian cells. Follow-up
experiments involving protein crystallography and molecular dynamics (MD) simulations have provided
additional insights regarding the Xe-TEM1 CEST interaction. Additionally, our group has characterized the
periplasmic binding proteins (PBPs) as a platform for developing analyte-sensitive GE MRI contrast
agents. 129Xe hyper-CEST was used to quantify maltose (32 nM to 1 mM) through its modulation of
conformational change and xenon exchange in maltose binding protein (MBP). More recently, we have
engineered ribose binding protein (RBP) as a GE contrast agent suitable for ribose detection at
physiological concentrations, and efforts are underway to similarly develop glucose/galactose binding
protein (GGBP) for glucose detection.
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ABSTRACT

GENETICALLY ENCODED CONTRAST AGENTS FOR HYPERPOLARIZED XENON NMR
Benjamin W. Roose
Dr. Ivan J. Dmochowski

Genetically encoded (GE) contrast agents are proteins that enable visualization of gene
expression, cell proliferation, and metabolite flux. Optical GE contrast agents such as green
fluorescent protein (GFP) have revolutionized the field of biomolecular imaging, but their utility
in large opaque organisms is limited by the strong scattering of light by tissue. There is thus a need
for GE contrast agents detectable by alternative imaging modalities such as magnetic resonance
imaging (MRI). MRI is a non-invasive, non-ionizing imaging technique that offers excellent
spatiotemporal resolution at virtually unlimited penetration depths. Nuclear hyperpolarization of
129

Xe provides a novel strategy to overcome the sensitivity limitations of conventional 1H MRI.

Using hyperpolarized (hp) 129Xe in combination with chemical exchange saturation transfer, an MR
contrast approach known as hyper-CEST, enables ultrasensitive protein detection for biomolecular
imaging applications.
Our group identified TEM-1 β-lactamase (TEM1) as the first monomeric protein capable of
serving as a GE contrast agent for hp
60 ppm downfield of the

129

129

Xe NMR. TEM1 reports a unique CEST contrast response

Xe-H2O frequency, allowing nanomolar TEM1 to be detected in

mammalian cells. Follow-up experiments involving protein crystallography and molecular
dynamics (MD) simulations have provided additional insights regarding the Xe-TEM1 CEST
interaction. Additionally, our group has characterized the periplasmic binding proteins (PBPs) as
a platform for developing analyte-sensitive GE MRI contrast agents. 129Xe hyper-CEST was used to
quantify maltose (32 nM to 1 mM) through its modulation of conformational change and xenon
exchange in maltose binding protein (MBP). More recently, we have engineered ribose binding
protein (RBP) as a GE contrast agent suitable for ribose detection at physiological concentrations,
and efforts are underway to similarly develop glucose/galactose binding protein (GGBP) for
glucose detection.
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Chapter 1: Introduction

1.1 Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is a routine medical procedure, with more than 60
million MRI scans performed across 25,000 MRI systems worldwide every year. [1] MRI delivers
detailed images of internal organs and tissues at unlimited penetration depths. Moreover, MRI is
a non-invasive technique, and unlike X-ray computed tomography (CT) and positron-emission
tomography (PET) scans, MRI does not require the use of ionizing radiation. Compared to CT, MRI
offers superior soft tissue contrast and can better differentiate between fat, water, and muscle. [2] In
addition to mapping anatomy, MRI can assess the functionality of internal systems, including
cardiopulmonary (e.g., MR angiography of vasculature), neurological (e.g., functional MRI of brain
activity), and renal (e.g., perfusion imaging of kidney function).[3] These capabilities make MRI a
versatile platform for developing novel diagnostic imaging techniques.
The underlying physics of MRI is based on that of nuclear magnetic resonance (NMR)
spectroscopy (Figure 1.1). Hydrogen (1H) nuclei (i.e., protons) are spin-½, and in the presence of
an external magnetic field (B0), 1H nuclei are split into two energy levels. Protons with nuclear spins
parallel and antiparallel to B0 occupy the lower and higher energy levels, respectively, following a
Boltzmann distribution. The energy difference (∆E) between the parallel and antiparallel protons
depends on the strength of B0 as well as the local electronic environment of the protons. Electrons
generate local magnetic fields that oppose B0, thus protons surrounded by high electron density
are shielded from B0 and ∆E decreases. Electron-shielded protons resonate at lower-energy
frequencies and exhibit smaller downfield chemical shifts. Conversely, protons surrounded by low

1

electron density experience a larger ∆E and larger downfield chemical shifts. The ability for NMR
to distinguish between protons in different physical and chemical environments has made it an
indispensable characterization tool for determining molecular structure. MRI also takes advantage
of this phenomenon, where chemical-shift MRI can highlight specific biomolecules (e.g., lipids)
and tissues based on the chemical shifts of their protons.[4]
1

H MRI signal arises from the relative populations of protons in the lower and higher

energy states. More protons occupy the lower-energy state, giving rise to an overall magnetic
moment (M0) vector aligned with the external magnetic field (B0). Mz is the vector component along
the z-axis, parallel to B0. To generate signal, a radio frequency (RF) pulse is used to tilt M0 by 90°,
creating a magnetic moment that extends into the x-y plane (Mxy). As M0 returns to its equilibrium
state, a free induction decay (FID) signal is measured in receiver coils and converted to MRI signal.
T1 relaxation, also known as longitudinal relaxation, is the process by which M0 returns to
equilibrium along the z-axis. T2 relaxation, also known as transverse relaxation, is the process by
which FID signal decays in the x-y plane. The rates of T1 and T2 relaxation are inverse to their T1
and T2 times, respectively. Protons in different biological tissues exhibit different spin relaxation
rates, making T1 and T2-weighted MRI a powerful diagnostic tool. MRI can also take a densiometric
approach to contrast, detecting differences in NMR signal that arise from varying water content in
tissues.[5] In short, MRI is a versatile imaging modality, capable of using different RF pulse
sequences and detection schemes to generate contrast among tissues that have different 1H
densities (i.e. water content), T1 and/or T2 relaxation times, rates of water diffusion, or 1H chemical
shifts.[6]

2

Figure 1.1. Summary of the mechanisms of NMR. (A) 1H nuclei (i.e. protons) precess in the presence
of an external magnetic field (B0). (B) The RF pulse creates a magnetic moment in the x-y plane
(Mxy), producing FID signal. After the RF pulse, the overall magnetic moment of the precessing 1H
nuclei returns to equilibrium via T1 and T2 relaxation. Reproduced from reference [7] with
permission of The Royal Society of Chemistry.

3

1.2 Contrast Agents for 1H MRI
The sensitivity of 1H NMR and MRI, however, is inherently limited by the weak signal
produced from thermally polarized 1H nuclei. In the magnetic field of a typical 1.5 T human clinical
MRI scanner at 37 °C, there is only a miniscule population difference between the low and high
energy spin states – only 2 protons in a million produce MRI signal! The abundance of 1H nuclei in
biological tissues (~90 M) compensates for this weak signal output, yet many diagnostic MRI scans
require more robust image contrast, defined here as the difference in signal intensity between
tissues or anatomic spaces.[8] Contrast agents are substances that improve MRI contrast by
catalytically shortening the T1 and T2 relaxation times of nearby water protons.[6] In the clinic,
contrast agents are employed in approximately 35% of all MRI examinations to improve image
quality and resolution.[7] Contrast agents are also employed in biomedical research as probes to
label specific cell populations and visualize molecular events in vivo.[9] Most current contrast agents
are either paramagnetic metal chelates or superparamagnetic nanoparticles and are broadly
categorized depending on whether they primarily influence T1 or T2 relaxivity. T1 agents increase
signal intensity (i.e. appear “brighter”) in T1-weighted MRI scans employing pulse sequences that
accentuate differences in longitudinal relaxation times (Figure 1.2). T2 agents, on the other hand,
decrease signal intensity (i.e. appear “darker”) in T2-weighted MRI scans.

4

Figure 1.2. T1- and T2-weighted images of Fe3O4 nanoparticle contrast agents. Increasing contrast
agent concentration brightens the T1 image and darkens the T2 image. Reproduced from reference
[10] with permission of The Royal Society of Chemistry.
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In the clinic, the most widely used contrast agents are gadolinium complexes that act to
brighten T1-weighted images. Gd3+ has a large magnetic moment due to its seven unpaired f-orbital
electrons, which, in turn, shortens the longitudinal relaxation times of coordinated water protons
and increases signal in T1-weighted MRI scans (Figure 1.3).[11] The first Gd3+ contrast agent,
gadopentetic acid (Magnevist®) entered the market in 1988, and currently nine gadolinium
contrast agents are approved for clinical use in the United States. Gadolinium’s unique magnetic
properties make it the prevailing paramagnetic metal for designing MRI contrast agents. A concern
with gadolinium contrast agents, though, is the toxicity of free Gd3+ ions to biological systems (LD50
GdCl3·6H2O: 100–200 mg/kg, IV in mice).[12] Additionally, Gd3+ precipitates with endogenous
anions such as hydroxides, carbonates, and phosphates, and the carbonate and hydroxide salts of
Gd3+ have been observed to stimulate fibroblast proliferation. [13,14] Moreover, Gd3+ has an ionic
radius closely matching Ca2+ (Gd3+ = 107.8 pm; Ca2+ = 114 pm), thus Gd3+ can bind to Ca2+ channels
and proteins requiring Ca2+ as a cofactor (e.g., calmodulin). To prevent free Gd3+ leakage,
gadolinium

contrast

agents

use

diethylenetriaminepentaacetic

acid

strongly-coordinating,
(DTPA)

and

multidentate

ligands

such

as

1,4,7,10-tetraazacyclododecane-N,N,N,N-

tetraacetic acid (DOTA) to tightly chelate the Gd3+ ion. Nevertheless, in 2006 the use of gadolinium
contrast agents was implicated in the development of nephrogenic systemic fibrosis (NSF) in
patients with compromised renal systems.[15] Though revised guidelines pertaining to the
administration of contrast agents have limited new cases of NSF, recent studies have reported the
accumulation of Gd3+ in neural tissue, particularly in patients who have received Gd3+ chelates on
four on more occasions.[16] Such findings compelled the European Medicines Agency (EMA) to
restrict the use of certain gadolinium contrast agents such as gadoxetic acid and gadobenic acids. [17]

6

Figure 1.3. A Gd3+ contrast agent and the mechanism of longitudinal relaxation acceleration of
nearby water protons. Reproduced from reference [18] with permission of The Royal Society of
Chemistry.
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Compounding these toxicity issues is the fact that high concentrations (> 0.1 mM) of Gd 3+
contrast agents are typically required in order to effect a measurable change on the 90 M pool of
bulk 1H nuclei.[6] A relaxation rate change of at least 0.5 s-1 is needed to produce useful contrast in
an MRI scan,[6] and the T1 relaxivities (r1) of commercially available Gd3+ contrast agents in a 3 T
scanner range from 3.5 to 9.9 mM-1 s-1 in plasma at 37 °C.[19] Strategies to increase contrast agent
relaxivities include using dendrimers,[20–22] viral capsids,[23] and nanotubes.[24] Recently Yang and
coworkers have taken the novel approach of using a protein scaffold to chelate Gd 3+, as the much
larger size of proteins gives a longer rotational correlation time (τR) between exchanging water and
Gd3+, thereby increasing relaxivity.[25] Engineering high-affinity Gd3+ binding sites into the calciumbinding protein parvalbumin yielded a protein-based contrast agent, proCA32, possessing r1 and
r2 relaxivities of 66.8 and 89.2 mM-1 s-1, respectively, and capable of imaging early liver
metastases.[26] However, despite their improved relaxivities, these new agents have yet to achieve
commercial success in the clinic. While gadolinium-based contrast agents will undoubtedly
continue to play an indispensable role in MRI examinations, the development of less toxic and/or
more robust T1/T2 contrast agents are an active area of research, and alternative approaches to MR
contrast are also under investigation.
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1.3 Chemical Exchange Saturation Transfer (CEST)
While T1 and T2 contrast agents remain standard in the clinic, an innovative approach to
MR contrast – chemical exchange saturation transfer (CEST) – has given rise to a new class of
contrast agents for 1H MRI.[27] CEST is a magnetization transfer[28,29] technique that generates MR
contrast by magnetically labelling exchangeable protons and monitoring the subsequent alteration
in bulk proton magnetization (Figure 1.4).[30,31] A CEST MRI contrast agent is a solute that possesses
exchangeable proton(s) that resonate at a frequency different from water protons (∆ω). Solutebound protons are selectively saturated via a RF pulse, and exchange with water protons attenuates
the water MRI signal, thereby producing measurable contrast.[32] The novel feature of CEST is the
continuous transfer of spin saturation to bulk water as a means of amplifying MRI signal. [33] If
proton exchange is sufficiently fast (millisecond range) and the RF saturation pulse duration is
sufficiently long (second range), relatively little contrast agent is needed to transfer measurable
saturation onto the pool of bulk water protons. For CEST contrast to be observed, however, proton
exchange needs to be in the slow-to-intermediate regime on the NMR time scale. More precisely,
the equilibrium proton exchange rate (kex) between solute and solvent must be less than ∆ω. Thus,
a key challenge to the design of CEST contrast agents is balancing the need for signal amplification
(fast exchange) and the physical constraints of magnetic resonance (slow exchange).
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Figure 1.4. Simplified CEST scheme showing a “two-pool” model. A selective radiofrequency (RF)
pulse depolarizes the smaller pool of exchangeable protons, leading to the depolarization of the
larger pool of bulk water protons via continuous proton exchange. Reprinted with permission from
reference [34]. Copyright 2003 American Chemical Society.
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The sensitivity afforded by CEST has led to its incorporation in the field of theranostics to
track drug delivery without the use of chemical labels. For example, gemcitabine, a widely used
anticancer drug, has an exchangeable amino proton (~2.3 ppm downfield of bulk water), and its
delivery to tumors can be observed by 1H CEST MRI.[35] Likewise, the exchangeable hydroxyl and
amine protons of pharmaceutical excipients (e.g. sucrose, ascorbic acid, meglumine) have been
used to detect drug accumulation in tumor regions (exciCEST).[36] CEST can also be used to
visualize the distribution of endogenous biomolecules possessing exchangeable protons. Notably,
CEST MRI has been used to visualize glucose uptake (glucoCEST) in tumor xenograft models,
presenting a non-invasive alternative to PET imaging for differentiating tumors from normal tissue
(Figure 1.5).[37] CEST has been used to detect other biomolecules relevant to disease diagnosis such
as glycogen (glycoCEST),[38] proteoglycans (gagCEST),[39] and myo-inositol (MICEST).[40]
Additionally, because proton exchange rates are affected by local chemical environment, CEST has
been used to monitor physiological parameters such as pH (acidoCEST). [41]
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Figure 1.5. Scheme for glucose detection by CEST (glucoCEST). Reprinted with permission from
reference [37]. Copyright 2013 Springer Nature.
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The sensitivity of CEST can be further enhanced through the incorporation of
paramagnetic species (paraCEST). Whereas the proton chemical shifts (∆ω) of diamagnetic species
(e.g. -NH and -OH groups) are within 5 ppm of bulk water, paraCEST agents vastly expand the
∆ω range of exchanging protons.[34,42] Increasing ∆ω increases the maximum exchange rate
permissible in the slow-exchange condition (kex < ∆ω) required for CEST contrast, thus allowing
more spins to be transferred during the selective RF pulse. [43] Although water exchange with T1
Gd3+ agents is too rapid on the NMR timescale, other paramagnetic lanthanide(III) compounds are
suitable as paraCEST agents. Europium(III), in particular, is an attractive candidate given the large
(~50 ppm) chemical shift and slow exchange of coordinated water protons.[44] A palette of Eu3+DOTA-tetraamide chelates, each with a unique bound water resonance frequency, has been
developed for multiplexing applications.[45] Cell labeling via paraCEST was demonstrated using
rat hepatoma tumor cells containing a Eu3+(dotamGly) chelate.[46] Picomolar detection of paraCEST
agents has been achieved by encapsulating a Ln3+ chelate inside a unilamellar liposome, an
approach known as lipoCEST.[47]
As a means of detecting MRI contrast agents, the CEST approach offers several advantages
over currents methods.[48] Unlike T1 and T2 contrast agents, which continuously generate MR signal
until they are cleared from the patient, CEST signal arises only when the selective RF saturation
pulse is applied. Additionally, because CEST contrast arises only when the RF pulse matches the
resonance frequency of the exchangeable protons, multiplexing can be achieved from multiple
contrast agents if their respective exchangeable protons resonate at sufficiently different
frequencies. This multiplexing capability is a significant advance over T1 and T2 contrast agents,
which generate contrast in only one dimension. The benefits of CEST MRI have spurred the
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development of a variety of CEST contrast agents, including analyte-sensitive compounds capable
of measuring metal ion[49] and metabolite concentrations.[50]
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1.4 Hyperpolarized 129Xe for MRI
Nevertheless, the aforementioned CEST MRI contrast agents are still limited by the low
sensitivity of thermally polarized 1H nuclei. The emerging field of hyperpolarized (hp) NMR/MRI
can overcome this limitation by increasing nuclear polarization levels (i.e. MRI signal) of spin-½
nuclei by several orders of magnitude.[51] Established methods for hyperpolarizing

13

C in

biomolecular probes include parahydrogen-induced polarization (PHIP) and dynamic nuclear
polarization (DNP).[52,53] PHIP uses a paramagnetic catalyst to first enrich the singlet state paraform of H2 before transferring spin order to the probe molecule via a hydrogenation reaction. DNP
involves cooling the probe molecule to 1-2 K in the presence of a stable radical species, followed
by irradiation with a selective radiofrequency to achieve electron-to-nuclei polarization transfer.
These methods have been used to hyperpolarize small organic molecules and obtain angiographic
images[54] as well as visualize pulmonary[55] and cerebral[56] perfusion by detection of hp 13C. In vivo
metabolite detection has also been achieved using hp 13C-labelled pyruvate,[57] 13C-lactate,[58] and
13

C-glutamine.[59] A recently developed hyperpolarization technique, signal amplification by

reversible exchange (SABRE), offers a means of hyperpolarizing probe molecules without changing
their chemical identity.[60,61] SABRE employs a metal catalyst to mediate polarization transfer from
p-H2 (in the form of coordinated hydrides) to the coordinated probe via scalar coupling. While the
range of hyperpolarizable substrates is largely limited to Lewis-base-containing molecules,
methods such as SABRE-RELAY have expanded the substrate scope by using the exchangeable
NH protons of SABRE-hyperpolarized amines and ammonia to relay polarization into the
molecule of interest.[62] SABRE-RELAY offers a cost efficient, facile alternative to PHIP and DNP
for hyperpolarizing organic molecules and is expected to facilitate chemical analysis and disease
diagnosis.
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HP 3He and 129Xe have also been investigated for MRI applications due to their inertness,
rapid diffusion in biological tissue, and ease of hyperpolarization using laser-based methods such
as spin-exchange optical pumping (SEOP).[63] SEOP uses circularly polarized light to polarize the
unpaired electronic spins of an alkali metal vapor (typically Rb), and gas-phase collisions transfer
this electronic polarization to the noble gas nuclei. SEOP efficiency has improved considerably in
recent years due to high-power light sources offered by spectrally-narrowed laser diode arrays. [51]
Notably, “open-source” designs for a SEOP polarizer capable of producing ~1 L/h hp 129Xe gas have
recently been made available,[64] and commercial polarizers such as XeBox E-10 (Xemed) can
produce multi-liter volumes of hp

129

Xe gas in roughly fifteen minutes.[65] HP

129

Xe was first used

to acquire MR images of mouse lungs in 1994[66] and human lungs in 1997.[67] Soon thereafter, 3He
superseded 129Xe for hp MRI due to its larger gyromagnetic ratio (3He = -32.4 MHz T-1; 129Xe = -11.8
MHz T-1) and its historically superior levels of hyperpolarization.[68] However, 3He is primarily
obtained through tritium decay in nuclear warheads, and thus its availability is limited. In recent
years, 3He reserves have been largely diverted for use in 3He-based neutron detectors for the
purposes of national security (3H emits γ radiation upon neutron absorption), causing the cost of
3

He to increase exponentially.[51] As a result,

129

Xe has re-emerged as the leading candidate for

hyperpolarized MRI.
129

Xe is relatively inexpensive (ca. $20 per L) due to its natural isotopic abundance (26%)

and ready accessibility in air (8.7 x 10-6 mole percent). The safety of administering Xe to humans
has been well-established through xenon’s historical use as a general anesthetic. With a van der
Waals radius of 2.2 Å, Xe is the largest of the stable noble gases and hence has the greatest
polarizability – 4.0 Å3 for Xe, compared to just 0.2 Å3 for He and 1.5 Å3 for water.[69] This
polarizability makes Xe relatively soluble in water (~5 mM per atm) and thus well-suited for MRI
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scans of biological tissue. Furthermore, after inhalation hp Xe rapidly saturates pulmonary blood
and is distributed to distal organs such as the brain faster than the T1 relaxation times of hp Xe in
biological tissues (e.g. ~13 s in oxygenated blood; ~15 s in brain tissue).[70,71] Additionally, the
chemical shift of Xe in water is large (> 300 ppm) and highly sensitive to its local environment. [72]
Collectively, these advantageous properties of xenon have made

129

Xe MRI a practical diagnostic

tool in the clinic, having been used to image respiratory diseases[73] such as chronic obstructive
pulmonary disorder (COPD),[74] asthma,[75] pulmonary fibrosis,[76] and cystic fibrosis.[77] More
recently, chemical shift imaging 129Xe MRI has been employed to image the human brain.[78] Some
of these experimental approaches to

129

Xe MRI have already matured into clinically-useful

protocols, while others show promise for future imaging applications.[70]
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1.5 Contrast agents for 129Xe NMR/MRI
While 129Xe MRI has found clinical success for diagnosing respiratory defects and disease,
there is additional interest in utilizing the high sensitivity of Xe for biomolecular imaging. One aim
is to use hp

129

Xe to visualize tumor-associated proteins as a means of improving early cancer

detection and staging.[79] The primary challenge to achieving such molecular imaging aims is
localizing MR contrast from

129

Xe to the biomarker of interest. Practically speaking, one cannot

covalently functionalize Xe with a targeting moiety (though its chemical inertness has been
overcome to form inorganic[80] and organic[81] compounds with Xe). Rather, the current approach is
to sequester 129Xe via a host-guest interaction and attach the targeting moiety to the host molecule.
The first Xe contrast agent, or “biosensor”, to follow this design was reported by Pines and
coworkers in 2001.[82] Their construct consisted of a cryptophane-A cage appended with a biotin
targeting moiety via a solubilizing linker (Figure 1.6). Direct detection NMR experiments with hp
129

Xe showed a clear shift chemical difference between “free” and “avidin-bound” biosensor,

thereby demonstrating for the first time the feasibility of localizing
biomolecular target.
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129

Xe MR contrast to a

Figure 1.6. A cryptophane-A biosensor targeting avidin. (Top) The cryptophane-A cage (black)
binds Xe with high affinity and the biotin targeting moiety (red) directs the bound Xe to avidin
with high affinity and specificity. The cryptophane-A cage and biotin are linked by a tether (blue).
(Bottom)

129

Xe direct detection NMR spectra showing the binding of biotin-functionalized Xe to

avidin. The peak at 193 ppm corresponds to Xe(aq), and the peaks around 70 ppm correspond to
cryptophane-bound Xe. Reproduced from reference [82]. Copyright 2001 National Academy of
Sciences.
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Since then, most Xe biosensors have continued to employ cryptophane-A to sequester Xe
due to its high affinity for Xe and functionalizability. Cryptophane-A binds Xe reversibly and with
high affinity (Ka > 3000 M-1 at 278 K in tetrachloroethane).[83] Notably, ITC measurements performed
in phosphate buffer at 293 K show that Xe affinity is significantly higher for water-soluble
cryptophane-A derivatives such tris(triazole propionic acid) cryptophane-A (TTPC [84]; Ka ≈ 17 000
M-1), tri-acetic acid cryptophane-A (TAAC[85]; Ka ≈ 33 000 M-1), and tris(triazole ethylamine)
cryptophane-A (TTEC[86]; Ka ≈ 42 000 M-1). Xe exchange is slow on the NMR timescale, allowing
individual Xe peaks to be resolved in an NMR spectrum. Moreover, MR contrast has been
amplified by attaching multiple cryptophane cages to a single dendrimer-based targeting
moiety.[87] To date, Xe contrast agents incorporating cryptophane-A have been developed to target
proteins,[88–90] glycans,[91] oligonucleotides,[92] metal ions,[93–95] and free thiols.[96,97] Additionally, the
sensitive chemical shift of encapsulated Xe has been exploited to create pH sensors [98,99] as well as
to monitor protein conformation.[100]
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1.6 129Xe hyper-CEST
While direct detection Xe NMR/MRI methods have traditionally been used with Xe
contrast agents, more recently the CEST approach to producing MR contrast has been adapted to
Xe NMR/MRI to further enhance its detection sensitivity. The use of CEST with hyperpolarized
129

Xe, known as hyper-CEST, is analogous to 1H CEST: frequency-selective RF pulses depolarize

host-bound

129

Xe, and this depolarization is transferred to bulk

129

Xe via chemical exchange,

resulting in MR contrast.[101] As with 1H CEST, sufficient separation between the host- and solventbound 129Xe resonance frequencies is requisite for CEST contrast. Also, as with 1H CEST, rapid Xe
exchange acts to amplify MRI signal: if Xe exchange between host and solvent is fast (kex ≈ 1000 s-1)
relative to the duration of the selective RF pulse, a single contrast agent can depolarize thousands
of

129

Xe atoms though the chemical exchange mechanism. On the other hand, the rate of Xe

exchange (kex) between host and solvent must be lower than the frequency difference between hostand solvent-bound

129

Xe (Δω).[102] Fundamentally, the advantage of Xe hyper-CEST is that MR

contrast arises from the detection of free

129

Xe(aq) resonance, and not the direct detection of

resonance arising from the relatively small pool of host-bound 129Xe.
The combination of rapid Xe exchange and high Xe affinity makes cryptophane-A and its
derivatives well-suited as contrast agents for hyper-CEST. Cryptophane detection by Xe hyperCEST was first reported in 2008, where 10 nM of modified cryptophane was detected, marking a
~4000-fold sensitivity enhancement over direct detection MR methods. [103] Subsequent
improvements to hyperpolarization and CEST protocols have extended this sensitivity even
further. Xe hyper-CEST has been employed to detect TAAC at 1.4 pM [104] and virus capsids coated
with ~125 cryptophane-A cages at 0.7 pM.[105] Moreover, Xe hyper-CEST has been used with
cryptophane-based contrast agents for a variety of biosensing applications. Cryptophane
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functionalized with a targeting oligopeptide has been used to detect major histocompatibility
complex (MHC) class II protein, a biomolecular target relevant to autoimmune disease, via the 1
ppm chemical shift difference between “free” and “bound” biosensor observed via hyper-CEST. [106]
Peptide-functionalized liposomal carriers have been used to deliver cryptophane-A to human
brain microvascular endothelial cells, enabling their detection using only 1 nM of biosensor. [107]
Modifying cryptophane-A with cell-specific antibodies enables the detection of target cells using
only 20 nM biosensor.[108] In addition to protein biomarkers, metabolically-labeled cell-surface
glycans have also been imaged using modified cryptophane-A. [91] Finally, beyond labeling cellsurface biomolecules, cryptophane constructs have been demonstrated to generate CEST contrast
upon cellular internalization.[109] It is important to note that 129Xe hyper-CEST contrast is observed
in cellular environments despite the exchange of hp Xe with endogenous proteins.
While cryptophane, specifically cryptophane-A, remains the gold standard for Xe contrast
agent design, its difficult and inefficient synthesis has spurred the search for alternative Xe hosts.
The most prominent of these are the cage-like cucurbit[n]uril (CB[n]) molecules, [110] namely CB[6],
which, unlike cryptophane, is commercially available (only ~$100 per gram). CB[6] has hexagonal
symmetry and possesses a hydrophobic interior roughly 4.4 Å in diameter. While CB[6] binds Xe
with a Ka of 490 M-1 in pH 7.2 PBS – roughly 40-fold lower than the published value for TAAC[84] –
CB[6] has a superior Xe exchange rate (kex = 1470 s-1) than TAAC (kex = 86 s-1) at 298 K,[104] making
CB[6] detectable at 1.8 pM concentration via hyper-CEST.[111] Recent imaging experiments have
visualized CB[6] in whole blood[112] as well as in living rat vasculature[113] using Xe hyper-CEST.
Although cucurbit[n]urils are not readily functionalizable, detection schemes incorporating twofaced guests or rotaxane complexes have been developed [114] to detect proteins[115,116] and monitor
enzyme activity[116,117] using CB[6] and Xe hyper-CEST. Moreover, methods have recently been
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developed for directly functionalizing cucurbit[n]urils, providing a means for directly localizing
MR contrast to biomolecular targets.[118–120] The utility of CB[6] as MR contrast agent, however, is
limited by its poor water solubility (18 μM).[121] Additionally, naturally occurring polyamines such
as spermine, spermidine, and putrescine have strong binding affinities for CB[6],[111,122,123] and the
competitive binding of these biomolecules lowers the effective concentration of cucurbit[n]uril
capable of producing Xe hyper-CEST contrast. Indeed, the minimum CB[6] concentration in blood
detectable by hyper-CEST was 10 μM (much higher than the minimum detection threshold in
PBS!), highlighting the significant signal attenuation largely caused by the interference of
endogenous molecular species.[112]
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1.7 Genetically encoded contrast agents
While synthetic contrast agents (e.g. Gd3+-chelates, cryptophanes) provide an exciting
range of biomolecular imaging capabilities, there is interest in developing genetically encoded (GE)
contrast agents for MRI. GE contrast agents offer several advantages over synthetic constructs.
Stably-transfected cells and transgenic organisms encoding contrast agent are suitable for longterm imaging and longitudinal studies.[124–126] Additionally, the expression levels of GE contrast
agents can be controlled through the use of constitutive or inducible promoters along with other
transcription factors.[127] The delivery of GE contrast agents can be accomplished using relatively
non-invasive transgenesis methods such as viral infection (Figure 1.7),[128–130] and by such methods
contrast can be targeted to specific cell types and subcellular compartments.[131,132] In short, GE
contrast agents can take of advantage of Nature’s genetic and biosynthetic machinery to offer a
fundamental advantage in basic research when used in cell and animal models. [133]
GE contrast agents also have clinical applications, especially in the fields of regenerative
medicine and gene therapy. Stem-cell based therapies are increasingly being used to treat various
diseases and pathologies, and non-invasively monitoring the viability of engrafted cells in vivo is
critical to evaluating the efficacy of treatment.[134–136] Stem cells stably-transfected with a GE contrast
agent maintain contrast after cell division, thereby enabling non-invasive longitudinal tracking. If
GE contrast agent expression is controlled by a specific promoter, contrast arises only if the stem
cell differentiates into the desired phenotype. [136,137] Moreover, fusion with a GE contrast agent
enables the visualization of the expression and localization of therapeutic transgenes delivered via
viral vectors or stem cells.[138,139] GE contrast agents will potentially play a critical role in
determining the clinical success of stem-cell and gene based treatments in the near future.
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Figure 1.7. Scheme of GE contrast agent delivery, expression, and detection.
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GE contrast agents also have clinical applications when the recombinant protein is
prepared ex vivo and delivered to the patient as an exogenous species. Protein drugs and antibodies
are frequently employed in medicine due to the specificity, potency, and favorable
pharmacokinetics attained from engineered proteins.[140,141] Recombinant DNA technology enables
the manipulation of protein structure at the genetic level to improve drug efficacy as well as
optimize production.[142] Moreover, the biologically active protein can be decorated by genetic
engineering and/or chemical modification to improve circulation times, reduce immunogenic
response (e.g., PEGylation), and confer binding specificity by attaching a biorecognition sequence
such as an oligopeptide sequence. GE contrast agents have the potential to be marketed using the
same strategies as protein therapeutics, allowing them to be administered to human patients for
use in MRI scans.
GE optical contrast agents such fluorescent proteins,[143,144] bioluminescent proteins,[145,146]
and even RNA aptamers[147,148] have become indispensable tools in molecular biology, allowing
gene expression and protein localization to be noninvasively imaged in living cells. Of these
contrast agents, green fluorescent protein (GFP) is the most widely used. First discovered in the
1950s in Aequorea victoria jellyfish, GFP has since been an active area of research, having been
engineered to improve stability, quantum yield, and brightness.[149,150] Notably, the primary
structure of GFP has been “humanized” to improve expression levels in mammalian cells. [151]
Unlike bioluminescent proteins such as luciferases, GFP does not require substrate to generate
contrast, and the GFP fluorophore is buried within the protein and is thus largely unaffected by its
external environment.[152] Mutations to GFP and other fluorescent proteins such as DsRed and
mCherry have led to the development of a library of fluorescent proteins spanning the visible light
spectrum. Fluorescent proteins have also been used to develop analyte-responsive GE contrast
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agents for visualizing metabolite concentrations and biochemical signaling. One approach involves
fusing fluorescent proteins to the N- and C-termini of “hinge-motion” proteins that undergo
conformational change upon ligand binding.[153] Contrast is then observed by monitoring Förster
resonance energy transfer (FRET) changes upon ligand binding. The bacterial periplasmic binding
proteins (PBPs) are a popular platform for developing such FRET biosensors, having been
engineered to detect maltose,[154] ribose,[155] glucose,[131] glutamate,[156] other small molecules and
metal ions.[157]
The widespread use of fluorescent proteins in cancer research demonstrates the usefulness
and versatility of GE contrast agents. Tumor cells can be stably transfected with fluorescent
proteins and transplanted into living animals, enabling tumor growth and metastasis to be
visualized in vivo (Figure 1.8).[158] In one study, mouse melanoma cells and human colon cancer
cells stably expressing GFP were transplanted into nude mice, and tumor metastasis and growth
were quantitatively measured in real time.[159] Investigators can take advantage of the wide palette
of fluorescent proteins by labelling different cancer cells with unique colors and/or using unique
colors to differentiate between xenografted tumor cells and healthy host cells. For example,
Yamamoto et al. used HT-1080 human fibrosarcoma cells expressing either GFP or red fluorescent
protein (RFP) to determine the clonality of metastatic colonies by fluorescence imaging. [160] Using
a similar two-color approach, Yang et al. imaged RFP-expressing tumors growing in GFPexpressing transgenic mice to visualize tumor-induced angiogenesis and other tumor-induced host
processes.[161] In addition to visualizing tumorigenesis and metastasis, GE contrast agents are useful
in evaluating the effectiveness of tumor growth inhibitors such as bisphosphonate zoledronic
acid[162] and angiostatin.[163] These representative studies attest to the capabilities offered by GE
contrast agents for aiding cancer research and drug efficacy at the molecular level.
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Figure 1.8. Tumor tracking using fluorescent proteins. (a) Whole-body image of orthotopically
growing HCT 116-RFP human colon cancer in GFP nude mouse. (b) Visualizing angiogenesis in
live tumor tissue after injecting B16F10-RFP melanoma cells. Host-derived GFP-expressing blood
vessels are differentiated from melanoma cells. Reproduced with permission from reference [161].
Copyright 2003 National Academy of Sciences.
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In the future, one could potentially use GE contrast agents to inform cancer treatment in
human patients. The primary tumor could be labeled with a GE contrast agent, allowing one to
track metastasis as well as evaluate the impact of different treatment strategies. Furthermore, to
ensure tumor-specific expression, the GE contrast agent could be placed under the control of a
tumor-specific promoter such as carcinoembryonic antigen (CEA) promoter for cancers of
epithelial cell origin,[164] α-fetoprotein for liver cancers,[165] prostate-specific antigen for prostate
cancers,[166] and the CXCR4 promoter for breast cancers.[167] Coupling the use of constitutivelyactive GE contrast agents with analyte-sensitive GE contrast agents could offer additional
information pertaining to tumor progression and treatment. For example, the selective transfection
of the PBP glucose/galactose binding protein (GGBP) into cancer cells to monitor glucose
concentration could offer information regarding the metabolism of the tumor and potentially
inform treatment strategies. Alternatively, recombinant GGBP fused to a tumor-targeting peptide
sequence could be prepared ex vivo and administered to localize the contrast agent to cancer cell
populations.
While optical GE contrast agents such as fluorescent proteins offer high detection
sensitivity in aqueous solution or single cells, the use of such agents in large, opaque organisms
such as humans is limited by the strong scattering of light by tissue. [168–171] As such, there is the need
for GE contrast agents detectable through alternative modalities such as positron-emission
tomography (PET) or MRI, which offer practically unlimited penetration depths. PET imaging
detects pairs of gamma rays emitted by a nuclear contrast agent containing a positron emitting
radionuclide. Frequently used radioisotopes for biological imaging include 14O, 15O, 13N, 11C, and
18

F.[172] The early 1990s saw the development of the first GE nuclear contrast agent, thymidine kinase

from herpes simplex virus (HSV-tk).[173] HSV-tk is transfected into target cells, and upon the
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administration of positron-emitting substrates such as

18

F-labeled 1-(2-deoxy-2-fluoro-D-

arabinofuranosyl)-5-iodouracil (FIAU), HSV-tk leads to the accumulation of the radioactive probe
in transfected cells. While nuclear contrast agents offer impressive sensitivities, their disadvantages
include patient exposure to high-energy radiation, low spatial resolution (mm-range), and the need
to prepare radionuclide-containing compounds.[2]
MRI, on the other hand, offers excellent spatial resolution (μm-range) without the need for
ionizing radiation or radioactive compounds. The first reported GE magnetic resonance (MR)
contrast agent was creatine kinase (CK).[174,175] The accumulation of phosphocreatine, the metabolic
product of CK, in transfected liver cells in mice was detected by 31P NMR spectroscopy. Using a
similar approach, arginine kinase (AK) was employed to generate excess phosphoarginine in
labeled cells and generate contrast measurable by 31P NMR spectroscopy.[176] Another strategy for
developing GE MR contrast agents has been to use transgenic enzymes to convert substrate to
NMR-active product. Such examples include cytosine deaminase [177] and β-galactosidase[178] which,
when expressed in target cells and presented with fluorinated substrates, give rise to contrast
detectable by

19

F NMR. Beyond
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P and

19

F, GE contrast agents have also been developed for

conventional 1H MRI. These proteins either produce MR contrast via the same mechanisms as
synthetic contrast agents (e.g., paramagnetic ions or exchangeable protons), or they catalyze the
accumulation of synthetic contrast agent in cells.[179] GE contrast agents for 1H MRI generally follow
one of four established mechanisms for generating contrast: accumulation/activation, diffusion,
T1/T2, or CEST (Figure 1.9).
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Figure 1.9. Mechanisms of MR contrast from GE contrast agents. Adapted with permission from
reference [179]. Copyright 2017 Elsevier.
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Proteins that activate or accumulate synthetic contrast agents can be used to label cells.
Enzymes, for example, can generate contrast when used in conjunction with substrate-capped
synthetic contrast agents. β-galactosidase (β-gal) generates T1 contrast when combined with a
galactopyranose-capped Gd3+ chelate. Upon cleavage of galactopyranose by β-gal, the
paramagnetic Gd3+ center becomes accessible to water and shortens the T1 relaxation times of
exchanging protons, thereby producing T1 contrast.[180] Another galactopyranoside-containing
substrate, S-Gal®, forms a paramagnetic precipitate in the presence of β-gal and Fe3+ ion, thereby
producing T2 contrast.[181] Following a similar strategy, overexpression of transport proteins can
also label cells. Overexpression of organic anion-transporting polypeptides (OATPs) leads to the
accumulation of exogenous Gd3+ chelates, thereby labeling the host cell with shortened T1
relaxivity.[182,183] While the activation and accumulation strategies are effective in amplifying
contrast, the major drawback to this hybrid GE/synthetic molecule approach is the need to
administer exogenous agents to generate contrast and ensure that sufficient quantities are
delivered to the transfected cells. Moreover, concerns pertaining to metal ion cytotoxicity persist
in this approach.
A more recent approach to MR contrast, diffusion-weighted imaging (DWI), circumvents
the need for synthetic contrast agents. Overexpression of water-permeable membrane channels on
cell surfaces increases water diffusivity and produces contrast in DWI-weighted MRI scans.
Mukherjee and coworkers showed that human water channel protein aquaporin 1 (AQP1)
produces contrast detectable at sub-micromolar concentrations by diffusion-weighted MRI. [184]
Overexpression of AQP1 in transfected cells enabled tumor detection without any adverse effects
on cell proliferation or viability, though it was noted that AQP1 generates negative contrast
enhancement (i.e., a “turn-off” signal), which is susceptible to confounding effects from lesions,
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abscesses, and other artifacts. Also, while AQP1 can effectively label cells, it is unsuitable as a
fusion partner for tracking gene expression within the cell.
Attempts to develop T1 GE contrast agents have relied on metalloproteins, transport
proteins, or enzymes that that catalyze the accumulation of paramagnetic species. Bacterial
cytochrome P450-BM3, which contains a paramagnetic Fe(III) heme cofactor, has been used as a
GE T1 contrast agent, with directed evolution successful converting the protein into a dopaminesensitive contrast agent.[185] Similarly, the bacterial protein MntR contains a solvent-accessible Mn2+
ion and is capable of generating robust T1 contrast upon overexpression in mammalian cells.[186]
Transport proteins such as Divalent Metal Transport 1 (DMT1) also accumulate Mn 2+ in cells as a
means of generating T1 contrast.[187] Finally, enzymes that lead to metal accumulation have also
been used as GE contrast agents. Tyrosinase is an enzyme involved in melanin synthesis. Melanin
has a high affinity for iron, and the accumulation of excess melanin catalyzed by tyrosinase
consequently gives rise to T1 contrast. Mouse fibroblasts, human embryonic kidney cells, and MBF7 breast cancer cells overexpressing tyrosinase showed shortened T1 times.[188,189]
T2 GE contrast agents follow similar strategies for generating contrast. Overexpression of
transgenic transferrin receptor (TfR) in tumor cells resulted in excess iron accumulation and
contrast detectable in T2-weighted MRI scans.[190,191] Following a similar iron-based approach,
ferritin has been used as a GE T2 contrast agent. Ferritin is a cage-like protein that stores iron in the
form of ferrihydrite. Although its magnetic core gives rise to relatively weak T2 contrast, the heavy
chain of murine ferritin has generated useable T2 (as well as T1) contrast when overexpressed in rat
glioma cells.[192] Combining the two approaches, Deans et al. coexpressed TfR and ferritin in mouse
neural stem cells to generate T2 contrast.[193] While T1 and T2 GE contrast agents avoid the need for
exogenous agents, they do come with some limitations, namely the need for sufficient quantities
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of metal to generate MR signal. Other concerns include signal loss from metal dilution during cell
division, persistent signal even after cell death, and issues of cytotoxicity related to excess metal
accumulation.
The CEST approach to MR contrast has also been used in the development of GE contrast
agents. Like synthetic CEST agents, CEST proteins need to possess a high concentration of
exchangeable protons with resonance frequencies sufficiently downfield of bulk water. Gilad and
coworkers designed a series of artificial lysine-rich proteins (LRPs) to generate CEST contrast from
the exchange of amide protons.[194] Amide protons were observed to resonate 3.76 ppm downfield
of water with an exchange rate of 403 s-1. CEST signal was detectable down to 10 μM protein in
vitro, and 9L rat glioma cells overexpressing LRP were able to be distinguished from control cells.
CEST contrast from LRP has been localized to tumor cells through oncolytic viral vector delivery [195]
as well as by placing LRP under the control of cancer-associated progression elevated gene-3 (PEG3) promoter.[196] Furthermore, delivery of LRP via an adeno-associated viral vector (AAV)
successfully localized CEST contrast to the myocardium of mice.[197] Subsequent work has been
successful in producing an array of artificial CEST proteins with unique resonance frequencies,
akin to the multicolor palette of fluorescent proteins. [198]
In addition to artificial protein constructs, naturally-occurring proteins have been used as
GE CEST contrast agents. The activity of cytosine deaminase, detectable by 19F NMR (vide supra),
can also generate CEST contrast by magnetically labeling the amine protons on the substrate. [199]
Similarly, the activity of herpes simplex virus thymidine kinase (HSV-tk), also a viable PET
reporter gene, can be detected via CEST through the use of a synthetic thymidine analog. [200,201] Still,
as with other enzyme-based contrast agents, contrast is dependent on the presence of sufficient
substrate, and concerns about product cytotoxicity are present. While measuring enzyme activity
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by MR can be informative, an ideal GE MR contrast agent would be detectable directly, rather than
using catalytic activity as a proxy. Human protamine-1, an arginine-rich nuclear protein, is
detectable at high-μM concentrations via 1H CEST, and the contrast observed is sensitive to pH,
phosphorylation state, nucleotides, and heparin.[202,203] Also, superpositively-charged variants of
GFP possessing excess Arg and Lys side chains are detectable by 1H CEST.[204]
The sensitivities of these 1H-based GE contrast agents, though, are inherently limited by
the difficulty in overcoming the large pool of background protons in water and fat. [205] As with
synthetic contrast agents, the use of hp 129Xe as an alternative to 1H can improve the sensitivity of
GE MR contrast agents. Xe interactions with proteins, however, are generally weak and transient
(vide infra), making direct detection MR methods unfeasible. It is this transient nature, though, that
enables detection of Xe binding by hyper-CEST. The first GE contrast agent detectable by hyperCEST was reported in 2014 by Shapiro and coworkers, who showed that bacterial gas vesicles
(GVs) are detectable at picomolar concentrations.[206] GVs are large, proteinaceous gas
compartments expressed by bacteria to control buoyancy, and are assembled from a GV gene
cluster consisting of at least eight proteins. The chemical shift of 129Xe inside the gaseous GV interior
is significantly upfield of aqueous

129

Xe, and Xe exchange is slow enough to resolve an upfield

saturation response in the hyper-CEST z-spectrum. Moreover, GVs from different bacteria report
different saturation response frequencies, enabling multiplexing. However, the GVs are extremely
large (0.1–2 μm long), thus raising issues of cytotoxicity when overexpressed in cells. Moreover,
GV assembly requires multiple gene products, and to date GV expression in mammalian cells has
yet to be demonstrated.
Moving forward, the goal is to identify proteins that can ultimately act as GE MRI contrast
agents in mammalian cells (i.e., a GFP-analog for MRI) (Figure 1.10). Ideally, these proteins would
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meet several criteria: (1) non-mammalian origin (e.g., from E. coli), to reduce background contrast;
(2) no post-translational modifications or cofactors, allowing the protein to be expressed in diverse
cellular environments; (3) small and monomeric, thus simplifying transfection and improving
expression; (4) biologically orthogonal, meaning that the enzymatic activity and/or ligand-binding
properties of the contrast agent should not perturb the host cell. Although there are many proteins
that satisfy these general criteria, the larger challenge is finding proteins that possess suitable
binding and exchange properties with Xe to generate useful hyper-CEST contrast.
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Figure 1.10. Simplified scheme of Xe hyper-CEST with a protein contrast agent. Exchangeable
solute-bound Xe atoms that resonate at a frequency different from bulk hyperpolarized Xe are
selectively spin-flipped using RF irradiation. Rapid Xe exchange leads to the depolarization of bulk
Xe, thereby generating contrast detectable by NMR/MRI. Figure adapted with permission from
reference [207] published by The Royal Society of Chemistry.
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1.8 Xenon-protein interactions*
Xenon has long been known to possess a broad range of beneficial biological properties
(e.g., anesthesia, analgesia), and its interactions with proteins have been extensively characterized
by such methods as X-ray crystallography, hyperpolarized
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Xe NMR and other NMR methods,

manometry, computational chemistry, and activity assays. [208] Xenon is spherically symmetric with
zero net charge or dipole moment, limiting its interactions to those arising from charge-induced,
dipole-induced, and London (dispersion) forces. Xenon interacts with proteins via non-covalent,
low-energy van der Waals forces and is driven by the weak but favorable enthalpies of
absorption.[209,210] Xe is observed to occupy a wide range of sites in proteins, though typically it is
found in small hydrophobic cavities, predominantly lined with short hydrophobic residues such
as leucine, isoleucine, valine, and alanine.[211] Xe binding at these sites is generally weak (Ka < 200
M-1) and transient (koff > 105 s-1).[212] Notably, these buried hydrophobic cavities are usually devoid
of water.[213] Although the atomic packing density of proteins is comparable to the packing
efficiency observed in small organic crystals,[214] internal void spaces (a.k.a. cavities) are nearly
always present in proteins larger than one hundred residues. [215] Xe binding typically does not
perturb protein structure, making it useful for overcoming the phase problem in X-ray
crystallography.[216–221] Xe binding, however, can affect protein function by restricting the number
of available conformational states. This Xe-mediated restriction is observed in the loss of rotational
degrees of freedom of protein-bound waters.[222] More recently, it has been proposed that xenon

Parts of this section originally published in: Roose, B. W.; Zemerov, S. D.; Dmochowski, I. J. Xenon–Protein Interactions:
Characterization by X-Ray Crystallography and Hyper-CEST NMR. In Methods in Enzymology; Academic Press, 2018; Vol.
602, pp 249–272.
*
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can reduce the biological function of proteins through the formation of nanobubbles at
hydrophobic sites on or near the protein surface. [223]
Myoglobin is the protein whose interactions with Xe have been most extensively
characterized, and it serves as a useful case study for understanding protein-Xe interactions in
general. Sperm whale myoglobin[224] and horse hemoglobin[225] were the first proteins whose
structures were solved in the presence of Xe. At a Xe pressure of 2.5 bar, a single Xe atom was
observed to bind inside a pre-existing void space in the interior of myoglobin. It was later shown
that at 30 bar Xe pressure, four additional Xe atoms bind to myoglobin, though at low (< 0.3)
occupancies.[226] Computations based on crystallography coordinates determined favorable
enthalpic contributions of 0.6 - 4.2 kcal/mol for Xe binding to myoglobin.[210] The
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spectrum of myoglobin in solution shows a single broadened peak near the Xe@solvent frequency,
indicating that the population of myoglobin-bound xenon is small relative to the pool of dissolved
xenon, and that exchange between the two Xe pools is fast on the NMR timescale. [227] Increasing
the concentration of myoglobin in solution moves the chemical shift of the lone NMR peak either
upfield or downfield depending on the oxidation state and spin state of the heme Fe. [212] In silico
analysis of Xe-myoglobin interactions suggests that Xe exchange is controlled by complex gating
processes in which structural fluctuations within the protein control the rate of Xe access to the
buried interior binding cavity.[228,229] Finally, although Xe binding minimally perturbs myoglobin
structure, Xe (as well as nitrogen and cyclopropane) binding to myoglobin alters its function,
specifically its binding affinity for carbon monoxide.[230] It has been proposed that such functional
inhibition may result from xenon reorienting the proximal histidine (H93), xenon disrupting the
side chains that control ligand entry, and/or xenon rigidifying the protein.[231]

39

It should again be cautioned, though, that while there are many known Xe-binding
proteins in the literature, there are still significant challenges to developing GE contrast agents for
hyperpolarized Xe NMR and, eventually, MRI. The protein must possess a Xe binding site
sufficiently buried from solvent as to provide a significant chemical shift difference from Xe in
solvent. Xe must have appreciable affinity for the binding site, as well as exchange kinetics slow
enough (ideally on the ms timescale) to be resolved on the NMR timescale. As such, these
constraints have guided our group’s search for proteins suitable for detection using
CEST.
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Chapter 2: TEM-1 β-Lactamase†

2.1 Introduction
TEM1 β-lactamase (TEM1) is a 29 kDa enzyme that hydrolyzes β-lactam antibiotics to
confer antibiotic resistance to its host bacterium. Given its clinical relevance, the structure and
function of TEM1 has been well characterized in the literature.[232–234] Our group chose to investigate
TEM1 as a potential GE contrast agent for 129Xe hyper-CEST NMR because the protein possesses a
known cryptic allosteric site[235,236] whose small size and hydrophobicity make it a likely site for Xe
exchange. Moreover, TEM1 is a bacterial protein, thus minimizing background signal in
mammalian cells. TEM1 is nontoxic when overexpressed in eukaryotic cells, [237,238] and can be
engineered to be minimally immunogenic.[239] TEM1 is monomeric with no cofactors or posttranslational modifications, making it amenable to expression in non-native cellular environments.
As such, TEM1 has been widely employed in molecular biology, acting as an effective fluorogenic
reporter gene[240–245] and for studying protein-protein interactions via protein fragment
complementation assays.[246–249]
In 2016 our group demonstrated that TEM1 can serve effectively as a Xe hyper-CEST
contrast agent in vitro as well as in mammalian cells.[250] Our hyper-CEST experiments were
motivated by initial MD results showing high-occupancy Xe regions in the same cryptic allosteric
sites reported previously (Figure 2.1).[235,236] The hyper-CEST z-spectrum for 80 μM TEM1 showed
a saturation response 60 ppm downfield of the Xe(aq) peak resulting from the Xe-TEM1 interaction.

Portions of this chapter originally published in: (a) Wang, Y.; Roose, B. W.; Palovcak, E. J.; Carnevale, V.; Dmochowski, I.
J. A Genetically Encoded β-Lactamase Reporter for Ultrasensitive 129Xe NMR in Mammalian Cells. Angew. Chem. Int. Ed.
Engl. 2016, 55 (31), 8984–8987. (b) Roose, B. W.; Zemerov, S. D.; Wang, Y.; Kasimova, M. A.; Carnevale, V.; Dmochowski, I.
J. A Structural Basis for 129Xe Hyper-CEST Signal in TEM-1 β-lactamase. ChemPhysChem 2018, accepted.
†
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Time-dependent saturation transfer experiments with 100 nM (2.9 μg/mL) TEM1 generated 0.23 ±
0.02 saturation contrast, on par with the CEST contrast produced from bacterial gas vesicles when
normalized to protein mass concentration.[206] TEM1 present at 700 nM in transfected HEK293T/17
mammalian cells produced 0.13 ± 0.01 saturation contrast, thereby demonstrating the ability of
TEM1 to act as a useful GE contrast agent detectable by Xe hyper-CEST.
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Figure 2.1. TEM1 cartoon shaded from red (N-terminus) to blue (C-terminus). Density of Xe
(purple) throughout 1 μs of MD trajectory shows Xe preferring residence inside a buried cavity.
(Inset) Detailed view of the buried Xe binding site, with Xe shown as blue spheres and side chains
establishing van der Waals contacts with bound Xe shown as sticks. Figures reproduced with
permission from reference [250]. Copyright 2016 Wiley-VCH.
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However, the origin of such CEST contrast and mechanism of Xe exchange had yet to be
experimentally elucidated. Gaining additional insight regarding the structural basis for
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hyper-CEST signal in TEM1 can inform rational mutagenesis experiments to enhance MR contrast
as well as guide the search for novel genetically encoded hyper-CEST contrast agents. The XeTEM1 interaction was first characterized by X-ray crystallography, validating the location of the
high-occupancy Xe binding site predicted by our prior MD simulations. Protein mutagenesis
combined with additional X-ray crystallography experiments and MD simulations was employed
to further elucidate the structural basis for hyper-CEST response and identify the entry and egress
pathways of Xe. Mutations made to the major Xe binding site in TEM1 confirm its role in generating
the 60 ppm downfield shift observed in the hyper-CEST z-spectrum. Further analysis of Xe
exchange with these mutants by X-ray crystallography and MD simulations reveals additional
insights regarding the relationship between Xe-protein interactions and CEST. Additionally, these
insights motivated fragment complementation assays with TEM1 which suggest that proteinmediated TEM1 assembly can provide a means for detecting protein-protein interactions via 129Xe
hyper-CEST NMR/MRI.
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2.2 Materials and methods

2.2.1 TEM1 expression and purification
The codon-optimized gene for TEM-1 β-lactamase (TEM1) from Escherichia coli (UniProt
acc. no. P62593) was synthesized and cloned into a pJ411 vector by ATUM (formerly DNA 2.0). A
M182T substitution was incorporated into the TEM1 gene to stabilize the native state of the
protein.[233] BL21(DE3) E. coli competent cells were transformed with the TEM1-pJ411 plasmid and
cultured on a LB-agar plate supplemented with 50 μg/mL kanamycin. Single colonies of
transformed cells were used to inoculate 5 mL of LB medium supplemented with 50 μg/mL
kanamycin. The 5 mL cultures were incubated overnight at 37 °C with shaking at 250 rpm. The 5
mL cultures were used to inoculate 6 x 1 L of LB medium supplemented with 50 μg/mL kanamycin
in baffled culture flasks. The 1 L cell cultures were incubated at 37 °C with shaking at 250 rpm until
OD600

reached

~0.7.

Protein

expression

was

induced

by

adding

isopropyl-β-D-

thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The induced cultures were
incubated overnight at 18 °C with shaking at 250 rpm. The cells were pelleted by centrifugation
and frozen at -80 °C for long-term storage.
The cells were lysed by one round of freeze-thaw lysis[251] in 50 mM Tris (pH 8.0), 10% (v/v)
glycerol. The lysate was clarified by centrifugation and the supernatant was loaded onto three 5
mL HiTrap Q HP anion-exchange columns (GE Healthcare Life Sciences) connected in series and
pre-equilibrated with 50 mM Tris (pH 8.0), 10% (v/v) glycerol. Protein was eluted from the column
with 50 mM Tris (pH 8.0), 10% (v/v) glycerol supplemented with 3.0 M NaCl. The flow-through
and eluted fractions were evaluated by SDS-PAGE, and fractions containing TEM1 were pooled,
concentrated, and then loaded onto a HiLoad 16/600 Superdex size-exclusion column (GE
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Healthcare Life Sciences) pre-equilibrated with 50 mM Tris (pH 7.4). Fractions containing pure
TEM1 were pooled, and analysis by SDS-PAGE indicated that the protein was over 95% pure.
Protein concentration was determined by measuring absorbance at 280 nm using the extinction
coefficient (ε280 = 28 085 M-1 cm-1) calculated by the PROTPARAM server.[252]

2.2.2 Site-directed mutagenesis
Mutations were introduced to the TEM1 gene via site-directed mutagenesis using the
forward and reverse primers listed in Table 2.1. The mutated plasmids were amplified in NEB-5α
competent E. coli cells (New England Biolabs) and then purified using a miniprep kit (Qiagen). All
mutated MBP genes were sequenced at University of Pennsylvania DNA Sequencing Facility to
verify the incorporation of the desired mutation and the integrity of the gene sequence.
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Table 2.1. Oligonucleotide primers used in TEM1 site-directed mutagenesis

I263D

I263N

I263A

I263L

I279N

I282A

Forward primer

5’– GCATTGTTGTGGACTATACCACCGG –3’

Reverse primer

5’– CCGGTGGTATAGTCCACAACAATGC –3’

Forward primer

5’– CCGAGCCGCATTGTTGTGAACTATACCACCGGTAGC –3’

Reverse primer

5’– GCTACCGGTGGTATAGTTCACAACAATGCGGCTCGG –3’

Forward primer

5’– GCATTGTTGTGGCGTATACCACCGG –3’

Reverse primer

5’– CCGGTGGTATACGCCACAACAATGC –3’

Forward primer

5’– GCATTGTTGTGCTGTATACCACCGG –3’

Reverse primer

5’– CCGGTGGTATACAGCACAACAATGC –3’

Forward primer

5’– GCCACGATGGATGAGCGTAACCGTCAGAACGCTGAAATCGGTGCGAGC –3’

Reverse primer

5’– GCTCGCACCGATTTCAGCGTTCTGACGGTTACGCTCATCCATCGTGGC –3’

Forward primer

5’– CAGATTGCTGAAGCCGGTGCGAGCCTG –3’

Reverse primer

5’– CAGGCTCGCACCGGCTTCAGCAATCTG –3’
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2.2.3 129Xe hyper-CEST spectroscopy
129

Xe was hyperpolarized (hp) and hyper-CEST z-spectra were acquired as follows: hp 129Xe

was generated using the spin-exchange optical pumping (SEOP) method with a home-built

129

Xe

polarizer based on the IGI.Xe.2000 commercial model by GE. A Shark 65 W tunable ultra-narrow
band diode laser (OptiGrate) set to 795 nm was used for optical pumping of Rb vapor. A gas
mixture of 89% helium, 10% nitrogen, and 1% natural abundance xenon (Linde Group, NJ) was
used as the hyperpolarizer input. 129Xe hyperpolarization level was roughly 10-15%. For each data
point in the hyper-CEST z-spectra, hp 129Xe was bubbled into the NMR tube through capillaries for
20 s, followed by a 3 s delay to allow bubbles to collapse. A Dsnob saturation pulse with 690 Hz
bandwidth was used, where pulse length τpulse = 3.80 ms, field strength B1,max = 77 μT, number of
pulses npulse = 400, and saturation time (tsat) = 1.52 s. NMR experiments were performed at 300 K
using a Bruker BioDRX 500 MHz NMR spectrometer and 10 mm PABBO probe. A 90° hard pulse
of this probe has a pulse length of 22 μs. For all z-spectra experiments, the protein concentration
was 80 μM, with 0.1% (v/v) Pluronic L81 (Aldrich) added to mitigate foaming.

2.2.4 Protein crystallization and Xe derivatization
Crystals of WT TEM1 were grown at 294 K by the hanging drop vapor diffusion method.
4 μL of 5 mg/mL TEM1 in 10-50 mM Tris (pH 7.0) was mixed with 4 μL of precipitant solution
consisting of 2% (v/v) tacsimate (pH 6.0), 0.1 M Bis-Tris (pH 6.5), 20% (w/v) PEG 3350 and
suspended over a 1 mL reservoir of precipitant solution. The hanging drop was streak seeded with
WT TEM1 microcrystals. Crystals of I263L TEM1 were also grown at 294 K by the hanging drop
vapor diffusion method. 5 μL of 7 mg/mL I263L TEM1 in 50 mM Tris (pH 7.4) was mixed with 5
μL of the same precipitant solution used to crystallize WT TEM1 and suspended over a 1 mL
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reservoir of precipitant solution. Crystals of I263N TEM1 were grown at 294 K by the sitting drop
vapor diffusion method. 500 nL of 7 mg/mL I263N TEM1 in 50 mM Tris (pH 7.4) was mixed with
500 nL of precipitant solution consisting of 0.2 M sodium formate (pH 7.0), 20% (w/v) PEG 3350
and suspended over an 80 μL reservoir of precipitant solution. The I263N TEM1 crystals later used
for Xe derivatization were grown at 294 K by the hanging drop vapor diffusion. 1 μL of 5 mg/mL
I263N TEM1 in 50 mM Tris (pH 7.4) was mixed with 1 μL of precipitant solution consisting of 0.2
M sodium formate (pH 7.0), 20% (w/v) PEG 3350 and suspended over a 1 mL reservoir of
precipitant solution. Crystals of I263A TEM1 were grown at 294 K by the sitting drop vapor
diffusion method. 500 nL of 10 mg/mL I263A TEM1 in 50 mM Tris (pH 7.4) was mixed with 500 nL
of precipitant solution consisting of 2% (v/v) tacsimate (pH 6.0), 0.1 M Bis-Tris (pH 6.5), 20% (w/v)
PEG 3350 suspended over an 80 μL reservoir of precipitant solution. The I263A TEM1 crystals used
for Xe derivatization were grown at 294 K by the sitting drop vapor diffusion method. 4 μL of 10
mg/mL I263A TEM1 in 50 mM Tris (pH 7.4) was mixed with 4 μL of precipitant solution consisting
of 2% (v/v) tacsimate (pH 6.0), 0.1 M Bis-Tris (pH 6.5), 20% (w/v) PEG 3350 and suspended over a
0.5 mL reservoir of precipitant solution. The sitting drop was streak seeded with WT TEM1
microcrystals.
TEM1 crystals were flash-cooled in liquid nitrogen after being briefly immersed in
cryoprotectant solution consisting of precipitant solution supplemented with either 30% (v/v)
glycerol or 15% (w/v) (+/-)-2-methyl-2,4-pentanediol (MPD) and 15% (v/v) PEG 400. Xe derivatives
were prepared by sealing the cryoprotected TEM1 crystal inside a xenon derivatization chamber
(Hampton Research) and incubating the crystal with pressurized Xe (AirGas) at 1.2 MPa for 15
minutes. Following Xe incubation, the derivatized crystal was removed from the chamber and
immediately flash-cooled in liquid nitrogen.
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2.2.5 X-ray data collection and structure refinement
X-ray diffraction data were collected remotely at the following beamlines: beamline 4.2.2
of the Advanced Light Source (ALS) synchrotron at the Lawrence Berkeley National Laboratory;
beamlines 24ID-C and 24ID-E of the Advanced Photon Source (APS) synchrotron at the Argonne
National Laboratory; beamline 14-1 at the Stanford Synchrotron Radiation Lightsource (SSRL) of
the National Accelerator Laboratory. All diffraction data were collected at 100 K. Diffraction
images were indexed and integrated with either XDS [253] or iMosflm[254] and then processed by
AIMLESS[255] in the CCP4 suite of programs.[256] The structure of native TEM1 was solved by
molecular replacement in Phaser[257] using a high-resolution TEM1 structure (PDB ID 1BTL)[258] less
the solvent and ions as a search model. All other TEM1 structures were phased by molecular
replacement using the refined model of native TEM1 (PDB ID 5HVI) less the solvent and ions as
the search model. Iterative cycles of refinement and manual model adjustments were performed
using PHENIX (version 1.9)[259,260] and COOT (version 0.8.1),[261,262] respectively. Translationlibration-screw (TLS) refinement was performed during the later stages of refinement using TLS
groups determined by PHENIX. Xe atoms were identified by inspection of electron density peaks
in isomorphous Fourier difference maps generated from the structure factor amplitudes |F Xe| |Fnative| and phases from the refined model of native protein. The occupancies of Xe atoms were
calculated using a combination of occupancy and B-factor refinement. Disordered protein atoms
showing no electron density in the 2Fo-Fc map were deleted from the protein model, and electron
density peaks that were not confidently interpretable were left unmodeled. Refinement proceeded
until Rfree converged at its lower limit. The quality of the final models were assessed using
MolProbity.[263] Data collection and refinement statistics are presented in Table 2.2. All structure
figures were generated using PyMOL.[264]
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Structural superpositions and root-mean-square deviation (rmsd) measurements were
performed using the SuperPose (v. 1.0) server.[265] Protein cavity volumes were measured using
Swiss-PdbViewer (v. 4.1.0).[266] Input structures consisted of PDB coordinate files from which all
water molecules and Xe atoms had been removed.
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Table 2.2. X-ray data collection and refinement statistics

beamline
wavelength (Å)
resolution limits (Å)

TEM1

TEM1-Xe

TEM1
(I263L)

TEM1
(I263L)-Xe

TEM1
(I263N)

TEM1
(I263N)-Xe

TEM1
(I263A)

TEM1
(I263A)-Xe

ALS 4.2.2

APS 24ID-E

SSRL 14-1

SSRL 14-1

APS 24ID-C

SSRL 14-1

APS 24ID-E

APS 24ID-E

1.000

0.979

1.181

1.181

0.979

1.181

0.979

0.979

63.20-1.64
(1.67-1.64)

51.27-1.70
(1.73-1.70)

62.92-1.82
(1.85-1.82)

43.65-1.50
(1.53-1.50)

95.78-1.75
(1.78-1.75)

63.36-1.95
(2.00-1.95)

95.91-1.86
(1.90-1.86)

95.97-1.44
(1.46-1.44)

unit cell
space group
a, b, c (Å)
α, β, γ (°)
no. of total/unique
reflections
redundancya
Rmergea,b
Rpima,c
CC1/2a,d

P21

P21

P21

P21

P21

P21

P21

P21

60.7, 84.2,
95.7
90.0, 90.1,
90.0

60.7, 84.6,
95.9
90.0, 90.1,
90.0

60.5, 84.0,
94.9
90.0, 90.4,
90.0

60.4, 84.1,
95.6
90.0, 90.0,
90.0

60.0, 83.5,
95.8
90.0, 90.1,
90.0

60.1, 84.2,
96.2
90.0, 90.0,
90.0

60.1, 84.3,
95.9
90.0, 90.0,
90.0

60.7, 84.8,
96.0
90.0, 90.2,
90.0

409738/
113836

752752/
106586

314492/
82018

544324/
148928

635352/
93490

258898/
68222

540260/
79520

1138030/
174485

3.6 (3.4)

7.1 (7.1)

3.8 (3.8)

3.7 (3.6)

6.8 (6.6)

3.8 (3.8)

6.8 (6.4)

6.5 (6.1)

0.05 (0.30)

0.09 (0.32)

0.11 (0.40)

0.07 (0.32)

0.15 (0.75)

0.14 (0.56)

0.15 (0.47)

0.14 (1.16)

0.05 (0.26)

0.06 (0.20)

0.10 (0.35)

0.06 (0.27)

0.06 (0.34)

0.12 (0.48)

0.10 (0.31)

0.09 (0.78)

0.998 (0.927)

0.998 (0.962)

0.987 (0.848)

0.996 (0.904)

0.995 (0.868)

0.985 (0.875)

0.992 (0.936)

0.996 (0.657)

I/σ(I)a

15.1 (3.4)

13.1 (5.6)

6.3 (2.3)

9.0 (2.8)

10.3 (3.1)

7.2 (3.1)

8.7 (3.6)

7.5 (1.6)

completeness (%)a

96.9 (89.6)

100.0 (100.0)

96.5 (94.8)

97.7 (95.6)

98.3 (97.7)

97.8 (96.3)

98.2 (97.4)

99.6 (99.3)

Rworke

0.17

0.15

0.18

0.17

0.17

0.18

0.21

0.20

Rfreef

0.21

0.19

0.23

0.19

0.22

0.22

0.25

0.22

protein chainsg

4

4

4

4

4

4

4

4

protein atomsg

8082

8038

8056

8079

8042

7998

8023

7996

water moleculesg

967

812

558

1210

806

608

1019

1015

0

13

0

13

0

8

0

14

bonds (Å)

0.008

0.009

0.011

0.008

0.007

0.005

0.002

0.006

angles (°)

1.13

1.20

1.14

0.99

1.06

0.85

0.61

1.05

Xe atomsg
root-mean-square
deviations

average B factors (Å2)
protein

11

9

11

10

14

12

11

14

water

22

18

15

19

24

21

17

28

-

15

-

15

-

21

-

19

favored

98.1

98.0

97.2

97.5

98.0

97.1

96.7

97.8

allowed

1.9

2.0

2.8
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Rmerge = ∑|Ih – ⟨Ih⟩|/∑⟨Ih⟩; Ih = intensity measure for reflection h; ⟨Ih⟩ = average intensity for reflection h calculated from replicate data.
c Rpim = ∑(1/(n – 1)1/2|Ih - ⟨Ih⟩|/∑⟨Ih⟩; n = number of observations (redundancy).
d CC1/2 = στ2/(στ2 + σε2), where στ2 is the true measurement error variance and σε2 is the independent measurement error variance.
e Rwork = ∑||Fo| - |Fc||/∑|Fo| for reflections contained in the working set. |F o| and |Fc| are the observed and calculated structure factor amplitudes,
respectively.
f Rfree = ∑||Fo| - |Fc||/∑|Fo| for reflections contained in the test set held aside during refinement (5% of total).
g per asymmetric unit
a

b

h calculated

by MolProbity
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2.2.6 Circular dichroism (CD) spectroscopy
The CD spectra of WT TEM1 and pre- and post- hyper-CEST TEM1(I263A) and
TEM1(I279N) samples were acquired as described prevsiously.[250] Briefly, measurements were
taken using a 1 mm quartz cuvette on an AVIV model 425 circular dichroism spectrometer. The
samples consisted of 10 μM protein in 10 mM sodium phosphate (pH 8.0). CD spectra were
acquired at 298 K with a wavelength step of 1 nm. The CD spectra of all prepared TEM1 mutants
were measured using a Jasco J-1500 CD spectrometer equipped with a Peltier temperature
controller. Protein was diluted to 10 μM in 10 mM sodium phosphate (pH 8.0) and analyzed using
a quartz cuvette with a 1 mm path length (Figure 2.2).
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Figure 2.2. (Top) CD spectra of TEM1 mutants I263A and I279N before and after hyper-CEST. The
spectrum of WT TEM1 is included for reference. (Bottom) CD spectra of WT TEM1 and mutants.
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2.2.7 Thermal stability measurements
CD spectroscopy experiments to measure protein thermal stability were performed using
a Jasco J-1500 CD spectrometer equipped with a Peltier temperature controller. Protein was diluted
to 10 μM in 10 mM sodium phosphate (pH 8.0) and analyzed using a quartz cuvette with a 1 mm
path length. The protein sample temperature was initially increased from 10 to 90 °C at a rate of
0.5 °C/min. Secondary structure was monitored at 222 nm with a step size of 1 °C and data
integration time of 8 s. Thermal denaturation assays were repeated twice more for each protein,
but with the temperature range changed to 20 to 70 °C. Data were analyzed and melting
temperature (Tm) was calculated using the Spectra Analysis tool in the J-1500 CD spectrometer
software package (Jasco).
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Table 2.3. Thermal stabilities of TEM1 variants

a

Protein

Tm (C)a

WT

55.4 ± 0.7

I263L

51.3 ± 0.1

I263A

49.4 ± 0.5

I263N

46.8 ± 0.9

I279N

47.0 ± 0.3

I282A

47.5 ± 0.5

Data reported as mean ± standard deviation (n=3)
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2.2.8 Activity assays
The hydrolase activities of 5 nM TEM1(I263A)[250] and TEM1(I279N) were measured in 50
mM Tris (pH 7.4), 5% (v/v) DMSO using 450 μM nitrocefin (EMD Millipore) as a substrate. Product
formation was monitored at A482 using an Infinite M1000 Pro plate reader (Tecan). The assays were
performed in triplicate for pre- and post- hyper-CEST TEM1(I263A) and TEM1(I279N) samples.

2.2.9 Molecular dynamics (MD) simulations
MD simulations were performed in collaboration with the lab of Dr. Vincenzo Carnevale
at the Institute for Computational Molecular Science at Temple University. All MD simulations
were performed using the CHARMM36 force field.[267] Water molecules were described using the
TIP3P model.[268] Periodic boundary conditions were employed for all of the MD simulations, and
the long range electrostatic interactions were evaluated using the particle-mesh Ewald method. [269]
The lengths of all bonds containing hydrogen were constrained with the SHAKE algorithm. [270] The
system was maintained at a temperature of 300 K and pressure of 1 atm using the Langevin
thermostat and barostat methods as implemented in the MD code NAMD2.12,[271] which was used
for the simulations with a 2.0 fs time step.

2.2.10 TEM1 fragment assembly
Codon-optimized versions of the TEM-1 β-lactamase (TEM1) enzyme fragments reported
by Wehrman et al.[247] were synthesized by GenScript and cloned into a pRSFDuet-1 expression
vector (Novagen) under the control of a T7 promoter (Figure 2.3). The first fragment, T1Fα,
consisted of TEM1 residues 26 through 197, followed by a stabilizing Asn-Gly-Arg tripeptide,
(GGGGS)3 linker repeat, then a c-Fos helix sequence (UniProt acc. no. P01100). The second
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fragment, T1Fω, consisted of TEM1 residues 198 through 290, followed by a (GGGGS) 3 linker and
then a c-Jun helix sequence (UniProt acc. no. P05412). The sequences for the Fos-Jun leucine zipper
domain were referenced from Ransone et al.[272]
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T1Fα
T1Fω

TEM1 (26-197)

c-Jun

NGR

(GGGS)3

Figure 2.3. TEM-1 β-lactamase fragment (T1F) constructs
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(GGGS)3

TEM1 (198-290)

c-Fos

A STOP codon was inserted into the T1Fα gene between the (GGGS) 3 and c-Fos sequences
via site-directed mutagenesis using the forward and reverse primers listed in Table 2.4. The
mutated plasmid was amplified in NEB-5α competent E. coli cells (New England Biolabs) and then
purified using a miniprep kit (Qiagen). The mutated T1Fα gene was sequenced at University of
Pennsylvania DNA Sequencing Facility to verify the incorporation of the desired mutation and the
integrity of the remaining gene sequence.
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Table 2.4. Oligonucleotide primers used in T1Fα site-directed mutagenesis

STOP_c-Fos

Forward primer

5’– GGCAGCGGTGGCGGTGGCAGCTAAGATACCCTGCAGGCGGAAACC –3’

Reverse primer

5’– GGTTTCCGCCTGCAGGGTATCTTAGCTGCCACCGCCACCGCTGCC –3’
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The plasmid encoding the full-length T1Fα and T1Fω sequences was transformed into
BL21(DE3) E. coli competent cells. The cells were cultured on a LB-agar plate supplemented with
50 μg/mL kanamycin. A single colony of transformed cells was used to inoculate 5 mL of LB
supplemented with 50 μg/mL kanamycin. The 5 mL culture was incubated overnight at 37 °C with
shaking at 250 rpm. The 5 mL cultures were used to inoculate 2 x 1 L of LB medium supplemented
with 50 μg/mL kanamycin in baffled culture flasks. The 1 L cell cultures were incubated at 37 °C
with shaking at 250 rpm until OD600 reached 0.6-0.8. One flask was set aside and stored at 4 °C,
while

protein

expression

the

other

flask

was

induced

by

adding

isopropyl-β-D-

thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM. The induced culture was
incubated overnight at 18 °C with shaking at 250 rpm. The next morning cells from both flasks
were pelleted, washed in cold PBS, and then diluted in cold PBS to a OD600 of 1. The same cell
preparation procedure was followed with plasmid encoding the truncated (i.e. no c-Fos) T1Fα
sequence and full-length T1Fω sequence.
The concentrations of assembled, active TEM1 in the E. coli samples were measured by
activity assay. E. coli were lysed with B-PER Complete Bacterial Protein Extraction Reagent
(Thermo) and clarified to isolate soluble protein. Activity assays were performed at rt in 50 mM
potassium phosphate (pH 7.0), 10% (v/v) glycerol, 2.2% (v/v) DMSO using 200 μM nitrocefin as
substrate. Product formation was measured by absorbance at 412 nm. The activity of 100 nM TEM1
was used as a benchmark for determining concentration.
Saturation transfer experiments with E. coli were performed as previously described.[250]
Briefly, saturation frequencies of d-SNOB-shaped pulses were positioned +60 ppm and -60 ppm,
referenced to the Xe(aq) peak, for on- and off-resonance, respectively. Pulse length, τ pulse = 1.0496 ms;
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field strength, B1,max = 279 μT. Both on-resonance and off-resonance data were fitted with first-order
exponential decay curves.
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2.3 Results and discussion

2.3.1 Xe binding to TEM1
The Xe derivative of wild-type (WT) TEM1 was isomorphous to native protein, with a rootmean-square deviation (rmsd) of 0.11 Å between the Cα positions of the native and Xe-derivative
crystal structures. TEM1 crystallized as a tetramer, and three Xe atoms (hereafter designated Xe1,
Xe2, and Xe3) were observed at the same positions in all four TEM1 molecules in the asymmetric
unit. Density present in the anomalous Fourier map further confirmed the presence of Xe at these
three sites. Because Xe binding was nearly identical among all four TEM1 chains, for simplicity a
representative TEM1 molecule (chain A in the crystal structure) is discussed in the remainder of
this chapter.
The protein side chains surrounding Xe1, Xe2, and Xe3 are predominantly hydrophobic
(Figures 2.4 and 2.5) and are within van der Waals distances of the bound Xe. Notably, none of the
three Xe binding sites contains water in the native TEM1 structure, indicating that Xe binding is
not driven by hydrophobic stabilization – an observation consistent with Xe binding to
myoglobin.[224] Additionally, computational studies of Xe binding to organic host molecules such
as cryptophane concluded that the occupancy of water molecules in the hydrophobic interior of
the cryptophane is anti-correlated to the free energy of Xe binding. [273] The TEM1-Xe complex
shows an additional Xe atom, Xe4, bound at the interface between protein chains A and D. Xe4,
however, is likely an artifact of crystal packing given its proximity to the protein surface and the
fact that Xe4 is enclosed by neighboring TEM1 molecules in the crystal structure.
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Figure 2.4. Chain A of the TEM1-Xe complex (PDB ID 5HW1), with Xe shown as red spheres (van
der Waals radii enlarged for clarity). (Inset) Xe1 binding site, with surrounding protein side chains
shown as sticks (Xe-derivative in gray, native TEM1 in cyan). Gray dashes indicate protein-Xe
contacts within 4.5 Å. Isomorphous difference Fourier map for Xe1 shown as blue mesh and
contoured at 10 σ.
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Figure 2.5. Isomorphous difference maps of Xe2 and Xe3. TEM1 complexed with Xe shown in gray
with residues lining the Xe binding pockets shown as sticks. (a) Xe2 shown as a red sphere. The
isomorphous difference Fourier map shown as blue mesh contoured at 7 σ. (b) Xe3 shown as a red
sphere. The isomorphous difference Fourier map shown as blue mesh contoured at 4 σ.
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During structural refinement of the Xe-TEM1 model, Xe1 converged to the highest average
occupancy (68%), whereas Xe2 and Xe3 converged to average occupancies of 21% and 10%,
respectively. That these occupancies sum to nearly 100% is likely coincidental, as the three Xe
binding sites are far enough apart within TEM1 that it is highly unlikely that Xe binding is mutually
exclusive. Nevertheless, future crystallization experiments in which Xe pressure and incubation
time is systematically varied may prove informative. The much higher occupancy of Xe1 indicates
that the Xe1 cavity represents the predominant site of Xe exchange in TEM1. From the occupancy
of Xe1, the association constant (Ka) of Xe1 is estimated to be roughly 40 M-1, approximating a
solubility of Xe in solution of 4.4 mM atm -1.[274] This Ka for Xe is comparable to the experimentallydetermined Ka values for Xe binding to MBP and T4 lysozyme, which are 20 ± 10 M -1 and 60.2 ± 0.2
M-1, respectively.[274] Xe1 lies at the terminus of a cryptic (i.e., not visible in the native TEM1
structure) channel lined by predominantly hydrophobic side chains. This hydrophobic channel is
the same one uncovered in crystal structures of TEM1 complexed with allosteric inhibitors. [235] The
back wall of the Xe1 cavity consists of residues A36, L40, and V44, flanked by T265 and Q278. The
methylenes of the R275 side chain cap the binding site, shielding Xe1 from solvent. Three isoleucine
side chains – I263, I282, and I279 – separate the Xe1 cavity from the rest of the hydrophobic channel
and together comprise the entry portal for Xe1 binding. Notably, the positions and conformations
of the side chains surrounding Xe1 are nearly identical in native and Xe-derivatized TEM1,
revealing that the native conformation of TEM1 has a pre-existing cavity capable of
accommodating Xe. The refined B-factor of Xe1 is 11.0 Å2, and the average B-factor of protein atoms
within 6 Å of Xe1 is 7.8 Å2. These comparable thermal mobility values indicate that Xe1 is well
localized in the pocket, as expected given that the van der Waals volume of Xe is approximately 42
Å3 and the Xe1 cavity volume is 62 Å3.
67

2.3.2 Allostery with the active site
To further probe the structural dynamics of the Xe1 cavity, the

129

Xe hyper-CEST z-

spectrum of TEM1 was acquired in the presence of the competitive β-lactamase inhibitor
tazobactam (Ki = 20 nM).[275] We hypothesized that because ligand binding at the Xe1 site affects the
hydrolytic activity of TEM1,[235,236] inhibitor binding at the active site should have some measurable
effect on Xe1 binding and exchange. Indeed, the z-spectrum of TEM1 complexed with tazobactam
shows broadening of the Xe-TEM1 peak (Figure 2.6), indicative of faster Xe exchange between
protein and solvent. This result suggests that inhibitor binding at the active site of TEM1 increases
the accessibility of the Xe1 cavity through the allosteric mechanism identified by Horn et al. [235]
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Figure 2.6. 129Xe hyper-CEST z-spectra of 80 μM TEM1 in pH 7.2 PBS at 300 K. Unliganded TEM1
(red) compared to TEM1 in the presence of 1 mM tazobactam (green). Z-spectrum of PBS only
(gray) shown for reference. Pulse length, τpulse = 3.80 ms; field strength, B1,max = 77 μT.
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2.3.3 Mechanism of Xe1 exchange
The results of our X-ray crystallography experiments were compared to our prior Xe-TEM1
MD simulations.[250] These MD simulations were performed in the presence of an excess of Xe (i.e.,
“flooding”) for a 1 μs trajectory. The atomic coordinates of unliganded TEM1 (PDB ID 1BTL) [258]
were used as the starting point of the simulation. At the outset of the simulation, TEM1 remained
in its closed conformation with the position of the C-terminal α-helix (helix 12) blocking Xe access
to the protein interior. Over the course of the simulation, helix 12 moved away from helix 11 and
the nearby β-sheet wall to allow Xe entry to the hydrophobic channel leading to the Xe1 cavity.
Inspection of the Xe density map through the final 400 ns of the trajectory reveals a continuous
“Y”-shaped density throughout the channel, revealing pathways of Xe exchange (Figure 2.7). There
are two distinct Xe entry points into the hydrophobic channel. Xe can pass either above or below
the contact point between helices 11 and 12. Both pathways converge into a single route leading to
the Xe1 cavity at the terminus of the hydrophobic channel. The contours of the Xe density
approximate the hydrophobic moieties of detergent-like ligands complexed with TEM1. [235] The Xe
density shows discrete lobes along this pathway, suggesting that the outward movement of helix
12 leads to the formation of a series of connected cavities that transiently bind Xe. Our X-ray
crystallography experiments affirm the results of the MD simulations, as Xe3 is positioned at the
entrance to one of these exchange pathways and Xe1 lies at the terminus of the Xe density.
Although our MD simulations did not predict the binding of Xe2, this binding site was recently
identified as a cryptic pocket in TEM1 using Markov State Models. [276]
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Figure 2.7. Xe occupancy map calculated from a 1 μs trajectory (only the last 400 ns included in the
map). Blue shading is the density at an arbitrary isovalue. Red spheres are Xe atoms from a
representative frame of the MD trajectory. Yellow spheres are Xe atoms found in the Xe-derivative
crystal structure of WT TEM1.
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Inspection of the Xe-TEM1 crystal shows no open pathway from the protein surface to the
Xe1 cavity. Xe1 binding therefore involves dynamic fluctuations of the protein structure to allow
Xe access to this buried cavity, an observation made previously to rationalize Xe binding to
collagenase.[277] Comparison of an “open” TEM1 structure complexed with an allosteric inhibitor
(PDB ID 1PZO)[235] to the structure of unliganded TEM1 complexed with Xe (PDB ID 5HW1) shows
that the side chains of I263 and I279 shift roughly 1.3 Å apart, thereby allowing access to the Xe1
cavity (Figure 2.8a). This expansion allows ~3 Xe atoms to simultaneously occupy the cavity based
on the results of the MD simulation (Figure 2.8b, c), though at present there is no experimental
evidence corroborating the simultaneous presence of multiple Xe atoms inside the Xe1 cavity.
Inspection of the dynamic distance between I263 and I279 through the MD trajectory reveals that
approximately halfway through the 1 μs trajectory, the distance between I263 and I279 sharply
increases – a conformation change that coincides with Xe access to the Xe1 cavity. The transient
widening of this “isoleucine portal” controls the rate of Xe1 entry and likely plays an integral role
in the hyper-CEST mechanism.
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Figure 2.8. (a) Xe1 shown as a red sphere, with nearby side chains shown as sticks (Xe-derivative
in gray, “open” TEM1 bound to allosteric inhibitor in magenta). (b) Number of Xe atoms in the
major binding site correlated to the minimum distance between I263 and I279 (minimum among
all possible pairwise atom-atom distances). (c) Number of Xe atoms in the major binding site anticorrelated to the number of atom-atom contacts between I263 and I279.
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2.3.4 CEST contrast originates from Xe1
At this point the following conclusions were drawn from our X-ray crystallography
experiments and MD simulations: (1) TEM1 possesses a high-affinity Xe binding site at the Xe1
cavity; (2) up to three Xe atoms can simultaneously occupy this cavity; (3) Xe exchange is coupled
to local protein conformation and is relatively slow. These observations support our initial
hypothesis that Xe exchange at the Xe1 cavity gives rise to the unusual 60 ppm shift observed in
the 129Xe hyper-CEST z-spectrum. To further test this hypothesis, a series of single point mutations
were introduced to TEM1 to perturb Xe1 affinity and/or exchange rates and pathways (Figure 2.9).
Residues I263 and I279 were chosen because they regulate Xe access to the Xe1 cavity, and likely
affect binding affinity as well. I263 was mutated to leucine, asparagine, aspartate, and alanine, and
I279 was mutated to asparagine. Residue I282, which also makes van der Waals contacts with Xe1,
was mutated to alanine. All TEM1 mutants, with exception of I263D (which expressed exclusively
as insoluble inclusion bodies), expressed at levels comparable to WT and were purified following
the same procedure. TEM1 mutants were characterized by circular dichroism (CD) to verify proper
folding, and the CD thermal melts were performed to assess the effects of the point mutations on
protein stability.
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Figure 2.9. Xe1 cavity of the Xe-derivative of WT TEM1, with mutated side chains highlighted in
green. Closest side chain contacts to Xe1 shown in Å.
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The

129

Xe hyper-CEST z-spectra of the TEM1 mutants were acquired following the same

protocol used for WT (Figure 2.10). The I263A and I279N mutants showed complete loss of
downfield CEST contrast; CD and activity assays performed pre- and post-CEST verified that loss
of contrast was not the result of protein denaturation during hyper-CEST. The z-spectra of I263A
and I279N still showed broadening of the

129

Xe(aq) peak relative to PBS alone, characteristic of a

chemical exchange mechanism contributing to a magnetic susceptibility difference between TEM1bound and solvent-bound Xe.[206] These spectral data indicate that Xe binding to the I263A and I279
mutants is preserved, but at a more rapid exchange rate compared to WT TEM1.
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Figure 2.10. 129Xe hyper-CEST z-spectra of 80 μM TEM1 in pH 7.2 PBS at 300 K. TEM1 mutants
(various colors) compared to WT TEM1 (red). Z-spectrum of PBS only (gray) shown for reference.
Pulse length, τpulse = 3.80 ms; field strength, B1,max = 77 μT.
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The I282A and I263N mutants showed appreciable CEST contrast at 255 ppm (60 ppm
saturation offset), although at roughly half the intensity of WT TEM1, suggesting that while Xe1
binding is preserved, these alterations to the Xe1 cavity adversely affect binding affinity and/or Xe
exchange rates. The signal from I263L at 255 ppm, on the other hand, was only slightly lower than
WT, as might be expected from this minor structural perturbation. An unusual feature of the zspectra of I282A, I263N, and I263L is the broadened signal between 255 and 195 ppm. The spectrum
of WT can be deconvolved into two peaks: 255 ppm for Xe-TEM1, and 195 ppm for Xe-solvent (the
minor peak at 235 ppm was interpreted as an artifact). The TEM1 mutants, however, show only a
peak at 195 ppm with significant asymmetric broadening towards 255 ppm. The z-spectra of these
mutants remeasured at 10 uM protein concentration verified the lack of downfield saturation
response. The signal arising from this “intermediate” range can be interpreted as resulting from Xe
bound to TEM1 but not fully shielded from solvent. Collectively, these TEM1 mutant z-spectra
confirm that Xe1 is the origin of TEM1’s unique hyper-CEST signal at 255 ppm.

78

2.3.5 Xe binding to TEM1 mutants
To further investigate the structural basis of

129

Xe hyper-CEST signal, X-ray

crystallography experiments were performed on three representative TEM1 mutants – I263A (total
loss of contrast); I263N (major loss of contrast), and I263L (minor loss of contrast). Native protein
crystals were derivatized with Xe following the same procedure used for WT. Xe1 binding was
preserved for all three mutants (Figure 2.11). The occupancy of Xe1 bound to I263L is on par with
WT (83% vs. 68%), whereas the occupancies of Xe1 bound to I263N and I263A are 33% and 34%,
respectively. In the I263N mutant, the carboxamide nitrogen of N263 donates a hydrogen bond to
the carbonyl oxygen of G45, orienting the carboxamide directly towards Xe1 and shifting its
location slightly compared to Xe1 bound to WT. It is worth noting that despite the presence of the
asparagine side chain inside the Xe1 pocket, no water was observed in the native I263N structure,
highlighting the hydrophobicity of this buried cavity.
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Figure 2.11. Xe1 and Xe5 (red spheres) bound to TEM1 mutants I263L (a), I263N (b), and I263A (c),
with distances shown in units Å. Isomorphous difference maps corresponding to Xe shown as blue
mesh and contoured at 5 σ. Simulated annealing (SA) omit maps corresponding to mutated I263L
and I263N side chains shown as green mesh and contoured at 3 σ. The I263 side chain of WT TEM1
(yellow sticks) and Xe bound to WT TEM1 (yellow sphere) shown for reference.
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Remarkably, the crystal structures of all three mutants revealed a new cavity capable of
binding Xe (hereafter designated Xe5). Similar to the binding sites of Xe1, Xe2, and Xe3, Xe5 is
predominantly lined by hydrophobic residues. Inspection of the WT structure shows that Xe5
binding is effectively blocked by the γ1 and δ carbons of the I263 side chain. The occupancies of
Xe5 are 22%, 28%, and 35% in the I263L, I263N, and I263A mutants, respectively (Table 2.5).
Notably, the B-factors of Xe5 are on par with the B-factors of nearby protein atoms, indicating that
Xe5 is well-localized inside the cavity. Xe5 is positioned between Xe1, which is completely shielded
from solvent, and Xe3, which lies at the entrance of the hydrophobic channel. Xe5 is therefore
expected to produce a chemical shift somewhere between 255 and 195 ppm. The presence of Xe5
bound to I263L and I263N can explain the broadened CEST response of these mutants. The Xe
interaction with WT TEM1 can be approximated as a two-state system, where Xe is either aqueous
or bound in the Xe1 cavity. However, for I263L and I263N, Xe can transiently occupy an
intermediate binding site in the hydrophobic channel connecting the protein core to solvent.
Finally, it is revealing that the I263A mutant reports no CEST contrast even though Xe
binding at the Xe1 and Xe5 cavities is preserved. This result highlights a fundamental feature of
protein hyper-CEST: Xe binding does not guarantee useful MR contrast. Rather, the kinetics of Xe
exchange plays a more critical role in determining CEST contrast. The importance of Xe exchange
kinetics has also been observed in other systems, notably MBP where our group demonstrated that
the protein must adopt a maltose-bound, closed conformation to slow Xe exchange and report
CEST contrast.[207] Additionally, hyper-CEST experiments with sperm-whale myoglobin, the
protein with the highest known affinity for Xe (Ka = 190 M-1),[212] have shown that no downfield
saturation response is observed (unpublished data), likely due to fast exchange (koff = 1.5 x 105 s).

1 [212]
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Table 2.5. Xe atom statistics in WT TEM1-Xe crystal structure

Xe

Xe1

Xe2

Xe3

Chain

Occupancy (%)

B-factor (Å2)

A

65

11.0

B

72

9.9

C

67

12.3

D

67

11.5

Avg.

68

11

A

26

21.5

B

17

14.1

C

19

16.0

D

20

32.2

Avg.

21

21

A

10

10

B

6

6.0

C

9

7.2

D

16

12.4

Avg.

10

9
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Table 2.6. Xe atom statistics in TEM1(I263L)-Xe crystal structure
Xe

Xe1

Xe2

Xe3

Xe5

Chain

Occupancy (%)

B-factor (Å2)

A

87

13.4

B

82

11.9

C

76

13.3

D

85

13.2

Avg.

83

13

A

5

11.1

C

12

15.9

D

21

21.2

Avg.

13

16

A

18

19.1

B

17

24.7

Avg.

18

22

A

25

14.9

B

27

14.2

C

25

13.9

D

10

10.4

Avg.

22

13
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Table 2.7. Xe atom statistics in TEM1(I263N)-Xe crystal structure
Xe

Xe1

Xe5

Chain

Occupancy (%)

B-factor (Å2)

A

47

29.4

B

22

13.9

C

31

29.6

D

33

20.1

Avg.

33

23

A

24

11.7

B

32

15.0

C

31

22.3

D

26

23.7

Avg.

28

18
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Table 2.8. Xe atom statistics in TEM1(I263A)-Xe crystal structure
Xe

Xe1

Xe5

Chain

Occupancy (%)

B-factor (Å2)

A

32

16.5

B

37

16.5

C

31

17.9

D

33

17.8

Avg.

34

17

A

36

15.9

B

32

15.1

C

41

15.8

D

32

17.1

Avg.

35

16
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2.3.6 Computational studies of TEM1 mutants
To further investigate the effect of the I263 mutations on the structural dynamics of the Xebinding cavities, and to understand the molecular origins of the perturbed hyper-CEST z-spectra,
we performed long time scale MD simulations on the I263L, I263N, and I263A mutants.
Simulations were run starting with either a single Xe atom residing in the Xe1 site or with apoform TEM1 in the presence of a large excess of Xe atoms in solution (i.e., “flooding”). These two
complementary approaches were adopted to avoid artifacts resulting from insufficient statistical
sampling (single Xe simulations) and structural perturbation due to the large excess of Xe
("flooding" simulations). The patterns of occupancies calculated from these trajectories were
consistent with the experimental structures (Figure 2.12a) and between the two computational
approaches (Figure 2.12b).
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Figure 2.12. Comparison of Xe binding among WT TEM1 and mutants. (a) Xe occupancy maps
calculated by “flooding” simulations for each mutant (red shading) are overlaid with that of WT
(blue). The positions of Xe atoms determined by X-ray crystallography are indicated by green and
yellow spheres for WT and mutants, respectively. (b) comparison of the occupancy maps calculated
by single Xe simulation (red shading) vs "flooding" simulations (blue shading).
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All I263 mutants showed increased Xe density in the region surrounding the Xe5 cavity,
whereas in WT there was a density node at this site. This agreed with our crystallography results,
where Xe5 was observed bound to I263L, I263N, and I263A but not to WT. Moreover, I263N
showed a smaller, more localized density within the Xe1 cavity, consistent with the reduced
occupancy of Xe1 observed in the X-ray crystal structure and decreased hyper-CEST contrast at
255 ppm. Quantitative analysis of the number of Xe atoms occupying the binding sites during the
MD simulations confirmed that this was indeed the case. The occupancy map of I263A, which
showed the most perturbed hyper-CEST profile (i.e., complete absence of 255 ppm peak), showed
some features distinct from the other three TEM1 variants. Notably, there was continuous Xe
density within the Xe1 cavity of I263A, while WT and I263L presented two spheres of density and
I263N presented only one. Additionally, in I263A the Xe density along the length of the
hydrophobic channel was nearly continuous – only a small gap was observed between Xe densities
corresponding to the inner and outer segments of the channel. This is a marked difference from
WT, where Xe density was observed as discrete spheres along the channel. These features,
collectively, indicate that I263A is generally more accessible to Xe than the other TEM1 variants.
To further ascertain whether mutations to the I263 side chain can affect Xe accessibility as
well as occupancy, we analyzed all the Xe entry and egress events that occurred in MD simulations
for WT TEM1 and the I263 mutants. As observed for WT TEM1, Xe enters and exits the TEM1
mutants predominantly via pathway 1, proceeding by way of the Xe3 and Xe5 positions to the Xe1
cavity (Figure 2.13; Table 2.5). The number of Xe atoms following pathways 2 and 3 are minor and
fairly conserved for all TEM1 proteins.
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Figure 2.13. Combined Xe1 entry and exit pathways from 1 μs MD simulation for WT TEM1 (topleft). The thickness of each trace correlates to the number of Xe atoms following that trajectory.
Blue blobs indicate average Xe density. Plots show the correlation between Xe binding and interside chain distances of residues 263 and 279 from MD Xe flooding simulations of TEM1 mutants
following the same parameters used for WT TEM1 (Figure 2.8b, c).
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Table 2.9. Comparison of Xe counts for each trajectory

Xe counts
Pathway 1

Pathway 2

Pathway 3

WT

78

11

7

I263L

65

12

9

I263N

33

10

6

I263A

108

7

12
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Closer inspection of the side chain packing of residues 263 and 279 offers insights relating
to the relative accessibilities of Xe. Whereas WT showed a sharp step-wise increase in Xe
accessibility upon opening of the I263-I279 “gate”, mutants I263N and I263L showed no such
gating phenomenon. The inter-side chain distance of residues 263 and 279 remained relatively
unchanged through the MD trajectory, and as a result Xe occupancy in the Xe1 cavity was constant
as well. Likewise, the I263A mutant showed almost-immediate Xe binding due to the lack of steric
restriction imposed by the 263 and 279 side chain interaction. These MD analyses indicate that wellresolved CEST contrast is achieved when Xe exchange is moderated by side chains acting as gates
along the access pathway to the major binding site in TEM1.
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2.3.7 TEM1 fragment assembly
TEM1 possesses the unique property where its two catalytically-inactive halves (α and ω)
can assemble to form functional enzyme in cells.[247] When the α and ω fragments are fused to two
interacting proteins, the enzymatic activity of TEM1 can be used as a proxy to monitor the
interaction of the two proteins.[246,249,278] Having established the Xe binding site responsible for
generating CEST contrast from TEM1, we observed that this site lies at the interface between the α
and ω fragments (Figure 2.14). We therefore ventured that CEST contrast could be used to monitor
protein assembly in a “turn-on” manner using TEM1 fragment complementation. To test this
hypothesis, we used the same α and ω TEM1 fragments employed by Wehrman et al. [247] and fused
them to complementary c-Fos and c-Jun leucine zipper sequences, respectively (T1Fα and T1Fω;
Figure 2.3).
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Figure 2.14. TEM1α (blue; residues 26-197) and TEM1ω fragments (lime; residues 198-290) denoted
on the crystal structure of TEM-1 derivatized with Xe (PDB ID 5HW1).
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E. coli cells (normalized to OD600 1) expressing T1Fα and T1Fω showed CEST saturation
contrast of 0.18 ± 0.02, compared to 0.10 ± 0.02 for non-induced E. coli cells transformed with the
same plasmid (Table 2.10). Because the expression levels of soluble T1Fα and T1Fω were poor,
quantitative SDS-PAGE could not be used to determine the concentration of assembled TEM1.
Instead, the concentration of assembled, catalytically-active TEM1 was determined by activity
assay, using purified native TEM1 as a benchmark. Non-induced E. coli showed no significant
TEM1 activity, whereas induced cells showed activity corresponding to a TEM1 concentration of
140 ± 30 nM. This concentration marks the lower limit of TEM1 in cells, since this assay is based on
the assumption that the catalytic activity of assembled TEM1α and TEM1ω is on par with TEM1
expressed as a single chain. Admittedly, the concentration of assembled T1Fα and T1Fω in E. coli
needs to be corroborated by another technique, such as FRET or quantitative Western Blot.
To verify that the observed CEST contrast is dependent on the interaction of the c-Fos and
c-Jun helices, a construct was prepared in which T1Fα was prepared without the C-terminal c-Fos
helix. Cells were prepared as before, and both induced and non-induced E. coli showed saturation
contrasts of 0.12 ± 0.02, roughly equal to the level of background contrast from E. coli. As expected,
activity assays showed no catalytically-active TEM1 was present in the cells. Collectively, these
data indicate that TEM1, in addition to serving as a constitutively-active GE contrast agent, can
also serve as a means of monitoring protein interactions by Xe hyper-CEST NMR.
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Table 2.10 CEST saturation contrast from T1F constructs expressed in E. coli
T1,on (s)

T1,off (s)

Saturation
contrast

[TEM1]
(nM)‡

T1Fα + T1Fω (non-induced)

16.0 ± 0.6

19.0 ± 0.7

0.10 ± 0.02

4±7

T1Fα + T1Fω (induced)

16.0 ± 0.6

21.7 ± 0.7

0.18 ± 0.02

140 ± 30

T1Fα w/o c-Fos + T1Fω (non-induced)

14.1 ± 0.6

16.8 ± 0.3

0.12 ± 0.02

0±5

T1Fα w/o c-Fos + T1Fω (induced)

17.1 ± 0.5

21.3 ± 0.6

0.12 ± 0.02

2±2

E. coli†

†
‡

Cells normalized to OD600 of 1 in PBS
Determined from hydrolase activity
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2.4 Conclusions
We have investigated the origin of the 60 ppm downfield-shifted peak reported for TEM1
in the

129

Xe hyper-CEST NMR experiment. We hypothesized that the 60 ppm shift was the result

of Xe binding to the same hydrophobic pocket initially discovered by Horn et al. [235] and later
characterized in silico by Bowman et al.[235,236] MD simulations of Xe binding to TEM1 affirmed our
original hypothesis and motivated crystallization experiments to further study the interactions
between Xe and TEM1. Crystal structures of WT TEM1 derivatized with Xe revealed a highoccupancy Xe atom (Xe1) bound in the hydrophobic allosteric site as well as low-occupancy Xe
bound at two additional sites predicted in silico using MD simulations or Markov State Models.[276]
Mutagenesis studies confirmed Xe1 binding as the origin of CEST contrast and offered additional
insights as to the relationship between local protein structure and observed

129

Xe hyper-CEST

signal. Two TEM1 mutants, I263A and I279N, showed no hyper-CEST signal whereas three other
mutants – I282A, I263N, and I263L – retained contrast at saturation offset 60 ppm but presented
hyper-CEST profiles that differed from WT. Xe derivatives of crystallized TEM1 mutants I263L,
I263N, and I263A revealed that these mutations impact Xe occupancy at the primary site and also
establish a new Xe binding site. Additionally, MD simulations assessing Xe interactions with these
mutants revealed that even single point mutations can greatly impact Xe access to the protein
which, in turn, affects the measured CEST contrast. The results presented here provide key insights
into the mechanism of hyper-CEST with TEM1, which with further study should provide avenues
for engineering the protein to enhance hyper-CEST contrast and modulate the chemical shift for
multiplexing applications. Additionally, these insights have motivated fragment complementation
assays with TEM1 which suggest that protein-mediated TEM1 assembly can provide a means for
detecting protein-protein interactions via 129Xe hyper-CEST NMR/MRI.
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Chapter 3: SHV-1 β-Lactamase

3.1 Introduction
Having established TEM-1 β-lactamase (TEM1) as a viable GE contrast agent for hp

129

Xe

NMR,[250] our group sought to evaluate other members of the class A β-lactamase protein family
for Xe CEST contrast with the goal of developing multiplexing capabilities. Class A β-lactamases
have been extensively characterized due to their clinical impact, and the structures of many of these
proteins have been solved by X-ray crystallography. [237,238,279] Our candidate search was guided by
the hypothesis that the protein should possess a void space at the same approximate location as
the Xe1 binding site in TEM1. A representative selection of class A β-lactamase crystal structures
was analyzed by Swiss PDB Viewer (v 4.1.0)[266] to detect internal cavities and measure their
respective volumes (Table 3.1). Somewhat surprisingly, all the proteins analyzed reported cavities
smaller than the 42 Å3 van der Waals volume of Xe, with several possessing no measurable cavity
volume at all.
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Table 3.1. Xe1 cavity volumes in class A β-lactamases
Protein

PDB ID

Organism

Xe1 cavity volume (Å3)

TEM-1

1BTL[258]

Escherichia coli

49

SHV-1

1SHV[280]

Klebsiella pneumoniae

38

PER-1

1E25[281]

Pseudomonas aeruginosa

16

blaZ

1ALQ[282]

Staphylococcus aureus

-

PSE-4

1G68[283]

Pseudomonas aeruginosa

-

BEL-1

5EPH[284]

Pseudomonas aeruginosa

-

PenP

3M2J†

Bacillus licheniformis

CTX-M-14

1YLT[285]

Escherichia coli

-

KPC-2

3DW0[286]

Escherichia coli

14

NMC-A

1BUE[287]

Enterobacter cloacae

-

SME-1

1DY6[288]

Serratia marcescens

-

† unpublished
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16

Nevertheless, SHV-1 β-lactamase (SHV1) was selected for further study since it showed
the largest Xe1 cavity among the analyzed class A β-lactamases, excluding TEM1. Although the
predicted cavity volume was too small to accommodate Xe, we reasoned that perhaps the volume
expands when SHV1 is in solution, and, if not, the cavity could be enlarged through site-directed
mutagenesis. Also encouraging were the functional and structural similarities between SHV1 and
TEM1. SHV1 shares the same substrate hydrolytic activity profile as TEM1, [289] though β-lactamase
inhibitory protein (BLIP) binds to SHV1 much more weakly than TEM1. [280] Pairwise sequence
alignment by EMBOSS-Needle[290] showed that mature SHV1 and TEM1 share 68% sequence
identity and 82% similarity. Moreover, the Cα atoms of crystallized SHV1 and TEM1 align with a
rmsd of 1.4 Å (Figure 3.1).[280] The binding mode of Cymal-6, a detergent-like ligand, to SHV1
reveals that SHV1 possesses the same cryptic hydrophobic channel found in TEM1 and indicates a
potential trajectory by which Xe can access the Xe1 binding site in SHV1. Collectively, these
conserved features motivated our investigation of Xe binding to SHV1.
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Figure 3.1. Structural comparison of SHV1 and TEM1. SHV1 complexed with Cymal-6 (blue
cartoon; PDB ID 1SHV[280]) aligned to TEM1 derivatized with Xe (gray; PDB ID 5HW1). Cymal-6
shown as green sticks; Xe atoms shown as red spheres. (b) Comparison of ligand binding to SHV1
and TEM1. The 6-cyclohexylhexyl tail of Cymal-6 bound to SHV1 occupies the same cryptic
hydrophobic channel as the phenyl tail of 3-(4-phenylamino-phenylamino)-2-(1H-tetrazol-5-yl)acrylonitrile (magenta sticks) bound to TEM1 (red cartoon; PDB ID 1PZP [235]).
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3.2 Materials and methods

3.2.1 SHV1 expression and purification
An IPTG-inducible T7 promotor pJ411 vector containing the codon-optimized gene for
SHV-1 β-lactamase (SHV1) from Klebsiella pneumoniae (UniProt acc. no. P0AD64) was purchased
from ATUM. The pJ411-SHV1 plasmid was transformed into BL21(DE3) competent E. coli cells
(New England Biolabs) and grown in 6 x 1 L of LB media supplemented with 50 μg/mL kanamycin
to a OD600 of ~1. SHV1 expression was induced by adding isopropyl-β-D-thiogalactopyranoside
(IPTG) to a final concentration of 1 mM. The induced cells were incubated overnight with shaking
at 18 °C, harvested by centrifugation, then frozen at -80 °C for long-term storage. The frozen cell
pellet was thawed and resuspended in 50 mM Tris (pH 8.0), 10% (v/v) glycerol and lysed by
additional freeze-thaw cycles. The cell lysate was treated with DNAse (Sigma) to reduce viscosity,
then clarified by centrifugation. The lysate supernatant was loaded onto a Q anion-exchange
column (GE Life Sciences) pre-equilibrated with 50 mM Tris (pH 8.0), 10% (v/v) glycerol. Pure
SHV1 (over 95% as indicated by SDS-PAGE) was collected from the flow-through, while bound
impurities were eluted from the column using 50 mM Tris (pH 8.0), 3 M NaCl, 10% (v/v) glycerol.
SHV1 was loaded onto a HiLoad 16/600 Superdex size-exclusion column (GE Life Sciences) preequilibrated with 50 mM Tris (pH 7.4). Fractions containing pure SHV1 were pooled and
concentrated using an Amicon Ultra-15 (MWCO = 10 kDa) centrifugal filter. SHV1 concentration
was determined from the absorbance at 280 nm using the extinction coefficient ε 280 = 32 095 M-1 cm1

calculated by the PROTPARAM server.[252]
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3.2.2 Site-directed mutagenesis
Point mutations were introduced to the pJ411-SHV1 plasmid via site-directed mutagenesis
using the forward and reverse oligonucleotide primers listed in Table 3.2. Mutant plasmids were
amplified in NEB-5α competent E. coli cells (New England Biolabs), purified using a miniprep kit
(Qiagen), and sequenced at the University of Pennsylvania DNA Sequencing Facility to verify the
incorporation of the desired mutation and the integrity of the SHV1 gene. SHV1 mutants were
expressed and purified following the same procedure used for wild-type (WT) SHV1, and protein
concentration was calculated using the same ε280 extinction coefficient.
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Table 3.2. Oligonucleotide primers used in SHV1 site-directed mutagenesis

L265T

L265A

L286C

Forward primer

5'– GTATTGTCGTCATTTATACCCGCGACACCCCTGC –3'

Reverse primer

5'– GCAGGGGTGTCGCGGGTATAAATGACGACAATAC –3'

Forward primer

5'– GTATTGTCGTCATTTATGCGCGCGACACCCCTGC –3'

Reverse primer

5'– GCAGGGGTGTCGCGCGCATAAATGACGACAATAC –3'

Forward primer

5'– GGTATTGGTGCGGCATGCATCGAGCACTGGCAG –3'

Reverse primer

5'– CTGCCAGTGCTCGATGCATGCCGCACCAATACC –3'
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3.2.3 Circular Dichroism (CD) spectroscopy
The CD spectra of WT SHV1, SHV1(L265T), and SHV1(L265A) were collected on a AVIV
model 425 circular dichroism spectrometer using a 1 mm quartz cuvette. The samples consisted of
10 μM protein in 10 mM sodium phosphate (pH 8.0) buffer. CD spectra were acquired at 298 K
with a wavelength step of 1 nm.

3.2.4 Thermal stability measurements
Thermal melts were performed on a Jasco J-1500 CD spectrometer equipped with a Peltier
temperature controller. Thermal stability was measured by increasing temperature from 20 to 90
°C at a rate of 0.5 °C/min. Protein secondary structure was monitored at 222 nm with a step size of
1 °C and data integration time of 8 s. Thermal denaturation was repeated in triplicate, and the
melting temperature (Tm) was calculated using the Spectra Analysis tool in the J-1500 CD
spectrometer software package (Jasco).

3.2.5 Protein crystallization and Xe derivatization
Crystals of WT SHV1 were grown at 294 K by the sitting drop vapor diffusion method
using a 24-well Cryschem plate (Hampton Research). 3 μL of 39.6 mg/mL SHV1 in 50 mM Tris (pH
7.4) was mixed with 7 μL of 50 mM HEPES (pH 7.0), 15% (w/v) PEG 6000 in a sitting drop
suspended over 0.5 mL of 100 mM HEPES (pH 7.0), 30% (w/v) PEG 6000. Plate crystals appeared
within a week. The crystals were briefly immersed in a cryoprotectant solution of 50 mM HEPES
(pH 7.0), 15% (w/v) PEG 6000, 15% (v/v) (+/–)-2-Methyl-2,4-pentanediol (MPD), 15% (w/v) PEG
400, then flash-cooled in liquid nitrogen. Xe derivatives of SHV1 were prepared by incubating
cryoprotected SHV1 crystals in 1.2 MPa Xe (AirGas) inside a Xenon Derivatization Chamber
104

(Hampton Research) for 15 minutes. Following Xe derivatization, the crystals were immediately
flash-cooled in liquid nitrogen. Crystals of native and Xe-derivatized SHV1(L265T) were prepared
following the same procedure but using protein at a concentration of 20 mg/mL.
Crystals of SHV1(L265A) were grown at 294 K by the sitting drop vapor diffusion method
using a 24-well Cryschem plate (Hampton Research). 2 μL of 25.4 mg/mL SHV1 in 50 mM Tris (pH
7.4) was mixed with 2 μL of 1% (w/v) tryptone, 50 mM HEPES (pH 7.0), 20% (w/v) PEG 3350 in a
sitting drop suspended over 0.5 mL of 1% (w/v) tryptone, 50 mM HEPES (pH 7.0), 20% (w/v) PEG
3350. Plate crystals appeared within a few days. The crystals were briefly immersed in
cryoprotectant solution consisting of 50 mM HEPES (pH 7.0), 15% (w/v) PEG 6000, 15% (v/v) MPD,
15% (w/v) PEG 400, then flash-cooled in liquid nitrogen. Crystals of SHV1(L265A) were derivatized
following the same procedure used for WT SHV1 and SHV1(L265T).
Diffraction data was collected remotely from beamlines 24ID-C and 24ID-E of the
Advanced Photon Source (APS) synchrotron as well as from beamline 14-1 of the Stanford
Synchrotron Radiation Lightsource (SSRL). Diffraction images were indexed and integrated using
either XDS[253] or iMosflm[254] and then processed by AIMLESS [255] in the CCP4 suite of programs.[256]
The structure of native WT SHV1 was solved by molecular replacement in Phaser[257] using a
monomer of SHV1 crystallized with Cymal-6 (PDB ID 1SHV[280]) less the solvent and ions as a
search model. All other SHV1 structures were phased by molecular replacement using the refined
model of native WT SHV1 less the solvent and ions as the search model. Iterative cycles of
refinement and manual model adjustments were performed using PHENIX (version 1.9) [259,260] and
COOT (version 0.8.1),[261,262] respectively. Translation-libration-screw (TLS) refinement was
performed during the later stages of refinement using TLS groups determined by PHENIX. Xe
atoms were identified by inspection of electron density peaks in isomorphous Fourier difference
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maps generated from the structure factor amplitudes |FXe| - |Fnative| and phases from the refined
model of native protein. The occupancies of Xe atoms were calculated using a combination of
occupancy and B-factor refinement. Disordered protein atoms showing no electron density in the
2Fo-Fc map were deleted from the protein model, and electron density peaks that were not
confidently interpretable were left unmodeled. Refinement proceeded until Rfree converged at its
lower limit. The quality of the final models were assessed using MolProbity. [263] Data collection and
refinement statistics are presented in Table 3.3. All structure figures were generated using
PyMOL.[264]
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Table 3.3. Data collection and refinement statistics for SHV1 crystal structures
SHV1

SHV1-Xe

SHV1(L265T)-Xe

SHV1(L265A)

SHV1(L265A)-Xe

APS; 24-ID-E

SSRL; 14-1

SSRL; 14-1

APS; 24-ID-C

APS; 24-ID-C

0.979

1.181

0.979

0.979

0.979

111.13-1.90
(1.94-1.90)

46.15-1.72
(1.75-1.72)

55.73-1.74
(1.77-1.74)

55.88-1.74
(1.77-1.74)

55.79-1.71
(1.74-1.71)

C2

C2

C2

P21

P21

a, b, c (Å)

62.1, 68.5, 111.2

62.3, 68.8, 111.5

62.2, 68.4, 111.5

46.2, 111.8, 46.2

46.2, 111.6, 46.2

α, β, γ (°)

90.0, 92.1, 90.0

90.0, 92.3, 90.0

90.0, 92.1, 90.0

90.0, 95.5, 90.0

90.0, 95.7, 90.0

263900/36019

175220/47365

181256/48018

318308/47198

295285/47826

97.9 (96.2)

94.9 (89.8)

100.0 (99.8)

98.9 (98.5)

95.6 (91.6)

7.3 (7.3)

3.7 (3.6)

3.8 (3.6)

6.7 (6.6)

6.2 (6.0)

Diffraction source
Wavelength (Å)
Resolution limits (Å)a
Space group
Unit-cell parameters

Total/unique
reflections
Completeness (%)a
Multiplicitya
I/σ(I)

a

Rmergea,b

9.5 (2.0)

9.7 (1.5)

8.2 (1.9)

12.9 (3.0)

15.3 (4.9)

0.26 (1.12)

0.08 (0.82)

0.08 (0.56)

0.10 (0.69)

0.07 (0.30)

Rpima,c

0.16 (0.68)

0.07 (0.78)

0.08 (0.54)

0.06 (0.44)

0.04 (0.20)

CC1/2a,d

0.986 (0.566)

0.996 (0.503)

0.996 (0.735)

0.997 (0.789)

0.998 (0.949)

Rworke

0.19

0.20

0.18

0.16

0.17

Rfreef

0.24

0.23

0.22

0.20

0.22

2

2

2

2

2

Protein residues

264

265 (A)
264 (B)

264

264

264

Solvent molecules

298

340

322

173

359

-

-

-

-

4

Bonds (Å)

0.006

0.002

0.005

0.003

0.005

Angles (°)

0.806

0.490

0.753

0.583

0.735

Protein chains

Xe atoms
R.m.s. deviations

Mean B value (Å2)
Protein

16.0

21.4

20.3

19.0

12.5

Solvent

22.0

28.4

29.8

21.7

18.3

-

-

-

-

25.2

Favored

98.1

97.1

97.7

97.3

98.1

Allowed

1.9

2.9

2.3

2.7

1.9

Outliers

0

0

0

0

0

1.24

1.15

1.07

1.29

1.35

Xe
Ramachandran plot
(%)g

MolProbity score

Values in parentheses refer to the highest-resolution shell of the data.
Rmerge = ∑|Ih – ⟨Ih⟩|/∑⟨Ih⟩; Ih = intensity measure for reflection h; ⟨Ih⟩ = average intensity for reflection h calculated from replicate data.
c
Rpim = ∑(1/(n – 1)1/2|Ih - ⟨Ih⟩|/∑⟨Ih⟩; n = number of observations (redundancy).
d
CC1/2 = στ2/(στ2 + σε2), where στ2 is the true measurement error variance and σε2 is the independent measurement error variance.
e
Rwork = ∑||Fo| - |Fc||/∑|Fo| for reflections contained in the working set. |Fo| and |Fc| are the observed and calculated structure factor
amplitudes, respectively.
f
Rfree = ∑||Fo| - |Fc||/∑|Fo| for reflections contained in the test set held aside during refinement (5% of total).
g
calculated by MolProbity
a

b
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3.2.6 129Xe hyper-CEST spectroscopy
129

Xe hyper-CEST z-spectra were acquired following the same parameters used for TEM1

(see section 2.2.3; 129Xe hyper-CEST spectroscopy).

3.2.7 Activity assays
The procedure used to measure specific activity was based on the procedure used by
Bowman and co-workers.[276] Briefly, the activity of 1 nM of SHV1 was measured in 50 mM
potassium phosphate (pH 7.0), 10% (v/v) glycerol, 1.5% (v/v) DMSO using 200 μM nitrocefin (EMD
Millipore) as a substrate. The hydrolysis of nitrocefin was monitored via absorbance at 482 nm
(A482) using an Infinite M1000 Pro plate reader (Tecan). SHV1 and TEM1 hydrolase activities in the
presence of 0, 10, 50, and 100 μM Cymal-6 or Cymal-2 was measured in triplicate.

3.2.8 DTNB assays
Adduct formation between thiol side chains and 5,5′-dithiobis(2-nitrobenzoic acid) (DTBN,
also known as Ellman’s Reagent) was monited via absorbance at 412 nm (A 412) using a Cary 60 UVVis spectrophotometer (Agilent Technologies). As a control, 30 μM of protein was incubated in
excess DTNB in denaturing solution [100 mM sodium phosphate (pH 8.0), 1 mM EDTA, 8 M urea]
for 30 min at rt. The number of free thiols per protein molecule was calculated using a molar
absorptivity ε412 of 13 700 M-1 cm-1. Assays to measure the rate of DTNB adduct formation were
performed under native conditions in 100 mM sodium phosphate (pH 8.0), 1 mM EDTA. A 412 was
measured every 15 s for 30 min, and initial adduct formation rates were determined from the first
2 min of the reaction during which the slope was linear.
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3.3 Results and Discussion

3.3.1 Xe binding to WT SHV1
WT SHV1 was crystallized and derivatized with Xe to evaluate Xe binding at the Xe1 cavity
as well as detect any additional Xe binding sites within the protein. Although 6-cyclohexylhexyl βD-maltoside (Cymal-6) is commonly used as an additive when crystallizing SHV1, [280,291,292] in our
study Cymal-6 was excluded so as not to interfere with Xe binding to SHV1. Even in the absence
of Cymal-6, SHV1 crystals diffracted to resolutions of 1.90 Å (native WT) or better. Crystals of WT
SHV1 were pressurized with 1.2 MPa Xe for 15 min following the same procedure used for
derivatizing TEM1. Inspection of the isomorphous difference map generated from |F Xe| - |Fnative|
and phased with native WT SHV1 showed no Xe atoms bound to the Xe1 cavity, nor at any other
site within the protein. Closer examination of the Xe1 cavity in SHV1 shows the Leu-265 side chain
protruding into the cavity (residue 265 is a Thr in WT TEM1), effectively blocking Xe binding
(Figure 3.2). As such, no measurable Xe1 cavity volume was detected in one chain of the SHV1-Xe
structure, and a 16 Å3 cavity volume was measured in the other chain.
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Figure 3.2. Xe1 cavity of WT SHV1 (blue) compared to TEM1 derivatized with Xe (PDB ID 5HW1).
The side chain of L265 in SHV1 occupies the interior of the cavity, effectively blocking Xe1 binding.
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3.3.2 Xe binding to SHV1 mutants
Our next step was to enlarge the Xe1 cavity of SHV1 via site-directed mutagenesis. Two
SHV1 mutants were prepared: L265T (to mimic the Thr side chain present in TEM1), and L265A
(to further enlarge the cavity). Swiss PDB Viewer (v 4.1.0)[266] predicted the L265T and L265A
mutations to create cavity volumes of 65 and 67 Å 3, respectively. Both SHV1 mutants expressed at
levels comparable to WT SHV1, and characterization by circular dichroism (CD) showed the global
fold of the SHV1 mutants to be nearly identical to WT SHV1 as well as TEM1 (Figure 3.3).
Additionally, thermal stability measurements reported only moderate decreases in stability upon
mutation of the Leu-265 residue (Table 3.4).
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Figure 3.3. CD spectra of SHV1 variants and WT TEM1 in 10 mM sodium phosphate buffer (pH
8.0).
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Table 3.4. Thermal stabilities of SHV1 variants
Protein

Melting Temperature (°C)

WT SHV1

52.0

SHV1(L265T)

49.5

SHV1(L265A)

47.5

TEM1(L286C)

49.9

SHV1(L286C)

48.5

SHV1(L265A/L286C)

42.6
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To assess Xe binding, SHV1 L265T and L265A were crystallized and derivatized with Xe
following the same procedure used for WT. Both mutants crystallized in similar morphologies to
WT SHV1 and diffracted to comparable resolutions. The Fo-Fc difference map of SHV1(L265T)
showed no electron density corresponding to bound Xe. The isomorphous difference map
generated from |FXe,L265T |- |Fnative,WT| and phased with native WT SHV1 also no electron density
indicative of bound Xe. Comparison of the side chains lining the Xe1 cavities of SHV1(L265T) and
TEM1 reveals that the side chain of Thr-265 in SHV1(L265T) adopts a different rotameric state. This
variation arises due to the different hydrogen bonding network resulting from a water molecule
donating a hydrogen bond to the carbonyl oxygen of Gly-242 (Figure 3.4). The γ-carbon of SHV1
Thr-265 protrudes into the cavity, leaving only 2.4 Å of space between any bound Xe, well below
the typical 3-6 Å typically seen for Xe-side chain interactions. Cavity volume measurement of the
SHV1(L265T) crystal structure gives 26 Å3 – too small to accommodate Xe.
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Figure 3.4. Xe1 cavity of SHV1(L265T) (blue) and TEM1-Xe (gray; PDB ID 5HW1). (a) SA omit map
of the Thr-265 side chain of SHV1(L265T) shown in green and contoured at 4σ. The methyl group
of the Thr-265 side chain prevents Xe1 binding. Xe1 bound to TEM1 (red transparent sphere) shown
for reference. (b) The Thr-265 side chain of SHV1(L265T) adopts a different rotameric state than in
TEM1. The hydroxyl group of TEM1 Thr-265 hydrogen bonds to a water molecule (gray sphere)
hydrogen bonded to the carbonyl oxygen of Gly-242. The methyl group of the Thr-268 side chain
in SHV1(L265T) disrupts this hydrogen bonding network observed in TEM1.
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SHV1(L265A), on the other hand, showed weak but unambiguous electron density
corresponding to Xe binding in the Xe1 cavity. Electron density at 3 σ was observed both the Xe
SA omit map as well as in the isomorphous difference map generated from |F Xe|- |Fnative| and
phased with native SHV1(L265A) (Figure 3.5). The Xe1 cavity in SHV1(L265A) was measured to
be 50 Å3 – smaller than predicted for SHV1(L265A), but nearly the same volume as the Xe1 cavity
in TEM1. Comparison of Xe1 cavities of SHV1(L265A) and TEM1 shows that the side chain
positions, as well as position of Xe1, is largely the same in the two proteins. A second Xe atom was
observed bound to SHV1(L265A) near Leu-102, though the proximity of this site to the protein
surface suggests that Xe binding is an artifact of crystal packing. Xe binding at this surface site was
not observed in the Xe derivative structures of WT SHV1 or SHV1(L265T) likely due to the different
space groups of those crystals (C2 vs. P21) as well as the different precipitant solutions used.
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Figure 3.5. Xe1 cavity of SHV1(L265A) (blue) with bound Xe shown as red sphere. The
isomorphous difference map of Xe shown in blue and contoured at 5 σ, and the SA omit map of Xe
shown in green and contoured at 3 σ.
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3.3.3 CEST contrast from SHV1 variants
The Xe hyper-CEST z-spectra of wild-type SHV1, SHV1(L265T), and SHV1(L265A) were
measured to corroborate the X-ray crystallography results and evaluate the presence of any
downfield CEST response from Xe binding to SHV1 (Figure 3.6). As expected from the lack of Xe
present in derivatized structure of WT SHV1, no CEST peak was observed for WT SHV1. The Xe (aq)
peak for WT SHV1 was narrower than that of TEM1, indicating fewer Xe-protein interactions. The
Xe hyper-CEST z-spectra of SHV1(265T) and SHV1(L265A) corroborate the conclusions drawn
from the X-ray crystal structures. The trace of L265T is largely the same as WT SHV1, with no
measurable downfield CEST response. SHV1(L265A) shows a broad, weak CEST response up to
~80 ppm downfield, suggesting that Xe binds to SHV1(L265A), though much weaker and faster
than to TEM1. The lack of a distinct, unambiguous CEST response indicates, unfortunately, that
SHV1(L265A) is not a suitable contrast agent for Xe hyper-CEST, and that efforts to convert SHV1
to a CEST agent comparable to TEM1 will likely require engineering beyond single point mutations
near the Xe site.
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Figure 3.6. Xe hyper-CEST z-spectra of 80 μM WT SHV1 and mutants in pH 7.2 PBS at 300 K. The
z-spectra of PBS only and of 80 μM wild-type TEM1 are included for reference.
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3.3.4 Structural dynamics of SHV1 versus TEM1
We hypothesized that SHV1’s relatively weak CEST response can be attributed to
dissimilar degrees of Xe accessibility to the hydrophobic channel between helices 11 and 12 in
SHV1 and TEM1. To test this hypothesis, a Cys side chain was introduced at residue 286, near the
entrance of the hydrophobic channel. An assay using DTNB was used to monitor the rate of thiol
adduct formation at this site, thus providing a measure of the accessibility of the hydrophobic
channel (Figure 3.7). This approach was based on the DTNB assays used by Bowman and coworkers to characterize cryptic allosteric sites in proteins.[276] The rates DTNB adduct formation for
TEM1(L286C)

and

SHV1(L286C)

were

nearly equal,

though

the

rate

observed

for

SHV1(L265A/L286A) was roughly three times faster. Coupled with the thermal stability data, this
result suggests that enlarging the Xe1 cavity destabilized SHV1 and led to increased accessibility
to its hydrophobic core. This increased accessibility, in turn, leads to Xe exchange rates too fast to
produce a downfield CEST response.
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Figure 3.7. Rates of DTNB adduct formation with TEM1 and SHV1 mutants.
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Finally, to compare the connection between the hydrophobic channel to catalytic activity
in TEM1 and SHV1, the hydrolytic activities of both proteins were measured in the presence of
Cymal-6, a detergent-like ligand (and common crystallization additive) known to bind between
helices and 11 and 12 of SHV1 and, very likely, TEM1 (Figure 3.8). Though both TEM1 and SHV1
showed slightly increased activity at 10 μM Cymal-6, TEM1 activity was inhibited at higher
concentrations of Cymal-6, as expected from the inhibition assays performed by Horn and
Soichet.[235] Surprisingly, Cymal-6 enhanced the hydrolytic activity of SHV1, an unexpected result
given the structural similarity of TEM1 and SHV1. To verify that TEM1 inhibition and SHV1
activation were the result of the cyclohexylhexyl tail of Cymal-6 binding at the hydrophobic
channel, the assays were repeated in the presence of 6-cyclohexylethyl β-D-maltoside (Cymal-2)
since the cyclohexylethyl tail of Cymal-2 would be too short to penetrate the hydrophobic interior
of TEM1 and SHV1. Indeed, Cymal-2 showed no effect on the hydrolytic activities of TEM1 and
SHV1. Collectively, these activity data indicate that the structural dynamics of TEM1 and SHV1
are different, and that this dissimilarity might explain the differences in Xe-protein interactions
observed for these two proteins by hyper-CEST.
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Figure 3.8. Effect of Cymal-6 and Cymal-2 on the hydrolase activity of SHV1 and TEM1.
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3.4 Conclusions
Despite the considerable sequence and structural similarity of SHV1 and TEM1, Xe hyperCEST with SHV1 shows no downfield contrast signal, most likely due to its significantly smaller
Xe1 cavity. Moreover, in silico analysis of crystallized WT SHV1 indicates that the protein does not
possess any Xe binding sites elsewhere in the protein (though crystallization experiments at higher
Xe pressures and incubation times may reveal cryptic Xe binding sites). Attempts to engineer a
larger cavity to accommodate Xe were successful: a Leu-to-Ala truncation at residue 265 enlarged
the Xe cavity to match the volume found in TEM1, and X-ray crystallography confirmed Xe binding
to the SHV1(L265A) mutant. However, SHV1(L265A) showed a weak, broad downfield CEST
response, and thus unsuitable as a GE contrast agent. DTNB assays to characterizing the
accessibility of the Xe1 channel showed that the accessibility is largely the same between WT TEM1
and SHV1, but much greater for the L265A mutant. This result, coupled with thermal stability data,
suggests that the L265A mutation destabilizes the core of the protein and makes Xe exchange too
rapid for CEST. Moreover, activity assays with Cymal-6 indicate that ligand binding at the Xe1
hydrophobic channel affects the hydrolytic activity of TEM1 and SHV1 differently, suggesting that
the “breathing” motions of the two proteins differ, which likely affects Xe exchange. In short, our
investigation of SHV1 demonstrates that while Xe binding sites can be introduced into class A βlactamases, engineering such proteins for Xe hyper-CEST must take into account the structural
dynamics of the protein in solution and the effects of such motions on the rates of Xe exchange. It
is evident that using class A β-lactamases beyond TEM1 to develop multiplexing capabilities will
require higher-level rational design guided by computational methods for predicting Xe-protein
interactions.
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Chapter 4: Maltose Binding Protein‡

4.1 Introduction
The development of molecular probes for quantifying the in vivo distribution of
biologically active species (e.g., metabolites, neurotransmitters) is critical to understanding both
normal physiology and disease pathologies. Magnetic resonance imaging (MRI) offers excellent
spatiotemporal resolution and penetration depth without the use of ionizing radiation. Functional
MRI (fMRI) has spurred the development of “smart” contrast agents that are responsive to specific
physiological triggers[293] such as metal ions,[49] metabolites,[50] and enzymes.[180] Genetically
encoded (GE) contrast agents have been tailored to bind specific analytes through biomolecular
engineering techniques such as directed evolution.[185,294] In pioneering work, Shapiro and
coworkers evolved bacterial cytochrome P450-BM3 (BM3h) to bind dopamine near the
paramagnetic heme, which was designed to decrease 1H MRI T1 enhancement: 89 μM BM3h
enabled detection of 75 μM dopamine in live rat brain.[185] An alternative contrast approach is 1H
chemical exchange saturation transfer (1H-CEST). By this method, Oskolkov and coworkers
observed MR contrast from 733 μM human protamine-1, an arginine-rich nuclear protein sensitive
to pH, phosphorylation state, nucleotides, and heparin. [203] Notably, the low sensitivity of 1H MRI
has limited the development of GE T1, T2, and 1H-CEST contrast agents for molecular imaging,[295]
thereby motivating the development of contrast agents detectable by other MR methodologies such
as 129Xe hyper-CEST.

Portions of this chapter originally published in: Roose, B. W.; Zemerov, S. D.; Dmochowski, I. J. Nanomolar Small-Molecule
Detection Using a Genetically Encoded 129 Xe NMR Contrast Agent. Chem. Sci. 2017, 8 (11), 7631–7636.
‡
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Our group developed maltose binding protein (MBP) as a small-molecule-responsive, GE
contrast agent capable of detecting nanomolar concentrations of maltose using the hyper-CEST
129

Xe NMR technique (Figure 4.1). Xe binding to MBP has been well-characterized by NMR, which

showed that

129

Xe chemical shift depends on MBP conformation.[296] X-ray crystallography

identified a single Xe-binding site near the maltose binding cleft of MBP (Figure 4.2).[274] MBP is a
periplasmic protein encoded by the MalE gene that serves as an initial receptor in the
maltose/maltodextrin transport systems of gram-negative bacteria. [297] Wild-type (WT) MBP binds
maltose with good affinity (Kd ≈ 1 μM),[297] as well as other maltodextrins, between two nearly
symmetrical lobes that transition from an “open” (MBPopen) to “closed” (MBPclosed) conformation
upon ligand binding.[298] This structural response to ligand binding has led to the utilization of MBP
as a versatile platform for biosensing applications.[299] Small-molecule detection with MBP, as well
as other periplasmic binding proteins (PBPs),[300] has been achieved through a variety of signal
transduction modalities, including fluorescence,[154] fluorescence resonance energy transfer
(FRET),[301] and electrochemical response.[302] Moreover, MBP has been engineered to increase
ligand affinity[303,304] and to bind non-maltodextrin ligands such as sucrose[305] and zinc.[306] Thus, we
set out to evaluate the hyper-CEST NMR contrast generated by MBP as a function of maltose
binding.
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Figure 4.1. Ultrasensitive detection of a metabolite-protein (in this study, maltose-MBP) interaction
via hyper-CEST NMR. HP 129Xe (green) binds maltose-bound MBP, where the unique Xe resonance
frequency is saturated by shaped RF pulses. Xe exchange leads to depolarization of solution-phase
Xe pool, thereby generating MR contrast (yellow peak).
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Figure 4.2. Xe (red sphere) bound to MBPopen (PDB ID 1LLS[274]), with the N-terminal domain
colored blue, C-terminal domain colored green, and linking segments colored orange. (Inset)
Detailed view of the Xe-binding cavity of MBP.
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4.2 Materials and methods

4.2.1 MBP expression and purification
MBP was expressed from the pET His6 MBP TEV LIC cloning vector, a gift from Scott
Gradia acquired via Addgene (plasmid #29656). The MBP vector was transformed into BL21(DE3)
competent E. coli cells (New England Biolabs) and grown in 6 x 1 L of LB media supplemented with
50 μg/mL kanamycin to a OD600 of ~1. MBP expression was induced by adding isopropyl-β-Dthiogalactopyranoside (IPTG) to a final concentration of 1 mM. The induced cells were incubated
overnight at 18 °C, harvested by centrifugation, then frozen at -80 °C for long-term storage. The
frozen cell pellets were thawed and resuspended in 20 mM sodium phosphate (pH 7.4), lysed with
lysozyme (Sigma), and treated with benzonase nuclease (Sigma) to reduce the viscosity of the
lysate. After stirring the lysate at rt for 30 min, NaCl was added to 0.5 M and imidazole was added
to 20 mM. The lysate was clarified by centrifugation, and the supernatant was loaded onto a
HisTrap nickel affinity column (GE Life Sciences) pre-equilibrated with 20 mM sodium phosphate
(pH 7.4), 0.5 M NaCl, 20 mM imidazole. MBP was eluted from the column with 20 mM sodium
phosphate (pH 7.4), 0.5 M NaCl, 500 mM imidazole. The eluate was concentrated and further
purified by size-exclusion chromatography in PBS (HyClone) using a HiLoad 16/600 Superdex
column (GE Life Sciences). Fractions containing pure protein (over 95% as indicated by SDS-PAGE)
were pooled and concentrated. Protein concentration were determined from the absorbance at 280
nm using the extinction coefficient ε280 = 67 840 M-1 cm-1 calculated by the PROTPARAM server.[252]
All MBP mutants were expressed and purified following the same procedure used for WT MBP.
The concentrations of MBP(V293L) and MBP(V293A) were determined from the absorbance at 280
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nm using the same extinction coefficient as WT MBP, and the extinction coefficient ε 280 = 88 240 M1

cm-1 was used for MBP(I329Y)-GFP.

4.2.2 Site-directed mutagenesis
Mutations were introduced to either the MBP or MBP-GFP plasmid via site-directed
mutagenesis using the forward and reverse primers listed in Table 4.1. The mutated plasmids were
amplified in NEB-5α competent E. coli cells (New England Biolabs) and then purified using a
miniprep kit (Qiagen). All mutated MBP genes were sequenced at the University of Pennsylvania
DNA Sequencing Facility to verify the incorporation of the desired mutation and the integrity of
the MBP gene sequence.
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Table 4.1. Oligonucleotide primers used in MBP site-directed mutagenesis

V293L

V293A

I329Y

G69C

S337C

Forward primer

5'– GAAGGTCTGGAAGCGCTGAATAAAGACAAACCG –3'

Reverse primer

5'– CGGTTTGTCTTTATTCAGCGCTTCCAGACCTTC –3'

Forward primer

5'– GAAGGTCTGGAAGCGGCGAATAAAGACAAACCG –3'

Reverse primer

5'– CGGTTTGTCTTTATTCGCCGCTTCCAGACCTTC –3'

Forward primer

5'– CGCCCAGAAAGGTGAATACATGCCGAACATCCCGC –3'

Reverse primer

5'– GCGGGATGTTCGGCATGTATTCACCTTTCTGGGCG –3'

Forward primer

5'– GCACACGACCGCTTTGGTTGCTACGCTCAATCTGGCCTG –3'

Reverse primer

5'– CAGGCCAGATTGAGCGTAGCAACCAAAGCGGTCGTGTGC –3'

Forward primer

5'– CCGAACATCCCGCAGATGTGCGCTTTCTGGTATGCCGTG –3'

Reverse primer

5'– CACGGCATACCAGAAAGCGCACATCTGCGGGATGTTCGG –3'
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4.2.3 MBP-GFP cloning, expression, and purification
The gene encoding a “superfolder” variant of GFP[307] was amplified from the pET GFP LIC
cloning vector, a gift from Scott Gradia acquired via Addgene (plasmid #29772). The primers used
for amplification are listed in Table 4.2. The GFP insert was added to the pET His6 MBP TEV LIC
cloning vector by ligation independent cloning (LIC). The resulting MBP-GFP gene was sequenced
at the University of Pennsylvania DNA Sequencing Facility to verify the integrity of the fusion
construct. MBP-GFP was expressed and purified following the same protocol used for MBP.
Protein concentration were determined from the absorbance at 280 nm using the extinction
coefficient ε280 = 86 875 M-1 cm-1.
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Table 4.2. Oligonucleotide primers used for GFP insert amplification

GFP insert

Forward primer

5'– TACTTCCAATCCAATGCAAGCAAGGGCGAGGAGCTGTTC –3'

Reverse primer

5'– TTATCCACTTCCAATGTTATTACTTGTACAGCTCGTCCATGCC –3'
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4.2.4 129Xe hyper-CEST of MBP

129

Xe was hyperpolarized and z-spectra of MBP were acquired following the same

procedure used for TEM-1 β-lactamase. Briefly, hp

129

Xe was generated using the spin-exchange

optical pumping (SEOP) method with a home-built

129

Xe polarizer based on the IGI.Xe.2000

commercial model by GE. A Shark 65 W tunable ultra-narrow band diode laser (OptiGrate) set to
795 nm was used for optical pumping of Rb vapor. A gas mixture of 88% helium, 10% nitrogen,
and 2% natural abundance xenon (Linde Group, NJ) was used as the hyperpolarizer input.

129

Xe

hyperpolarization level was roughly 10-15%. For each data point in the hyper-CEST z-spectra, hp
129

Xe was bubbled into the NMR tube through capillaries for 20 s, followed by a 3 s delay to allow

bubbles to collapse. A d-SNOB saturation pulse with 690 Hz bandwidth was used. Pulse length,
τpulse = 3.80 ms; field strength B1,max = 77 μT; number of pulses, npulse = 400; saturation time, Τsat = 1.52
s. NMR experiments were performed using a Bruker BioDRX 500 MHz NMR spectrometer and 10mm PABBO probe, at 300 K. A 90° hard pulse of this probe has a pulse length of 22 μs. Unless
otherwise noted, the protein concentration used was 80 μM, with 0.1% (v/v) Pluronic L81 (Aldrich)
added to mitigate foaming.
For the time-dependent saturation transfer experiments using 100 nM WT MBP, saturation
transfer was calculated using Equation 1.

𝐒𝐓 =
𝒌

𝑰𝒌𝐨𝐟𝐟 − 𝑰𝒌𝐨𝐧

𝑳𝒌

𝑰𝒌𝐨𝐟𝐟

∑ 𝒌 𝑳𝒌

Equation 4.1. Calculation of saturation contrast (ST), where I represents the acquired postsaturation Xe(aq) signal with set saturation frequency, duration, and power. L represents the
duration of hyper-CEST pulse sequences. The index k indicates each data point.
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Saturation frequencies of Dsnob-shaped pulses were positioned +95 ppm and -95 ppm, referenced
to the Xe(aq) peak, for on- and off-resonance, respectively. Pulse length, τpulse = 1.0496 ms; field
strength, B1,max = 279 μT. Both on-resonance and off-resonance data were fitted with first-order
exponential decay curves. For the time-dependent saturation transfer experiments using 100 nM
MBP(I329Y)-GFP, saturation frequencies of d-SNOB-shaped pulses were positioned +100 ppm and
-100 ppm, referenced to the Xe(aq) peak, for on- and off-resonance, respectively. For the timedependent saturation transfer experiments using 100 nM MBP(V293A), saturation frequencies of
d-SNOB-shaped pulses were positioned +36 ppm and -36 ppm, referenced to the Xe (aq) peak, for
on- and off-resonance, respectively.

4.2.5 129Xe hyper-CEST of WT MBP-GFP in E. coli
BL21(DE3) E. coli competent cells were transformed with the WT MBP-GFP plasmid and
cultured on a LB-agar plate supplemented with 50 μg/mL kanamycin. A single colony of
transformed cells was used to inoculate 5 mL of LB medium supplemented with 50 μg/mL
kanamycin. The 5 mL culture was incubated overnight at 37 °C with shaking at 250 rpm. The next
morning the cells were pelleted and resuspended in 4 mL of minimal media. The resuspended cells
were used to inoculate 4 x 1 L of minimal media supplemented with 50 μg/mL kanamycin in baffled
culture flasks. Two flasks were supplemented with 1 mM maltose. The cell cultures were incubated
at 37 °C with shaking at 250 rpm until OD600 reached ~1, at which point the two control flasks was
stored at 4 °C and the other two flasks were induced by adding IPTG to a final concentration of 1
mM. The induced culture flasks were incubated overnight at 18 °C with shaking at 250 rpm and
then stored at 4 °C. Aliquots from the control and induced cultures were centrifuged and the cell
pellets were resuspended in PBS buffer with or without maltose. The concentrations of MBP-GFP
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in the IPTG-induced growths were measured by fluorescence spectroscopy (489 nm excitation; 510
nm emission) using a standard curve constructed from pure MBP-GFP in PBS. Cells were diluted
so that the final MBP-GFP concentration was 1 μM. Cells from the control growths were diluted to
match the optical densities (OD6oo) of the induced cells. Saturation frequencies of d-SNOB-shaped
pulses were positioned +95 ppm and -95 ppm, referenced to the Xe (aq) peak, for on- and offresonance, respectively. Pulse length, τpulse = 1.0496 ms; field strength, B1,max = 279 μT. Both onresonance and off-resonance data were fitted with first-order exponential decay curves. Following
hyper-CEST experiment, the cell samples were gently pelleted and the fluorescence of the
extracellular solution was measured to check for cell lysis caused by xenon bubbling. 21% of the maltose/+IPTG cells were lysed, and 18% of the +maltose/+IPTG cells were lysed.

4.2.6 Circular dichroism (CD) spectroscopy
The CD spectra of WT MBP, MBP(V293L), and MBP(V293A) were measured on a Jasco J1500 CD spectrometer equipped with a Peltier temperature controller (Figure 4.3). Spectra were
acquired from 10 μM of protein in 10 mM sodium phosphate (pH 8.0) buffer inside a quartz cuvette
with a 1-mm path length. CD spectra were taken at 20 °C with a wavelength step of 1 nm. CD
spectra were performed in triplicate and averaged.
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Figure 4.3. CD spectra of MBP variants. 10 μM MBP without maltose (top) and with 1 mM maltose
(bottom) in 10 mM sodium phosphate buffer (pH 8.0).
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4.2.7 Thermal stability measurements
Thermal melts were performed on a Jasco J-1500 CD spectrometer equipped with a Peltier
temperature controller. Thermal stability was measured by increasing temperature from 20 to 90
°C at a rate of 0.5 °C/min (Table 4.3). Protein secondary structure was monitored at 222 nm with a
step size of 1 °C and data integration time of 8 s. Thermal denaturation was repeated in triplicate,
and the melting temperature (Tm) was calculated using the Spectra Analysis tool in the J-1500 CD
spectrometer software package (Jasco).

138

Table 4.3. Thermal stabilities of MBP variants
Protein

Tm (°C)a

WT MBP

53.9 ± 0.7

WT MTP + 1 mM maltose

61.0 ± 0.8

MBP(V293L)

53.8 ± 0.8

MBP(V293L) + 1 mM maltose

59.5 ± 0.9

MBP(V293A)

50.1 ± 0.7

MBP(V293A) + 1 mM maltose

55.7 ± 0.7

a

Data reported as mean ± standard deviation (n=3)
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4.2.8 Fluorescence spectroscopy
Fluorescence spectroscopy was performed to evaluate maltose binding (Figure 4.4).
Maltose binding to MBP results in quenched tryptophan fluorescence and produces a 2.5 nm red
shift of the intrinsic fluorescence emission spectrum.[308,309] EPR spectroscopy of spin-labeled MBP
showed that the red shift is indicative of MBP adopting a closed conformation. [310] The addition of
maltose to V293L and V293A produced similar fluorescence quenching and red shifting as WT
MBP, confirming maltose binding to the closed conformation. Fluorescence spectra were obtained
on a Tecan Infinite M1000 PRO microplate reader using black 96 well flat-bottom microplates
(Grenier Bio-One). MBP concentration was 4 μM in 20 mM HEPES (pH 7.4). Maltose was added to
a final concentration of 400 μM and incubated with MBP for 15 min prior to measuring
fluorescence. Excitation was at 280 nm and emission was scanned from 300 to 400 nm in 1 nm
increments. All fluorescence assays were performed in triplicate and averaged. Fluorescence
spectra were background corrected by subtracting the fluorescence spectrum of the well solution
in the absence of protein.
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Figure 4.4. Fluorescence emission spectra of 4 μM MBP in 20 mM HEPES (pH 7.4). Spectra show
the quenching of fluorescence upon maltose binding. The magnitude of fluorescence quenching
was roughly equal among WT MBP (22%), MBP(V293L) (20%), MBP(V293A) (20%). The addition
of maltose red-shifted the maximum emission wavelengths of all MBP proteins by 2-3 nm,
indicating the transition from open to closed conformation upon ligand binding.
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4.2.9 DTNB Assays
Adduct formation between free thiols and 5,5′-dithiobis(2-nitrobenzoic acid) (DTBN, also
known as Ellman’s Reagent) was monited via absorbance at 412 nm using a Cary 60 UV-Vis
spectrophotometer

(Agilent

Technologies).

30

μM

of

MBP(I329Y)-GFP

and

MBP(G69C/I329Y/S337C)-GFP were incubated in excess DTNB in denaturing solution [100 mM
sodium phosphate (pH 8.0), 1 mM EDTA, 8 M urea] for 1 h at rt. The number of free thiols present
was measured using a molar absorptivity ε412 of 13 700 M-1 cm-1. The spectrophotometer was zeroed
using the MBP(I329Y)-GFP sample. The A412 of the MBP(G69C/I329Y/S337C)-GFP was ~0,
indicating that the cysteine side chains of residues 69 and 337 were not present as thiols but had
formed a disulfide bond.

4.2.10 Isothermal titration calorimetry (ITC)
All ITC experiments were performed at 298 K on a GE Healthcare MicroCal TM iTC200
instrument. MBP(I329Y)-GFP and MBP(G69C/I329Y/S337C)-GFP were prepared at 30 μM in PBS.
Maltose was prepared at 10x the protein concentration in PBS. The sample cell was filled with 300
μL of protein solution, and the reference cell was filled with deionized water. Calorimetric data
were analyzed by performing nonlinear regression fitting to the binding isotherm using ORIGIN
software (Figure 4.5).
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4.3 Results and Discussion

4.3.1 Maltose detection by MBP
Xenon hyper-CEST z-spectra were acquired from recombinant MBP in both the presence
and absence of maltose to assess the magnitude and frequency of NMR saturation contrast (Figure
4.5a). Multiple selective d-SNOB saturation pulses were scanned over the chemical shift range of 100 to 180 ppm in 5 ppm steps, and the

129

Xe(aq) signal was measured as a function of saturation

pulse offset. MBP in the absence of maltose (MBPopen) showed a single saturation response
corresponding to free

129

Xe in solution centered at 0 ppm. In contrast, MBP in the presence of

maltose (MBPclosed) showed a pronounced saturation response 95 ppm downfield of the Xe (aq) peak,
corresponding to Xe@MBPclosed. This peak is 35 ppm further downfield than Xe@TEM1,[250]
suggesting that Xe@MBPclosed experiences a more hydrophobic environment. Also, the width of the
Xe@MBPclosed peak (35 ppm) is narrower than Xe@TEM1 (60 ppm), indicating slower Xe exchange
with MBP.
To assess the detection sensitivity of MBP, time-dependent saturation transfer experiments
were performed by measuring Xe(aq) polarization as a function of saturation time (Figure 4.6).
Saturation frequencies of d-SNOB pulses were positioned +95 ppm and -95 ppm, referenced to the
Xe(aq) peak, for on- and off-resonance, respectively. The normalized difference between on- and offresonance saturation transfer was measured as on-resonance hyper-CEST contrast. By this method,
100 nM MBP with 1 mM maltose reported 0.26 ± 0.01 saturation contrast; by comparison, 0.23 ±
0.02 saturation contrast was observed for 100 nM TEM1. To evaluate the responsiveness of MBP
MR contrast to maltose, additional saturation contrast measurements were taken for 100 nM MBP
with decreasing maltose. The lowest maltose concentration that could be readily detected by MBP
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was 100 nM, with an observed saturation contrast of 0.050 ± 0.007. For each maltose concentration,
the amount of MBPclosed (i.e., contrast “ON”) was calculated using a Kd of 1 μM. The observed
saturation contrast was linearly proportional (R2 = 0.953) to the percentage of MBP in the maltosebound closed conformation, which provides a measure of maltose concentration (Figure 4.5b).
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Figure 4.5. (a) Xe hyper-CEST z-spectra of 80 μM MBP with and without 1 mM maltose in pH 7.2
PBS at 300 K, with z-spectra of buffer only with and without maltose shown for reference. Pulse
length, τpulse = 3.8029 ms; field strength, B1,max = 77 μT (b) Saturation contrast for 100 nM WT MBP
and 100 nM MBP(I329Y)-GFP as a function of percent MBP in maltose-bound closed conformation.
For WT MBP, [maltose] = 0, 0.1, 0.3, 0.5, 1, 3, 1000 μM. For MBP(I329Y)-GFP, [maltose] = 0, 32, 72,
140, 5000 nM. Pulse length, τpulse = 1.0496 ms; field strength, B1,max = 279 μT. The number of pulses
increased linearly from 0 to 15000.
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(a)

(b)

(c)

(d)

(e)

(f)

(g)

Figure 4.6. (a) 0 μM maltose: saturation contrast = 0.022 ± 0.004; T1on = 41 ± 2 s and T1off = 44 ± 3 s. (b)
0.1 μM maltose: saturation contrast = 0.050 ± 0.007; T1on = 34 ± 1 s and T1off = 41 ± 3 s. (c) 0.3 μM
maltose: saturation contrast = 0.05 ± 0.01; T1on = 35 ± 1 s and T1off = 43 ± 1 s. (d) 0.5 μM maltose:
saturation contrast = 0.11 ± 0.01; T1on = 26.3 ± 0.9 s and T1off = 39 ± 1 s. (e) 1 μM maltose: saturation
contrast = 0.118 ± 0.007; T1on = 32.7 ± 0.7 s and T1off = 50 ± 1 s. (f) 3 μM maltose: saturation contrast =
0.161 ± 0.004; T1on = 26 ± 1 s and T1off = 46 ± 2 s. (g) 1 mM maltose: saturation contrast = 0.26 ± 0.01;
T1on = 21.8 ± 0.7 s and T1off = 55 ± 3 s. All measurements taken in pH 7.2 PBS at 300 K. Pulse length,
τpulse = 1.0496 ms; field strength, B1,max = 279 μT. The number of pulses increased linearly from 0 to
15000.
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4.3.2 Mutagenesis to modulate maltose detection sensitivity
To extend the detection threshold of MBP, Ile-329 was mutated to Tyr to greatly increase
maltose affinity (reported Kd = 22 nM).[303] This mutation alters the conformational dynamics of
MBP to disfavor the unliganded, open conformation, thereby promoting maltose binding through
conformational coupling.[303,304] Importantly, Ile-329 is located in a “hinge region” opposite the
maltose-binding cleft, far enough away from the Xe-binding site to reasonably assume that
mutations at this position should not affect Xe exchange. The I329Y mutation was introduced to
MBP-GFP fusion construct to facilitate protein quantitation during cell studies (vide infra). The Xe
hyper-CEST z-spectrum of MBP(I329Y)-GFP in the presence of 1 mM maltose is comparable to WT
MBP (Figure 4.7), though the saturation response of Xe@MBP(I329Y)-GFP is shifted 5 ppm
downfield and is slightly attenuated compared to WT. Saturation contrast measurements for 100
nM MBP(I329Y)-GFP followed the same procedure used for WT MBP, but with the saturation
frequencies of d-SNOB pulses positioned +100 ppm and -100 ppm (Figure 4.8). As observed for WT
MBP, saturation contrast was linearly proportional (R2 = 0.997) to the percentage of MBP in the
maltose-bound closed conformation (Figure 4.5b). The detection threshold for the I329Y mutant
was 32 nM maltose, which gave rise to saturation contrast of 0.07 ± 0.01. These saturation contrast
data demonstrate that MBP can be “tuned” through mutagenesis to detect maltose across varying
concentration ranges. High-affinity mutants such as I329Y can be employed for nM-to-low uM
maltose detection, whereas WT MBP can be used for low uM-to-mM maltose detection.
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Figure 4.7. Hyper-CEST z-spectra of 80 μM MBP(I329Y)-GFP with and without 1 mM maltose in
pH 7.2 PBS at 300 K. The z-spectra of 80 μM WT MBP with and without 1 mM maltose shown for
reference. Pulse length, τpulse = 3.8029 ms; field strength, B1,max = 77 μT.
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(a)

(b)
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(d)

(e)

Figure 4.8. Time-dependent saturation transfer data for 100 nM MBP(I329Y)-GFP at varying
concentrations of maltose. (a) 0 nM maltose: saturation contrast = 0.01 ± 0.01; T 1on = 19.0 ± 0.5 s and
T1off = 18.8 ± 0.6 s. (b) 32 nM maltose: saturation contrast = 0.07 ± 0.01; T1on = 17.1 ± 0.4 s and T1off =
19.0 ± 0.6 s. (c) 72 nM maltose: saturation contrast = 0.12 ± 0.02; T1on = 19.3 ± 0.7 s and T1off = 25.3 ±
0.6 s. (d) 140 nM maltose: saturation contrast = 0.173 ± 0.006; T1on = 15.2 ± 0.5 s and T1off = 22.3 ± 0.9
s. (e) 5 uM maltose: saturation contrast = 0.24 ± 0.01; T1on = 16.2 ± 0.6 s and T1off = 29.4 ± 0.8 s. All
measurements taken in pH 7.2 PBS at 300 K. Pulse length, τpulse = 1.0496 ms; field strength, B1,max =
279 μT. The number of pulses increased linearly from 0 to 15000.
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4.3.3 Hyper-CEST of MBP in E. coli
To evaluate the hyper-CEST contrast detectable from MBP in a cellular environment, MBP
with a C-terminal GFP tag (MBP-GFP) was expressed in BL21(DE3) E. coli cells and time-dependent
saturation transfer measurements were taken following the same protocol used for purified WT
MBP (Figure 4.9). Using the GFP tag, MBP concentration was quantified in real-time by
fluorescence intensity at 510 nm (λex = 489 nm). E. coli growths not induced with IPTG served as
controls to measure background contrast. Cells were washed with PBS and then transferred to an
NMR tube for data collection. Control E. coli reported saturation contrasts of 0.11 ± 0.01 and 0.09 ±
0.01 with and without 1 mM maltose, respectively. Background contrast at 95 ppm downfield Xe (aq)
likely arises from Xe exchanging with the hydrophobic interior of cellular membranes. E. coli
expressing MBP in the presence of maltose reported 0.25 ± 0.02 saturation contrast (Table 4.4),
nearly five-fold higher than E. coli expressing MBP in the absence of maltose (0.14 ± 0.01), after
subtraction of background (0.11 ± 0.01) from both. This highlights a mechanism for designing
xenon-based MRI molecular imaging agents capable of detecting a specific analyte in cellular
milieu.
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(a)

(b)

(c)

(d)

Figure 4.9. Time-dependent saturation transfer data for WT MBP-GFP in E. coli. (a) [MBP-GFP] <
0.001 μM, no maltose; saturation contrast = 0.09 ± 0.01 (b) [MBP-GFP] < 0.001 μM, 1 mM maltose;
saturation contrast = 0.11 ± 0.01 (c) [MBP-GFP] = 1.0 ± 0.2 μM, no maltose; saturation contrast = 0.14
± 0.01. (d) [MBP-GFP] = 1.00 ± 0.02 μM, 1 mM maltose; saturation contrast = 0.25 ± 0.02. All
measurements taken in pH 7.2 PBS at 300 K. Pulse length, τpulse = 1.0496 ms; field strength, B1,max =
279 μT. The number of pulses increased linearly from 0 to 10000.
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Table 4.4. Saturation contrast from MBP expressed in E. coli
T1on (s)

T1off (s)

Saturation
contrast

[MBP-GFP]
(µM)a

non-induced, no maltose

19.1 ± 0.8

26 ± 2

0.09 ± 0.01

< 0.001

non-induced, 1 mM maltose

18.9 ± 0.8

28 ± 2

0.11 ± 0.01

< 0.001

induced, no maltose

17.9 ± 0.7

28.5 ± 0.8

0.14 ± 0.01

1

induced, 1 mM maltose

13.3 ± 0.6

28 ± 2

0.25 ± 0.02

1

E. coli sample

a

MBP-GFP concentration measured by fluorescence
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4.3.4 Multiplexed MR contrast
The saturation frequency of Xe@MBP is sufficiently downfield of Xe@TEM1 that we
hypothesized that the two proteins could be detected sequentially and very sensitively with
minimal crosstalk using hyper-CEST in the same solution. The hyper-CEST z-spectrum of a
mixture of MBP and TEM1 was acquired, where the ratio of MBP to TEM1 was lowered to
approximately equalize the magnitude of contrast produced by the two proteins (Figure 4.10). The
z-spectrum of 27 μM MBP and 80 μM TEM1 in the absence of maltose showed two peaks: Xe (aq) at
0 ppm, and Xe@TEM1 at 60 ppm. In the presence of 1 mM maltose, three peaks were observed:
Xe(aq) at 0 ppm, Xe@TEM1 at 60 ppm, and Xe@MBP at 95 ppm. Critically, the magnitude of
saturation contrast at 60 ppm for Xe@TEM1 was not affected by maltose or whether MBP contrast
was “on” or “off”. We envision that the ability to multiplex the responsive hyper-CEST agent, MBP,
with a non-responsive hyper-CEST agent such as TEM1, should enable the in vivo quantitation of
maltose via ratiometric analysis. Indeed, ratiometric approaches employing fluorescent small
molecules and proteins have been widely applied for detection of ions and biomolecules in solution
and in cellular studies.[311]
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Figure 4.10. Hyper-CEST z-spectra of 27 μM MBP and 80 μM TEM1 with and without 1 mM
maltose in pH 7.2 PBS at 300 K. Blue and green lines show Lorentzian fits to the Xe-TEM1 and Xe (aq)
peaks, respectively. Pulse length, τpulse = 3.8029 ms; field strength, B1,max = 77 μT.
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4.3.5 CEST contrast dependence on MBP conformation
To ascertain whether hyper-CEST contrast with MBP results from the closed conformation
induced by maltose binding or from sugar binding alone, the z-spectrum of MBP in the presence
of β-cyclodextrin (βCD) was obtained (Figure 4.11). βCD binds MBP with good affinity (Kd = 1.8
μM) in the same cleft as maltose, but its larger size prevents MBP from adopting a closed
conformation.[312] The z-spectrum of MBP with βCD shows no downfield saturation response,
indicating that the maltose-bound closed conformation is required for producing hyper-CEST
contrast. The lack of saturation contrast with MBP+βCD was unexpected given that Xe has higher
affinity for MBP+βCD than MBP+maltose. Previous 1H-15N HSQC NMR experiments measured a
Ka of 20 ± 10 M-1 for Xe binding to MBP+βCD and concluded that Ka was too low to measure for Xe
binding to MBP+maltose: The addition of Xe to MBP+maltose produced no measurable changes in
the 1H-15N HSQC resonances.[274] Indeed, the fact that the Xe(aq) peak is broadened more by βCD
(FWHM = 60 ppm) than by maltose (47 ppm) reveals a greater degree of Xe exchange with
MBP+βCD than MBP+maltose. The structural basis for a difference in Xe affinity is not obvious,
however, as the contours of the Xe-binding cavity are largely conserved among several MBP
complexes (Figure 4.12). It therefore appears that the primary determinant of hyper-CEST contrast
in MBP is rate of Xe exchange, not Xe affinity. Xe exchange is likely too fast (~MHz frequency) with
MBPopen (with or without βCD), but the binding of maltose and the conformational change to
MBPclosed slows the rate of Xe exchange to resolve a separate peak in the z-spectrum.
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Figure 4.11. Comparison of CEST z-spectra from MBP with maltose or β-cyclodextrin. Hyper-CEST
z-spectra of 80 μM WT MBP in the presence of 1 mM maltose and 1 mM β-cyclodextrin in pH 7.2
PBS at 300 K. The z-spectra of 1 mM maltose and 1 mM β-cyclodextrin in the absence of MBP are
shown for reference. Pulse length, τ pulse = 3.8029 ms; field strength, B1,max = 77 μT.
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Figure 4.12. Comparison of the Xe-binding pocket in multiple MBP crystal structures. The
conformations of the hydrophobic residues lining the pocket are conserved among MBP open (cyan;
PDB ID 1OMP),[313] MBPopen derivatized with Xe (light blue; PDB ID 1LLS),[274] MBPopen bound to
βCD (violet; PDB ID 1DMB),[312] and MBPclosed bound to maltose (orange; PDB ID 1ANF).[314] There
is slight variation, though, in the position of the terminal amine of the Lys-15 side chain.
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Having ascertained that the closed conformation of MBP is required for CEST contrast, it
was next explored whether sugar binding is also necessary. To test this hypothesis, a disulfide bond
was introduced into the MBP(I329Y)-GFP construct via G69C and S337C mutations. This
interdomain disulfide bond had been previously shown to constrain MBP to the closed
conformation,

even

in

the

absence

of

bound

ligand.[315]

Upon

preparation

of

MBP(G69C/I329Y/S337C)-GFP, the formation of the disulfide linkage between C69 and C337 was
confirmed by DTNB assay. The conformational state of MBP(G69C/I329Y/S337C)-GFP was further
characterized by measuring the thermodynamics of maltose binding by ITC (Figure 4.13). Whereas
MBP(I329Y)-GFP reported a Kd of 58 nM for maltose, MBP(G69C/I329Y/S337C)-GFP showed no
measurable thermodynamic response upon maltose titration, further indicating that the protein is
in its closed conformation and is thus unable to bind ligand.
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Figure

4.13.

ITC

enthalpograms

for

maltose

MBP(G69C/I329Y/S337C)-GFP.
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binding

to

(a)

MBP(I329Y)-GFP;

(b)

The hyper-CEST z-spectrum of MBP(G69C/I329Y/S337C)-GFP showed no downfield CEST
response, indicating that maltose binding is indeed a requirement for Xe hyper-CEST with MBP
(Figure 4.14). Comparison to the z-spectra of unliganded and maltose-bound MBP(I329Y)-GFP
offers additional insights. The Xe(aq) peak width of MBP(G69C/I329Y/S337C)-GFP is broader than
closed, maltose-bound MBP(I329Y)-GFP, suggesting that the presence of bound ligand lowers Xe
affinity for MBP. Additionally, comparison of the downfield saturation responses of unliganded
MBP(I329Y)-GFP and MBP(G69C/I329Y/S337C)-GFP reveals that while the disulfide mutant gives
no CEST response at a specific frequency, this mutant shows more asymmetry in the downfield
direction, hinting that Xe exchange at a solvent-shielded site is occurring, but at a rate that is fast
on the NMR timescale. These data, combined with the z-spectrum of MBP + β-cyclodextrin,
demonstrate that maltose binding and a closed conformation are co-requirements for achieving
useable CEST contrast from MBP.
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Figure 4.14. Xe hyper-CEST z-spectra of 80 μM MBP(G69C/I329Y/S337C) in pH 7.2 PBS at 300 K.
The z-spectra of MBP(I329Y)-GFP in the presence and absence of maltose included for reference.
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4.3.6 Mutagenesis to identify origin of hyper-CEST contrast
We performed mutagenesis experiments to further probe the mechanism of Xe CEST with
MBP. Val-293 was chosen as the site for single-point mutations due to its proximity to bound Xe
identified in the maltose-free MBP structure (Figure 4.2). The methyl carbons of Val-293 are only
4.0 and 4.2 Å from Xe, respectively, thus it was expected that mutations at this position would
affect Xe binding affinity and/or kinetics. Val-293 was mutated to Leu to reduce the cavity volume,
and to Ala to enlarge the cavity. CD and fluorescence spectroscopy, along with thermal stability
assays, confirmed that the V293L and V293A mutants retained the same global structure and
maltose-binding properties as WT MBP (Figures 4.3 and 4.4; Table 4.3).
The Xe hyper-CEST z-spectra of MBP(V293L) and MBP(V293A) were obtained following
the same protocol used for WT MBP (Figure 4.15). MBP(V293L) with and without maltose showed
only a saturation response for 129Xe(aq), suggesting that substitution of valine for the bulkier leucine
sidechain effectively blocks Xe from occupying the MBP cavity. This result helps to confirm that
the crystallographically-determined Xe site for MBPopen is also the site of hyper-CEST with
MBPclosed. The

129

Xe(aq) peaks for MBP(V293L) are narrower (19.1 ppm without maltose, 21.5 ppm

with maltose) than WT MBP (41.8 ppm without maltose, 47 ppm with maltose), further confirming
the overall reduction of Xe exchange with MBP(V293L) relative to WT MBP. However, the 129Xe(aq)
peaks for MBP(V293L) are broader than PBS in the absence of protein, likely due to non-specific
Xe-protein interactions elsewhere on the surface of MBP. [316]
The z-spectrum of 80 μM MBP(V293A) without maltose showed only the

129

Xe(aq) peak,

though in the presence of maltose a plateau of saturation response was observed between 50 and 10 ppm. Lowering the protein concentration to 10 μM resolved this broad saturation response into
two peaks – one at 0 ppm for

129

Xe(aq), the other at 36 ppm for Xe@MBP(V293A)closed. This large
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change in chemical shift from 95 ppm observed for WT follows a trend observed in T4 lysozyme, [274]
clathrate cages,[317] and zeolites,[318] where it has been noted that larger cavities produce smaller
downfield 129Xe chemical shifts, and vice-versa. Notably, this mutation increased the magnitude of
CEST saturation contrast with 100 nM MBP from 0.26 ± 0.01 (WT) to 0.35 ± 0.02 for MBP(V293A)
(Figure 4.16). The molecular features of this signal enhancement and chemical shift change are
under investigation.
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Figure 4.15. Xe hyper-CEST z-spectra from MBP(V293L) and MBP(V293A). Hyper-CEST z-spectra
of 80 μM MBP(V293L) with and without 1 mM maltose, 80 μM MBP(V293A) with and without 1
mM maltose, and 10 μM MBP(V293A) with 1 mM maltose. All measurements taken in pH 7.2 PBS
at 300 K. Pulse length, τpulse = 3.8029 ms; field strength, B1,max = 77 μT.
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Figure 4.16. Time-dependent saturation transfer data for 100 nM MBP(V293A). The observed
saturation contrast is 0.35 ± 0.02. Saturation frequencies of Dsnob-shaped pulses were positioned
+36 ppm and -36 ppm, referenced to the Xe(aq) peak, for on- and off-resonance, respectively. Pulse
length, τpulse = 1.0496 ms; field strength, B1max = 279 μT. Both on-resonance and off-resonance data
were fitted with first-order exponential decay curves, with T1on = 11.6 ± 0.3 s and T1off = 22.0 ± 0.7 s.
Measurements taken in pH 7.2 PBS at 300 K. Pulse length, τpulse = 1.0496 ms; field strength, B1,max =
279 μT. The number of pulses increased linearly from 0 to 15000.
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4.4 Conclusions
We have demonstrated that 100 nM MBP generates significant saturation contrast in vitro
and that observed contrast is proportional to % MBPclosed, thereby characterizing MBP as a “smart”
analyte-sensitive biosensor. The MBP(I329Y)-GFP sensor at 100 nM concentration detected maltose
in the range 32 nM to 5 μM, whereas 100 nM WT MBP detected maltose in the range 100 nM to 1
mM. Notably, the large (+95 ppm) 129Xe NMR chemical shift was generated within the genetically
encoded MBP molecule and did not require post-translational modification or cofactor such as a
lanthanide or other paramagnetic shift agent. Additionally, WT MBP appended with GFP was
readily detected at 1 μM via hyper-CEST NMR when expressed in the cytoplasm of E. coli. The
large downfield shift of WT MBP (δ = 95 ppm) makes it compatible with TEM1 (δ = 60 ppm) for
multiplexing applications and ratiometric analysis. Notably, Xe-TEM1 was cleanly detected in the
multiplexing experiment with minimal crosstalk from Xe-MBP, by withholding maltose until XeMBP signal was desired. Experiments with MBP(I329Y)-GFP confirm 3-4 orders-of-magnitude
higher small-molecule sensitivity than that achieved with available GE T1 or 1H-CEST contrast
agents. Indeed, nM maltose detection via MBP hyper-CEST NMR rivals the small-molecule
detection sensitivity of many GE fluorescent sensors.
The increased contrast generated by the V293A mutation (and loss of contrast observed for
V293L) confirms that MBP-CEST efficiency can be enhanced with mutations to the xenon binding
site: coupling this with mutations promoting the maltose-bound, MBP-closed conformation [303,304]
should yield a superior biosensor. Furthermore, the modulated saturation frequency of V293A (δ
= 36 ppm, shifted 59 ppm upfield from WT MBP) suggests that rational mutagenesis will yield MBP
variants with a broad range of 129Xe NMR chemical shifts, akin to the palette of fluorescent proteins
such as GFP and mCherry commonly used for multiplexed cellular imaging. [319] Similar attempts
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to engineer TEM1 through site-directed mutagenesis have so far failed to improve or modulate its
CEST signal (unpublished data), which makes MBP a particularly versatile protein system for
elucidating the hyper-CEST mechanism. Finally, MBP variants that have been engineered
previously to bind different ligands highlight the exciting potential for employing MBP-enhanced
129

Xe NMR/MRI to detect bioactive molecules present in mammalian cells.

167

Chapter 5: Ribose Binding Protein

5.1 Introduction
Real-time, in vivo detection of metabolites is key to disease diagnosis and treatment
evaluation. The use of genetically encoded (GE) contrast agents for metabolite detection (a.k.a.
biosensors) confers several advantages, namely non-invasive delivery, stable expression within
specific cell types in a transgenic organism, and the capability for repeated, long-term
imaging.[124,128,131] A popular platform for developing such GE contrast agents are the periplasmic
binding proteins (PBPs), a family of bacterial proteins involved in the binding and transport of a
variety of metabolites, small molecules, and metal ions.[320] PBPs consist of two globular domains
and are categorized as either class I or class II depending on the number and order of β-strands in
each domain.[320,321] PBPs are attractive as biosensors because upon binding its respective ligand, a
PBP undergoes a conformational change akin to a “Venus flytrap” [320] by which the ligand is buried
in a hinge region positioned between the two globular lobes of the protein. Several strategies have
been developed to transduce ligand binding by PBPs into useful optical contrast, such as by
covalently attaching a fluorophore sensitive to the conformational state of the protein, or by fusing
fluorescent proteins to the N- and C-termini of the PBP. [322] The clinical utility of these optical
contrast agents, however, is limited by the strong scattering of light by tissue. NMR and MRI, on
the other hand, have virtually unlimited penetration depths. Thus, there is a need for adapting
PBPs into analyte-sensitive GE contrast agents detectable by MR contrast.
Having established maltose binding protein (MBP) as a GE, analyte-sensitive contrast
agent detectable by

129

Xe NMR/MRI,[207] we expanded our biosensing efforts to other members of

the PBP family. One such member is ribose binding protein (RBP), which mediates ribose import
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and chemotaxis in gram-negative bacteria and has been well-characterized in the literature. [323] RBP
from E. coli binds ribose with high affinity (Kd = 130 nM)[324] in the hinge region between its globular
N- and C-domains. In the absence of ribose, RBP exists in an open conformation, but upon binding
ribose RBP adopts a closed conformation. As with other PBPs,[153,300] RBP’s high selectivity for its
natural ligand has made it an attractive platform for biosensing applications. In 2003 Lager and
coworkers developed an optical biosensor for ribose by attaching fluorescent proteins to the Nand C-termini of RBP and monitoring ribose binding via changes in FRET fluorescence. [155]
Similarly, a fluorescent probe attached to the hinge region of RBP was shown to effectively
transduce ribose binding into optical contrast. [325] Interest in ribose biosensors is primarily
motivated by ribose’s involvement in metabolism and disease. Extracellular free ribose is imported
into mammalian cells through a process known as “ribose salvage,” where it is then
phosphorylated to ribose-5-phosphate before entering either the nucleotide synthesis or pentosephosphate pathways.[326,327] It has been hypothesized that different cell types and cancer cells utilize
ribose salvage to provide precursors for distinct cellular pathways.[328] The ability to monitor free
ribose concentration in vivo would be a useful tool for understanding the association between
ribose salvage and cell metabolism in healthy and diseased states.
Further exciting our interest in RBP was the fact that a xenon binding site has been
previously engineered into RBP through a leucine-to-alanine truncation at residue 19 (Figure
5.1).[329] 1H-15N HSQC NMR experiments determined the xenon binding affinities (Ka) of open and
closed RBP(L19A) to be 70 ± 30 M-1 and 40 ± 20 M-1, respectively. Moreover, prior direct detection
Xe NMR experiments have shown that the chemical shift of Xe is sensitive to the conformational
state of RBP(L19A) and, therefore, to the presence or absence of ribose in solution. [329] These data,
along with RBP’s structural similarity to MBP, motivated us to explore RBP as a GE hyper-CEST
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biosensor for ribose. The work presented in this chapter demonstrates that nanomolar
concentrations of RBP can effectively transduce ribose concentration into MR contrast measurable
by Xe hyper-CEST, and that the concentration range of ribose detectable by this method can be
tuned through site-directed mutagenesis of RBP.

170

Figure 5.1. Proposed Xe binding site in RBP(L19A). The protein model is based on the crystal
structure of ribose-bound RBP in its closed conformation (PDB ID 2DRI[323]). Xe (red dots) was
modeled at the center of the cavity created by the L19A mutation. Bound ribose shown as yellow
sticks. (Inset) Close-up view of the Xe binding site of RBP(L19A) in its closed (gray) and open
(green; PDB ID 1URP[330]) conformations. Open and closed RBP structures were aligned from
residues 1 to 100 using PyMOL

171

5.2 Materials and Methods

5.2.1 Plasmid preparation
The codon-optimized gene for mature ribose binding protein (RBP) from Escherichia coli
(UniProt acc. no. P02925) incorporating a L19A mutation was synthesized and cloned into a pJ411
vector by ATUM. The RBP(L19A) gene was later amplified using the primers listed in Table 5.1
and cloned via ligation independent cloning (LIC) into a pET-His-GFP-TEV LIC vector, a gift from
Scott Gradia acquired via Addgene (plasmid #29663). The resulting GFP-RBP(L19A) plasmid was
sequenced at the University of Pennsylvania DNA Sequencing Facility to verify the integrity of the
fusion construct.

5.2.2 Site-directed mutagenesis
Mutations were introduced to the GFP-RBP(L19A) gene via site-directed mutagenesis
using the forward and reverse oligonucleotide primers listed in Table 5.2. Mutant plasmids were
amplified in NEB-5α competent E. coli cells (New England Biolabs), purified using a Monarch®
miniprep kit (New England Biolabs), and sequenced at the University of Pennsylvania DNA
Sequencing Facility to verify the incorporation of the desired mutation and the integrity of the GFPRBP gene.
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Table 5.1. Oligonucleotide primers used for RBP(L19A) gene amplification
Forward primer

5'– TACTTCCAATCCAATGCAAAAGATACCATCGCGCTGGTCG –3'

Reverse primer

5'– TTATCCACTTCCAATGTTATTACTGTTTGACAACCAGTTTCAGG –3'
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Table 5.2. Oligonucleotide primers used for RBP site-directed mutagenesis

L19V

Q235A

T135A

Forward primer

5'– GTTCTTTGTCTCTGTGAAGGACGGCGCGC –3'

Reverse primer

5'– GCGCGCCGTCCTTCACAGAGACAAAGAAC –3'

Forward primer

5'– GCGACGATTGCAGCGCTGCCGGACCAG –3'

Reverse primer

5'– CTGGTCCGGCAGCGCTGCAATCGTCGC –3'

Forward primer

5'– GGTATCGCGGGTGCCAGCGCTGCGCGC –3'

Reverse primer

5'– GCGCGCAGCGCTGGCACCCGCGATACC –3'
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5.2.3 RBP expression and purification
Plasmid encoding either RBP(L19A) or GFP-RBP(L19A) was transformed into BL21(DE3)
competent E. coli cells (New England Biolabs) and grown in 6 x 1 L of LB media supplemented with
50 μg/mL kanamycin to a OD600 of ~1. Protein expression was induced by adding isopropyl-β-Dthiogalactopyranoside (IPTG) to a final concentration of 1 mM. The induced cells were incubated
overnight at 18 °C, harvested by centrifugation, then frozen at -80 °C for long-term storage. The
frozen cell pellet was thawed and resuspended in 20 mM sodium phosphate (pH 7.4), lysed with
lysozyme (Sigma), and treated with benzonase nuclease (Sigma) to reduce the viscosity of the
lysate. After stirring the lysate at rt for 30 min, NaCl was added to 0.5 M and imidazole was added
to 20 mM. The lysate was clarified by centrifugation, and the supernatant was loaded onto a
HisTrap nickel affinity column (GE Life Sciences) pre-equilibrated with 20 mM sodium phosphate
(pH 7.4), 0.5 M NaCl, 20 mM imidazole. RBP bound to the column was unfolded with 20 column
volumes (CVs) of 20 mM sodium phosphate (pH 7.4), 0.5 M NaCl, 20 mM imidazole, 8 M urea to
remove endogenous ribose bound to RBP. RBP was refolded on-column via a 12-CV gradient to 20
mM sodium phosphate (pH 7.4), 0.5 M NaCl, 20 mM imidazole, and then eluted with 20 mM
sodium phosphate (pH 7.4), 0.5 M NaCl, 500 mM imidazole. The eluate was concentrated and
further purified by size-exclusion chromatography in PBS (HyClone) using a HiLoad 16/600
Superdex column (GE Life Sciences). Fractions containing pure RBP (over 95% as indicated by SDSPAGE) were pooled and concentrated. Protein concentration were determined from the absorbance
at 280 nm (ε280 = 7 450 M-1 cm-1 for RBP(L19A); ε280 = 27 850 M-1 cm-1 for GFP-RBP(L19A)). GFPRBP(L19V), GFP-RBP(L19A/Q235A), and GFP-RBP(L19A/T135A/Q235A) were prepared following
the same procedure used for RBP(L19A) and GFP-RBP(L19A).
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5.2.4 Circular dichroism (CD) spectroscopy
The CD spectra of all RBP variants were measured on a Jasco J-1500 CD spectrometer
equipped with a Peltier temperature controller (Figure 5.2). Spectra were acquired from 10 μM of
RBP(L19A) and 5 μM of GFP-RBP(L19A) and variants in 10 mM sodium phosphate (pH 8.0) buffer
inside a quartz cuvette with a 1 mm path length. CD spectra were taken at 20 °C with a wavelength
step of 1 nm.
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Figure 5.2. CD spectra of 10 μM RBP(L19A) (top) and 5 μM GFP-RBP(L19A) and variants
(bottom) in 10 mM sodium phosphate buffer (pH 8.0).
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5.2.5 Isothermal titration calorimetry (ITC)
All ITC experiments were performed at 298 K on a GE Healthcare MicroCal TM iTC200
instrument. RBP(L19A), GFP-RBP(L19A), and GFP-RBP(L19V) were prepared at 30 μM in PBS,
GFP-RBP(L19A/Q235A) at 50 μM, and GFP-RBP(L19A/T135A/Q235A) at 200 μM. Ribose was
prepared at 10x the protein concentration in PBS. The sample cell was filled with 300 μL of protein
solution, and the reference cell was filled with deionized water. Calorimetric data were analyzed
by performing nonlinear regression fitting to the binding isotherms using ORIGIN software
(Figure 5.3; Table 5.3).
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Figure 5.3. ITC enthalpograms for ribose binding to (a) RBP(L19A); (b) GFP-RBP(L19A); (c) GFPRBP(L19V); (d) GFP-RBP(L19A/Q235A); (e) GFP-RBP(L19A/T135A/Q235A)
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Table 5.3. Summary of RBP ITC data
Protein

Kd (µM)

∆H (kcal mol-1)

∆S (cal mol-1 deg-1)

RBP(L19A)

0.41 ± 0.06

-4.45 ± 0.06

14.3

GFP-RBP(L19A)

0.34 ± 0.07

-3.65 ± 0.07

17.3

GFP-RBP(L19V)

0.19 ± 0.07

-4.5 ± 0.1

15.6

10 ± 3

-2.6 ± 0.3

14.4

130 ± 30

-1.7 ± 0.3

12.2

GFP-RBP(L19A/Q235A)
GFP-RBP(L19A/T135A/Q235A)
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5.2.6 129Xe hyper-CEST of RBP
129

Xe was hyperpolarized and the hyper-CEST z-spectra of RBP were acquired following

the same procedure used for MBP.[207] Briefly, hyperpolarized (hp)

129

spin-exchange optical pumping (SEOP) method with a home-built

Xe was generated using the

129

Xe polarizer based on the

IGI.Xe.2000 commercial model by GE. A Shark 65 W tunable ultra-narrow band diode laser
(OptiGrate) set to 795 nm was used for optical pumping of Rb vapor. A gas mixture of 88% helium,
10% nitrogen, and 2% natural abundance xenon (Linde Group, NJ) was used as the hyperpolarizer
input. 129Xe hyperpolarization level was roughly 10-15%. For each data point in the hyper-CEST zspectra, hp

129

Xe was bubbled into the NMR tube through capillaries for 20 s, followed by a 3 s

delay to allow bubbles to collapse. A d-SNOB saturation pulse with 690 Hz bandwidth was used.
Pulse length, τpulse = 3.80 ms; field strength B1,max = 77 μT; number of pulses, npulse = 400; saturation
time, Τsat = 1.52 s. NMR experiments were performed using a Bruker BioDRX 500 MHz NMR
spectrometer and 10-mm PABBO probe, at 300 K. A 90° hard pulse of this probe has a pulse length
of 22 μs. Unless otherwise noted, the protein concentration used was 10 μM, with 0.1% (v/v)
Pluronic L81 (Aldrich) added to mitigate foaming.
To assess the detection sensitivity of GFP-RBP(L19A) and mutants, time-dependent
saturation transfer experiments were performed by measuring Xe (aq) polarization as a function of
saturation time. Saturation transfer was calculated using Equation 5.1.

ST =

𝐼

−𝐼
𝐼

𝐿
∑ 𝐿

Equation 5.1. Calculation of saturation contrast (ST), where I represents the acquired postsaturation Xe(aq) signal with set saturation frequency, duration, and power. L represents the
duration of hyper-CEST pulse sequences. The index k indicates each data point.
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Shaped saturation pulses were applied at the chemical shift of Xe@GFP-RBP(L19A) closed, and the
residual aqueous

129

Xe signal after saturation transfer was measured as an on-resonance CEST

response. Saturation frequencies of Dsnob-shaped pulses were positioned at +42.5 and -42.5 ppm,
referenced to the Xe(aq) peak, for on- and off-resonance, respectively. The pulse length was 1.727
ms, and the field strength was 170 μT. The normalized difference between on- and off-resonance
signals was represented by the saturation contrast.
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5.3 Results and Discussion

5.3.1 CEST contrast from RBP
To evaluate whether RBP(L19A) reports any useable MR contrast, the Xe hyper-CEST zspectrum was acquired from 10 μM RBP(L19A) in the presence of 1 mM ribose (Figure 5.4).
Multiple selective Dsnob-shaped saturation pulses were scanned over the chemical shift range of
93-358 ppm in 5 ppm steps, and the 129Xe(aq) signal was measured as a function of saturation pulse
offset. A well-resolved response at 237.5 ppm, roughly 42.5 ppm downfield of the Xe (aq) peak, was
observed. The presence of separate peaks in the z-spectrum indicates that Xe exchange with
RBP(L19A) is slow on the NMR timescale and demonstrates that the protein is a suitable hyperCEST biosensor. The z-spectrum also showed an unexpected upfield peak at 120 ppm, though the
disappearance of this peak in subsequent z-spectra (vide infra) suggests that this peak is likely a
spectral artifact.
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Figure 5.4. Xe hyper-CEST z-spectra of 10 μM RBP(L19A) and GFP-RBP(L19A) constructs in pH
7.2 PBS at 300 K, with z-spectra of buffer only with and without ribose shown for reference. Pulse
length, τpulse = 3.80 ms; field strength, B1,max = 77 μT.
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Encouraged by this initial result, a His6-tagged GFP sequence was added to the RBP(L19A)
gene to enable facile protein quantification in future cell studies as well as demonstrate CEST
contrast from RBP(L19A) in the presence of a protein fusion partner. As expected, the Xe hyperCEST z-spectrum of 10 μM GFP-RBP(L19A) in the presence of 1 mM ribose reproduced the 42.5
ppm downfield CEST response, albeit slightly attenuated. Notably, the z-spectrum of GFPRBP(L19A) in the absence of ribose showed only a single saturation response at 195 ppm
corresponding to free

129

Xe(aq) in solution. The apparent ligand-activated MR contrast observed

from RBP(L19A) is similar to that observed from MBP, which reported its 95 ppm downfield peak
only in the presence of maltose. However, the noticeably different

129

Xe(aq) peak widths of GFP-

RBP(L19A) with and without ribose suggests some differences in the mechanisms of Xe exchange
between RBP and MBP. The z-spectra of MBP with and without maltose showed nearly-identical
129

Xe(aq) peak widths, indicating that ligand binding and/or protein conformation does not greatly

impact Xe affinity and that CEST contrast is dictated solely by Xe exchange rate. The z-spectrum
of GFP-RBP(L19A) without ribose, however, showed a

129

Xe(aq) peak that was markedly narrower

than that in the presence of ribose, suggesting that Xe affinity for unliganded, open RBP(L19A) is
much lower than for ribose-bound, closed RBP(L19A). This result is at odds with the Xe affinities
reported by Lowery et al., but experiments with MBP also showed this disagreement between
observed Xe affinities as measured by 1H-15N HSQC NMR and 129Xe hyper-CEST.
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5.3.2 Ribose detection by RBP
To verify the specificity of CEST contrast from RBP for ribose, Xe hyper-CEST z-spectra
were taken of 10 μM GFP-RBP(L19A) in the presence of either 1 mM glucose or 1 mM ribose-5phosphate (Figure 5.5). Prior work performed by Lager et al. using their FRET-RBP biosensor
construct showed no contrast upon the addition of glucose or ribose-5-phosphate. [155] As expected,
the z-spectra of GFP-RBP(L19A) with these two sugars showed no measurable CEST response.
Moreover, the widths of the Xe(aq) peaks in the glucose and ribose-5-phosphate spectra approximate
that of open, unliganded GFP-RBP, indicating that the presence of these two sugars does not affect
Xe exchange with open, unliganded RBP(L19A).
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Figure 5.5. Xe hyper-CEST z-spectra of 10 μM GFP-RBP(L19A) in presence of either 1 mM glucose
or 1 mM ribose-5-phosphate. Spectra taken in pH 7.2 PBS at 300 K with pulse length, τ pulse = 3.80
ms; field strength, B1,max = 77 μT.
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To assess the detection sensitivity of GFP-RBP(L19A), time-dependent saturation transfer
experiments were performed by measuring Xe(aq) polarization as a function of saturation time. By
this method, 100 nM ribose-bound GFP-RBP(L19A) in pH 7.2 PBS at 300 K reported a maximum of
0.30 ± 0.01 saturation contrast, which slightly exceeds the CEST contrast produced by 100 nM
maltose-bound MBP (0.26 ± 0.01) and 100 nM TEM-1 β-lactamase (0.23 ± 0.01). Measuring
saturation contrast as a function of percent GFP-RBP(L19A) in the closed conformation showed a
linear relationship with R2 > 0.99 (Figure 5.6), signifying that GFP-RBP(L19A) can serve as a
biosensor for detecting ribose in the high-nanomolar to low-micromolar range (Figure 5.6)
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5.6.

Saturation

contrast

for

100

nM

GFP-RBP(L19A)

and

100

nM

GFP-

RBP(L19A/T135A/Q235A) as a function of percent protein in the ribose-bound, closed
conformation. Saturation contrast for GFP-RBP(L19A) (Kd = 0.3 μM) was measured at the following
ribose concentrations (μM): 0 (0% closed); 0.15 (25% closed); 0.35 (50% closed); 0.975 (75% closed);
1000 (100% closed). Contrast for GFP-RBP(L19A/T135A/Q235A) (Kd = 130 μM) was measured at
the following ribose concentrations (μM): 0 (0% closed); 43 (25% closed); 130 (50% closed); 390 (75%
closed); 4000 (97% closed). Linear regressions of both series of data reported R2 values greater than
99%.
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5.3.3 Mutagenesis to modulate ribose detection sensitivity
To develop a RBP biosensor capable of measuring ribose at physiological concentrations
(10-100 μM in blood and cerebrospinal fluid),[331] mutations were added to RBP(L19A) to increase
the Kd of ribose binding from 0.34 μM measured for GFP-RBP(L19A) by ITC. The mutations made
to RBP(L19A) were based on those first reported and characterized by Lager et al., [155] being
mindful to avoid altering side chains lining the Xe binding site. Upon adding the Q235A mutation
to GFP-RBP(L19A), the Kd for ribose increased to 10 μM. The Xe hyper-CEST z-spectrum of GFPRBP(L19A/Q235A), however, showed that the downfield CEST response was adversely affected;
although the CEST response at 235 ppm was preserved, its magnitude was diminished by ca. 50%
(Figure 5.7). Unexpectedly, introducing the T135A mutation to GFP-RBP(L19A/Q235A) – designed
to further increase ribose Kd – restored the magnitude of downfield CEST contrast. The Kd of the
GFP-RBP(L19A/T135A/Q235A) mutant for ribose was measured as 130 μM by ITC. Measuring
saturation contrast of 100 nM GFP-RBP(L19A/T135A/Q235A) as a function of percent protein in
the closed conformation showed a linear relationship with R2 > 0.99, nearly identical to the riboseresponse contrast observed from GFP-RBP(L19A). The combination of L19A, L19A/Q235A, and
L19A/T135A/Q235A RBP variants covers a large (nanomolar-to-millimolar) range of ribose
concentration measurable by Xe hyper-CEST NMR.
To verify that CEST contrast indeed originates from the Xe cavity engineered via the L19A
mutation, GFP-RBP(L19V) was prepared via site-directed mutagenesis. It was expected that
reducing the cavity volume via the Ala-to-Val substitution would either modulate the chemical
shift of CEST response or block Xe binding to RBP entirely. ITC was performed to validate the
structural integrity of GFP-RBP(L19V) and confirm its ability to bind ribose. For the initial Xe
hyper-CEST z-spectrum with GFP-RBP(L19V), protein concentration was increased to 80 μM in
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case the protein CEST response was attenuated. The z-spectrum of GFP-RBP(L19V) showed no
downfield saturation contrast (Figure 5.7), indicating that the cavity created by the L19A is indeed
responsible for generating the MR contrast observed by Xe hyper-CEST. Notably, the 129Xe(aq) peak
width for 80 μM ribose-bound GFP-RBP(L19V) is roughly the same as 10 μM ribose-bound GFPRBP(L19A), indicating that the L19V mutation significantly lowers Xe affinity for RBP as well as
effectively eliminates CEST contrast.
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Figure 5.7. Xe hyper-CEST z-spectra of RBP variants in pH 7.2 PBS at 300 K. Pulse length, τ pulse =
3.80 ms; field strength, B1,max = 77 μT.
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5.4 Conclusions
Ribose binding protein (RBP) can be engineered to act as a GE contrast agent capable of
measuring ribose concentration across a wide range (nM-to-mM). Using RBP as the recognition
agent achieves high ligand specificity as well as provides a platform for directed evolution to bind
other ligands. The success of RBP as a GE contrast agent for Xe hyper-CEST demonstrates that both
class I (e.g., RBP) and class II (e.g., MBP) periplasmic binding proteins are capable of CEST
biosensing. Moreover, the case of RBP shows that even PBPs without naturally-occurring Xe
binding sites can be engineered for CEST via site-directed mutagenesis, thus it is expected that
other members of the PBP family can be engineered to serve as Xe hyper-CEST biosensors for a
variety of biomolecules. For example, glucose/galactose binding protein (GGBP) from E. coli
(UniProt acc. no. P0AEE5) is a class I PBP whose structure is nearly identical to RBP (rmsd = 1.8 Å).
It is likely that a Xe cavity can be engineered into GGBP protein near the glucose binding cleft
following the same rational design strategy used for RBP. In conclusion, the ability of RBP to act as
a GE biosensor for ribose offers a useful tool for measuring the concentration of a medicallyrelevant metabolite while also demonstrating the potential of PBPs to serve as a general platform
for developing a library of analyte-sensitive GE contrast agents for Xe hyper-CEST.
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Chapter 6: Glucose/Galactose Binding Protein

6.1 Introduction
Glucose concentration and metabolism are key indicators in several common diseases,
most notably cancer and diabetes. Increased rates of glucose consumption by cancer cells due to
aerobic glycolysis is a well-characterized phenomenon known as the “Warburg Effect.” [332] 2deoxy-2-(18F)fluoro-D-glucose (FDG) is a radiolabeled glucose analog detectable by positron
emission tomography (PET) that has become a critical clinical tool for detecting and staging tumor
growth in cancer treatment.[333] FDG has also been used to diagnose Alzheimer’s disease, where
impaired glucose metabolism is recognized as an early symptom of neural and synapse
dysfunction.[334] Additionally, blood glucose concentration is a key diagnostic indicator for diabetes
mellitus and related metabolic disorders.[335] Overall, glucose is a metabolite linked to a wide
variety of common diseases and pathologies, and the ability to non-invasively visualize glucose
concentration in vivo with high spatiotemporal resolution would have immediate impact as a
diagnostic tool in the clinic.
Glucose/galactose binding protein (GGBP), a class I periplasmic binding protein (PBP), has
been investigated as a potential biosensing platform for monitoring glucose concentration in vivo.
GGBP binds D-glucose and D-galactose with dissociation constants Kd of 0.2 μM and 0.4 μM,
respectively.[336] As with other PBPs, glucose binds between the globular N- and C-terminal
domains of GGBP and triggers a large conformational change in which GGBP clamps down on the
bound sugar.[337] GGBP functionalized with a fluorescent probe has been used as an optical
biosensor capable of detecting submicromolar concentrations of glucose. [338] More recently, GGBP
has been mutated to tune its glucose-detection range to approximately 1-100 mM, making it
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suitable for glucose monitoring in diabetes patients.[339] Moreover, computationally-guided
mutagenesis of GGBP has been used to convert GGBP into a L-lactate binding protein. [340] Glucosebound GGBP is nearly structurally identical to ribose-bound RBP (rmsd = 1.8 Å) (Figure 6.1), thus
it was expected that a Xe-binding site could be engineered into GGBP following the same alaninetruncation strategy used for RBP. It was also anticipated that because the Xe site is proximal to the
sugar-binding cleft of GGBP, Xe hyper-CEST contrast would be sugar-dependent and GGBP could
be an effective GE contrast agent for the in vivo detection of glucose.
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Figure 6.1. Structural comparison of ribose-bound RBP (gray; PDB ID 2DRI[323]) and glucose-bound
GGBP (green; PDB ID 2FVY[337]). Xe (red dots) was modeled in the center of the cavity created by
the L19A mutation in RBP. (Inset) Close-up view of the proposed Xe binding site, with neighboring
side chains of RBP and GGBP shown for comparison. GGBP residues targeted for initial
mutagenesis experiments are labeled.
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6.2 Materials and methods

6.2.1 Plasmid preparation
A pRSET-B plasmid encoding the gene for mature glucose/galactose binding protein
(GGBP) from Escherichia coli (UniProt acc. no. P0AEE5) was received as a gift from Wolf Frommer
via Addgene (plasmid #13562).[131] The GGBP gene was amplified using the primers listed in Table
6.1 and then cloned via ligation independent cloning (LIC) into the same pET-His-GFP-TEV LIC
vector used to express RBP(L19A) (Addgene plasmid #29663). The resulting GFP-GGBP plasmid
was sequenced at the University of Pennsylvania DNA Sequencing Facility to verify the integrity
of the fusion construct.

6.2.2 Site-directed mutagenesis
Mutations were introduced to GFP-GGBP via site-directed mutagenesis using the forward
and reverse oligonucleotide primers listed in Table 6.2. Mutant plasmids were amplified in NEB5α competent E. coli cells (New England Biolabs), purified using a Monarch® miniprep kit (New
England Biolabs), and sequenced at the University of Pennsylvania DNA Sequencing Facility to
verify the incorporation of the desired mutation and the integrity of the GFP-GGBP gene.
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Table 6.1. Oligonucleotide primers used for GGBP insert amplification
Forward primer

5'– TACTTCCAATCCAATGCAGCTGATACTCGCATTGGTGTAAC –3'

Reverse primer

5'– TTATCCACTTCCAATGTTATTAAGCCAGGTTGTCTTTATCTACG –3'
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Table 6.2. Oligonucleotide primers used in GGBP site-directed mutagenesis

F90A

V20A

M17A

F90V

Forward primer

5'– CCGGTGGTTTTCGCGAACAAAGAACCG –3'

Reverse primer

5'– CGGTTCTTTGTTCGCGAAAACCACCGG –3'

Forward primer

5'– CTTTATGTCTGTAGCGCGCAAGGCTATTG –3'

Reverse primer

5'– CAATAGCCTTGCGCGCTACAGACATAAAG –3'

Forward primer

5'– GACGATAACTTTGCGTCTGTAGTGCGC –3'

Reverse primer

5'– GCGCACTACAGACGCAAAGTTATCGTC –3'

Forward primer

5'– CCGGTGGTTTTCGTGAACAAAGAACCG –3'

Reverse primer

5'– CGGTTCTTTGTTCACGAAAACCACCGG –3'
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6.2.3 Protein expression and purification
Plasmid encoding GFP-GGBP was transformed into BL21(DE3) competent E. coli cells
(New England Biolabs) and grown in 3 x 1 L of LB media supplemented with 50 μg/mL kanamycin
to

a

OD600

of

~1.

GFP-GGBP

expression

was

induced

by

adding

isopropyl-β-D-

thiogalactopyranoside (IPTG) to a final concentration of 1 mM. Upon induction the growth media
was supplemented with 1 mM CaCl2. The induced cells were incubated overnight at 18 °C,
harvested by centrifugation, then frozen at -80 °C for long-term storage. GFP-GGBP mutants were
expressed following the same procedure used for WT.
GFP-GGBP, GFP-GGBP(F90A), and GFP-GGBP(V20A) were purified as follows: the frozen
cell pellet was thawed and resuspended in 20 mM sodium phosphate (pH 7.4), lysed with lysozyme
(Sigma), and treated with benzonase nuclease (Sigma) to reduce the viscosity of the lysate. After
stirring the lysate at rt for 30 min, NaCl was added to 0.5 M, imidazole to 20 mM, and CaCl 2 to 1
mM. The lysate was clarified by centrifugation, and the supernatant was loaded onto a HisTrap
nickel affinity column (GE Life Sciences) pre-equilibrated with 20 mM sodium phosphate (pH 7.4),
0.5 M NaCl, 20 mM imidazole, 1 mM CaCl2. GFP-GGBP bound to the column was unfolded with
20 column volumes (CVs) of 20 mM sodium phosphate (pH 7.4), 0.5 M NaCl, 20 mM imidazole, 8
M urea to remove any endogenous glucose or galactose bound to the protein. GFP-GGBP was
refolded on-column via a 12-CV gradient to 20 mM sodium phosphate (pH 7.4), 0.5 M NaCl, 20
mM imidazole, 1 mM CaCl2 and then eluted with 20 mM sodium phosphate (pH 7.4), 0.5 M NaCl,
1 mM CaCl2, 500 mM imidazole. The eluate was concentrated and further purified by sizeexclusion chromatography in DPBS containing Mg2+ and Ca2+ (Thermo) using a HiLoad 16/600
Superdex column (GE Life Sciences). Fractions containing pure protein (over 95% as indicated by
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SDS-PAGE) were pooled and concentrated. Protein concentration were determined from the
absorbance at 280 nm (ε280 = 58 330 M-1 cm-1).
GFP-GGBP(M17A) and GFP-GGBP(F90V) were purified as follows: the frozen cell pellet
was thawed and resuspended in 20 mM sodium phosphate (pH 7.4), lysed with lysozyme (Sigma),
and treated with benzonase nuclease (Sigma) to reduce the viscosity of the lysate. After stirring the
lysate at rt for 30 min, NaCl was added to 0.5 M and imidazole to 20 mM. The lysate was clarified
by centrifugation, and the supernatant was loaded onto 3 mL HisPur Ni-NTA spin columns
(Thermo) pre-equilibrated with 20 mM sodium phosphate (pH 7.4), 0.5 M NaCl, 20 mM imidazole.
Bound protein was washed with pre-equilibration buffer, then eluted with 20 mM sodium
phosphate (pH 7.4), 0.5 M NaCl, 500 mM imidazole. The eluted protein was buffer exchanged into
DPBS containing Mg2+ and Ca2+ (Thermo) via an Amicon Ultra-15 (MWCO = 30 kDa) centrifugal
filter (EMD Millipore). SDS-PAGE indicated the protein purity to be greater than 95%, and protein
concentration were determined from the absorbance at 280 nm (ε280 = 58 330 M-1 cm-1).
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6.2.4 Circular dichroism (CD) spectroscopy
The CD spectra of GFP-GGBP variants were measured on a Jasco J-1500 CD spectrometer
equipped with a Peltier temperature controller (Figure 6.2). Spectra were acquired from 5 μM
protein in 10 mM sodium phosphate (pH 8.0) buffer inside a quartz cuvette with a 1 mm path
length. CD spectra were taken at 20 °C with a wavelength step of 1 nm.
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Figure 6.2. CD spectra of 5 μM GFP-GGBP variants with and without glucose (left) and 5 μM GFPGGBP(M17A) and GFP-GGBP(F90V) with glucose in 10 mM sodium phosphate buffer (pH 8.0).
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6.2.5 Isothermal titration calorimetry (ITC)
ITC experiments were performed at 298 K on a GE Healthcare MicroCal TM iTC200
instrument. Unliganded GFP-GGBP was prepared at 30 μM in DPBS containing Mg 2+ and Ca2+, and
glucose was prepared at 300 μM in the same buffer solution. The sample cell was filled with 300
μL of protein solution, and the reference cell was filled with deionized water. Calorimetric data
were analyzed by performing nonlinear regression fitting to the binding isotherm using ORIGIN
software (Figure 6.2).

204

Figure 6.3. ITC enthalpogram of glucose binding to GFP-GGBP.
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6.3 Results and discussion

6.3.1 Cavity detection
Prior to performing any Xe NMR experiments, the crystal structure of glucose-bound
GGBP (PDB ID 2FVY) was analyzed to identify any preexisting internal cavities large enough to
accommodate Xe. No such cavities were found, meaning that it would be necessary to introduce a
suitable Xe site by site-directed mutagenesis. Using the Xe cavity of RBP(L19A) as a guide, the
following side chain truncations to GGBP were proposed: F90A, V20A, M17A, and F90V (Figure
6.1). The mutations were modeled into the structure of glucose-bound GGBP and assessed to
measure the volumes of the resulting cavities (Table 6.3). Although only the F90A mutation created
a cavity greater than the 42 Å3 volume of Xe, the cavity sizes produced from the other mutations
were large enough that it was reasoned that perhaps they could accommodate Xe binding if the
protein were allowed more flexibility (i.e. allowed to “breathe”) in solution.
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Table 6.3. Cavity volumes of GGBP and mutants
Protein

Xe cavity volume (Å3)†

GGBP

-

GGBP(F90A)

73

GGBP(V20A)

34

GGBP(M17A)

40

GGBP(F90V)

35

†

Calculated by Swiss-DBP Viewer (v 4.1.0)[266]

207

6.3.2 129Xe hyper-CEST of GGBP
Wild-type (WT) GGBP and mutants were expressed as a fusion to a N-terminal GFP in the
same vector used for GFP-RBP(L19A). To accelerate protein production for initial screening
experiments by Xe hyper-CEST, GFP-GGBP was purified via Ni 2+ resin spin columns without any
protein unfolding and refolding steps. It was figured that although some GFP-GGBP would be
bound to endogenous glucose and galactose, the initial z-spectra to detect CEST contrast would be
performed on GFP-GGBP in the presence of glucose anyway. GFP-GGBP was buffer exchanged
into DPBS containing Mg2+ and Ca2+ via an Amicon centrifugal filter unit prior to any Xe hyperCEST experiments. For experiments with GFP-GGBP, DPBS containing Mg 2+ and Ca2+ was used as
the buffer instead of PBS because the crystal structures of unliganded (PDB ID 2FW0) and glucosebound GGBP (PDB ID 2FVY) both contain bound Ca2+ coordinated to the side chains of residues
D134, N136, D138, Q142, E205 and the backbone carbonyl of Q140.[337] This quicker method of
protein purification still produced highly-pure protein, as measured by SDS-PAGE.
Initial Xe NMR experiments consisted of acquiring the Xe hyper-CEST z-spectra of 100 μM
WT GFP-GGBP, GFP-GGBP(F90A), and GFP-GGBP(V20A) in the presence of 1 mM glucose (Figure
6.4). Following the same procedure used for RBP(L19A), multiple selective Dsnob-shaped
saturation pulses were scanned over the chemical shift range of 93-358 ppm in 5 ppm steps, and
the 129Xe(aq) signal was measured as a function of saturation pulse offset. As expected from the lack
of native Xe-binding sites, the spectrum of WT GFP-GGBP showed only a single peak centered at
the Xe(aq) frequency. Disappointingly, the z-spectra of the F90A and V20A mutants also showed
only a single peak centered at the Xe(aq) frequency. However, the F90A and V20A Xe(aq) peaks were
asymmetrically broadened in the downfield direction compared to WT, indicating that these
mutants do in fact possess a solvent-shielded cavity capable of binding Xe, but that the rate of Xe
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exchange is too fast on the NMR timescale to resolve a separate Xe@GGBP peak. Due to the
broadness of the peaks produced by 100 μM protein, protein concentration was lowered to 20 μM
when acquiring the z-spectra of the M17A and F90V mutants. These GGBP mutants also showed
only a single peak centered at the Xe(aq) frequency, with no visible asymmetry in the downfield
direction (Figure 6.4).
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Figure 6.4. Xe hyper-CEST spectra of GFP-GGBP variants. Z-spectra acquired in DPBS (pH 7.2)
containing Mg2+ and Ca2+ at 300 K.
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90

6.3.3 Glucose detection by GGBP
To ascertain whether the Xe binding to GGBP is affected by bound glucose and/or the
conformational state of the protein, z-spectra were acquired for GFP-GGBP, GFP-GGBP(F90A), and
GFP-GGBP(V20A) mutants in the absence of glucose. To prepare protein for these experiments, a
more rigorous purification protocol was used in which GFP-GGBP was denatured by 8 M urea to
release any bound endogenous glucose/galactose and then refolded on-column by gradual
reduction of urea concentration, the same procedure used to prepare ribose-free RBP(L19A).
Ligand-free GFP-GGBP was then run on a size-exclusion column to buffer exchange into DPBS as
well as remove any aggregated or improperly folded protein. ITC was performed to verify that
GFP-GGBP prepared by this method was properly folded and indeed unliganded, as well as to
validate the ε280 molar extinction coefficient used to calculate protein concentration (Figure 6.2).
Figure 6.5 shows the comparison of Xe hyper-CEST z-spectra acquired for unliganded and
glucose-bound GFP-GGBP, GFP-GGBP(F90A), and GFP-GGBP(V20A). WT GFP-GGBP showed a
small increase in the width of Xe(aq) peak upon the addition of glucose, indicating that Xe has a
higher affinity for the glucose-bound, closed conformation. GFP-GGBP(F90A) showed a similar
increase in Xe(aq) peak width upon adding glucose. GFP-GGBP(V20A) showed the largest Xe (aq)
peak width difference between unliganded and glucose-bound species, suggesting that Xe
interactions with the cavity created by the V20A mutation are the most sensitive to glucose-binding
and/or conformation change among all the mutations made to GGBP. Interestingly, while the Xe (aq)
peak width of unliganded GFP-GGBP(V20A) is narrower than for WT, the width of glucose-bound
GFP-GGBP(V20A) is broader than for WT. These data indicate that the V20A mutation decreases
Xe affinity for open GGBP but increases affinity for the closed GGBP. The structural basis for this
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phenomenon is unclear, but X-ray crystallography experiments are underway to better
characterize the structural effects of the V20A mutation and its impact on Xe binding to GGBP.
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Figure 6.5. Xe hyper-CEST spectra of GFP-GGBP variants. Z-spectra acquired from 100 μM protein
with and without 1 mM glucose in DPBS (pH 7.2) containing Mg 2+ and Ca2+ at 300 K.
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Continuing the development of GGBP as a GE biosensor for glucose, the next challenge is
to mutate GGBP in such a way as to slow Xe exchange at the V20A cavity. The side chain of Met17 side separates the Xe cavity from the glucose binding site in GGBP – the presumed portal for Xe
entry and egress– so it stands to reason that alterations to this side chain will impact the
accessibility of the V20A cavity to Xe. The three proposed side chain substitutions are Phe, Lys,
and Leu. Phe would match the side chain found in RBP (Figure 6.1), and the steric bulk of the
phenyl group would likely slow Xe exchange. Similarly, Lys would mimic the side chain that
separates the Xe binding site from the maltose binding site in MBP. Finally, in the event that Phe
and Lys are too destabilizing to GGBP, Leu would be a less drastic substitution.
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6.4 Conclusions
Glucose is a metabolite whose concentration, flux, and metabolism are diagnostic for a
variety of common diseases and pathologies. Current methods for visualizing glucose in vivo
include PET scans with FDG tracer (expensive label; requires ionizing radiation) and fluorescent
probes (limited penetration depths). Developing a GE contrast agent capable of sensing glucose
concentration via MRI would enable imaging in large, opaque organisms (e.g., humans) and take
advantage of the high spatiotemporal resolution and non-invasiveness of MRI. Building upon our
success developing MBP and RBP as maltose and ribose biosensors, respectively, we have begun
to engineer into GGBP a Xe binding site capable of generating downfield CEST contrast in a ligandsensitive manner. Initial Xe hyper-CEST z-spectra indicate that the V20A mutant establishes a Xe
binding site sensitive to protein conformation, but the lack of a resolved downfield peak
corresponding to the Xe-protein interaction indicates that Xe exchange is fast on the NMR
timescale. Further mutations are therefore needed to sufficiently slow Xe exchange, but we are
optimistic, especially because such slow exchange has been achieved for MBP, RBP, and TEM-1 βlactamase. X-ray crystallography experiments, complemented by MD simulations and structural
1

H NMR experiments, will inform the rational design of GGBP into a protein suitable for biosensing

applications.
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Chapter 7: Conclusions

In vivo molecular imaging is an active and impactful area of biomedical research, with
implications for early disease diagnosis, treatment assessment, and drug development. Clinical
imaging techniques often rely on contrast agents – substances that are readily detectable by some
form of imaging modality (e.g. fluorescence, position emission tomography, magnetic resonance)
– to visualize anatomical structures or a biomarker of interest. Contrast agents are also used to label
specific cell populations, monitor gene expression and localization, and measure metabolite
concentration and flux. A routine molecular imaging technique involves the visualization of
optical contrast agents such as fluorescent small molecules (e.g. fluorescein) or proteins (e.g. GFP).
While this contrast approach is practical for molecular imaging in cells and small transparent
organisms, optical contrast agents are not fit for use in larger, opaque organisms due to the strong
scattering of light by tissue. Detection of radiolabeled contrast agents by positron emission
tomography (PET) can overcome this penetration depth limitation, though PET scans require the
costly synthesis of radiolabeled molecules and use of ionization radiation. Moreover, many
commonly used radionuclides (e.g. 18F in fluorodeoxyglucose) have short half-lives, necessitating
immediate air delivery or access to an on-site cyclotron. Magnetic resonance imaging (MRI), on the
other hand, achieves excellent spatiotemporal resolution at unlimited penetration depths without
the need for ionizing radiation. However, proton MRI has historically been limited by low
sensitivity due to the extremely small population difference between 1H nuclear spin energies at
thermal equilibrium. The persisting challenge to achieving molecular imaging by MRI has been the
development of contrast agents detectable by MRI at low (i.e. sub-μM) concentrations suitable for
visualizing biomolecules and biological processes.
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MRI contrast agents currently in clinical use act by shortening the T1 and T2 relaxation
times of nearby protons, thereby producing useful contrast T1- and T2-weighted MRI scans,
respectively. However, such agents must be employed at high concentrations, and many
incorporate exogenous paramagnetic metal ions (most notably Gd3+), thus raising cytotoxicity
concerns. An emerging MR contrast approach – chemical exchange saturation transfer (CEST) –
has garnered significant interest due to its considerable signal enhancement. While CEST can be
used with paramagnetic metal-containing contrast agents (paraCEST), other methods, namely
diaCEST, do not require the use of metal ions. While considerable advances have been made
developing increasingly-sensitive T1, T2, and CEST contrast agents for MRI, the detection
sensitivities of these agents are fundamentally limited by the large background signal of 1H in
tissue. Hence, MRI molecular imaging approaches with non- 1H nuclei are being explored.
Spin-½ nuclei such as 13C, 15N, 19F, 31P, 3He, and 129Xe are readily detectable by MRI, and of
these,
3

129

Xe has emerged as a leading candidate for molecular imaging applications.

129

Xe, unlike

He, is distilled from the atmosphere and is relatively inexpensive. Moreover, Xe has a large

polarizable electron cloud, which gives it millimolar solubility in water as well as makes its NMR
chemical shift extremely sensitive to its local environment. Xe can be hyperpolarized by spinexchange optical pumping (SEOP) to increase its magnetization signal by more than 10 5-fold.
Additionally, Xe can act as a guest to molecular hosts such as cryptophane-A and cucurbit[6]uril,
and this exchange is readily detectable by CEST. While these host molecules have found success in
a variety of molecular imaging applications, there is still a need for genetically encoded (GE)
contrast agents detectable by MRI that can be used for long-term, non-invasive molecular imaging.
The focus of much of my work as a graduate student at the University of Pennsylvania has
been to identify and characterize proteins that are detectable by hyperpolarized (hp)
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129

Xe NMR,

with the ultimate goal of developing a class of GE contrast agents practical for MRI molecular
imaging applications. My efforts have been marked by the success of TEM-1 β-lactamase (TEM1)
in achieving nanomolar detection sensitivity in mammalian cells. Moreover, preliminary
experiments indicate that fragment complementation assays with TEM1 can provide a means for
detecting protein-protein interactions via 129Xe hyper-CEST NMR/MRI. Additionally, my work led
to our group identifying maltose binding protein (MBP) and ribose binding protein (RBP) as the
first analyte-sensitive GE contrast agents detectable by hp

129

Xe NMR. Our success with MBP and

RBP suggest that periplasmic binding proteins (PBPs) constitute a new class of GE contrast agents
capable of detecting biomolecular analytes at physiological concentrations, a task that has proven
challenging for both small molecule and protein-based MRI contrast agents.
Future directions for our work on GE contrast agents include transitioning from MR
spectroscopy to MR imaging as a means of measuring CEST contrast. Inhaled

129

Xe rapidly

transfers to blood and distributes to other tissues while remaining hyperpolarized. It is thus
expected that TEM1 expressed in transgenic mice will be detectable by

129

Xe hyper-CEST MRI.

Additionally, we aim to visualize ribose metabolism in transgenic mice expressing RBP by
hyper-CEST MRI. As for expanding the library of GE MRI contrast agents for

129

Xe

Xe hyper-CEST,

129

the challenge continues to be overcoming the weak and transient nature of Xe binding to proteins.
For a protein to be detectable by Xe MRI, namely Xe hyper-CEST, Xe must bind at a site within the
protein sufficiently downfield of the Xe(aq) frequency, and exchange must occur in the slow-tointermediate (i.e. millisecond) NMR time scale. Moving forward, it is expected that molecular
dynamics will further guide our search for suitable protein candidates for Xe hyper-CEST, and
biophysical techniques such as protein NMR will further characterize the thermodynamics and
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kinetics of the Xe-protein interactions. It is expected that, in time, our group will develop a library
of GE MRI contrast agents akin to the colorful palette of fluorescent proteins so widely used today.
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